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ABSTRACT
This thesis consists of a literature review followed by four empirical chapters examining
the relationship between the chronic use of cannabis and cognitive and brain
electrophysiological functioning. In Chapter 2 recent literature is reviewed linking
chronic cannabis use with, primarily, memory dysfunction. Deficits in verbal memory
processes were noted in particular. It was hypothesised that poorer neural efficiency and
use of compensatory mechanisms were associated with chronic cannabis use.
Additionally, brain imaging measures sensitive to the often subtle alterations associated
with cannabis use, such as the use of psychophysiological recording techniques, were
indicated as a likely area of viable future research. Chapter 3 follows with a brief review
of the existing psychophysiological literature on the acute and chronic effects of
cannabis. From the, quite limited, available literature it was identified that acute and
chronic cannabis use are each associated with alterations in both early sensory
registration and later cognitive processing-related event-related brain potentials (ERPs).
In the empirical studies, Chapter 4 examines chronic cannabis use effects as they relate
to a task of verbal memory performance among 24 cannabis users and 24 matched
healthy controls. Poorer delayed free recall was present following a list learning task
with alterations noted in the amplitude of ERP components related to memory encoding
and consolidation, specifically the subsequent memory effect N4 and late positive
component. It is argued that chronic cannabis use disrupted the optimal functioning of
neural mechanisms related to verbal memory performance and that novel, albeit less
efficient, neural pathways are required by cannabis users to perform verbal memory
tasks, albeit to a poorer degree than controls. An additional relationship with a longer
history of use among cannabis users being related to improved memory performance
was observed. This effect was observed though within the context of overall poorer
performance within the cannabis-using group relative to controls. It is hypothesised that
this reflects neuroadaptive processes related to the brains of longer-term users
attempting to develop optimal neural pathways, during the presence of disruption by
continued cannabis use. In practical terms this means a longer history of use is related to
a recovery of functioning and/or more efficient neural pathways in comparison to a
shorter history of use.
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The study in Chapter 5 examines recognition memory performance among 21 cannabis
users and 22 controls. Previously seen and unseen words were discretely presented to
participants with the effects of simple (more novel words) and more difficult distractors
(related words) examined for each group. Evidence was present for increased
interference from distractors for cannabis users, in particular on the more difficult
distractor condition. Impairment of ERP components related to attention (N1 amplitude)
and stimulus recognition processing (N4 and P3 amplitudes in the OLD/NEW effect)
were present. As with chapter 4, evidence of processes that may indicate
neuroadaptation was present with a longer history of use among cannabis users related
to the formation of more efficient neural performance as well as more accurate detection
of target stimuli from among distractors.
In Chapter 6 the relationship between chronic cannabis use and inhibitory control was
examined using a variant of the Stroop colour naming task. Twenty-one cannabis users
and 19 controls were compared on Stroop task performance with ERPs generated to
stimulus presentations. Users were observed to have overall slower response times as
well as poorer performance for colour naming during instances of incongruent colour
naming presentations (e.g. the word “RED” appearing in blue ink). Opposite patterns of
brain electrical activity (i.e. amplitude) were observed for cannabis users versus controls
at central and parietal sites for a late positive potential, known as the Conflict SP. An
earlier age of cannabis use uptake was additionally related to poorer task performance.
Findings of this study suggest that chronic users of cannabis may have an impaired
inhibitory ability that may manifest as a reduced ability to refrain from future substance
misuse, with an earlier age of exposure possibly resulting in increased difficulties.
Lastly, Chapter 7 examines chronic cannabis use effects on a basic task of recognition
memory that also examined proactive interference. Twenty cannabis users and 20
controls were administered a variant of the Sternberg paradigm, where several stimuli
(consonants) were presented at the same time and followed by a probe stimulus (a single
consonant) that they were required to indicate was in the stimulus set or not. Cannabis
users showed an attenuated N2 ERP component, previously related to familiarity in
recognition memory, at central sites in comparison to controls, with variations in central
topography also present. Relationships between a longer history of use and improved
behavioural performance among cannabis users and more efficient electrophysiological
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outcomes were present, suggesting neuroadaptation. This study concluded that complex
tasks are required to elicit overt differences in behavioural responding among cannabis
users but that electrophysiological measures, such as ERPs are able to detect alterations
that may go unnoted otherwise.
The empirical findings of this thesis substantially add to the limited available literature
on psychophysiological effects associated with the chronic use of cannabis. In
particular, evidence that deficits in overt and neural functioning were present during the
unintoxicated state indicate that cannabis use impacts outside the period of acute
exposure. Relationships with a longer history of use further indicate that changes
associated with chronic cannabis use develop gradually and are enduring. Lastly,
findings related to neuroadaptive effects suggest an ability for the brains of cannabis
users to compensate for dysfunctional neural pathways. Although there were some
limitations related to an inability to completely rule out impacts of residual intoxication,
mood disturbances, withdrawal symptoms and tobacco use, this was heavily controlled
for or factored in where appropriate. Future research may benefit from taking further
measures to control for these potential influences.
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CHAPTER 1:

INTRODUCTION AND AIMS
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1.1.

INTRODUCTION

Cannabis sativa, also commonly known simply as cannabis, marijuana, marihuana, pot,
weed and grass, is the most commonly used illicit substance in the world (UNODC
2007). Given its widespread use, it is often the focus of social policy debate. In terms of
its potential as a drug of abuse, it is the properties of its primary psychoactive
compound, delta-9-tetrahydrocannabinol (THC), which have been considered a major
concern. Acute effects vary broadly and include those viewed as beneficial as well as
unpleasant. The former include a mild euphoria, calming of thought patterns, ability to
focus (fixate), a feeling of wellness, and laughter. The latter include paranoia, memory
disturbance, rapid heart rate, and psychotic episodes (Solowij 1998). These symptoms
are frequently cited as reasons for its illegality and its need to be controlled (Hall and
Lynskey 2009). Irrespective of these findings, it continues to be commonly and heavily
used, with access often as simple as a home hydroponics setup or a plant
inconspicuously located within a garden (Decorte 2010; Hall and Lynskey 2009). It is
also a thriving business on the illicit drug trade market due to its ease of growth, lack of
a processing requirement, and often domestic production (Decorte 2010). Further
complicating the social policy debate, however, are several medicinal properties of
cannabis with evidence for its use as a treatment for glaucoma, as an anti-emetic,
appetite stimulant, and for chronic pain relief and sleep disturbance (Green and DeVries 2010). Better informing these issues is a major driver for the increasing amount of
research into understanding the effects of cannabis use.
The cannabis sativa plant is considered to be a highly variable species with the
long period of human cultivation in geographically distinct regions associated resulting
in a very large number of phenotypically distinct varieties, potentially containing highly
variable levels of the various psychoactive compounds (Izzo et al. 2009; Knight et al.
2010). Of the many different chemicals that have been observed within the cannabis
plant, approximately 70 are unique to it. Of the different compounds that have been
observed within the cannabis sativa genus, delta-9-terahydrocannabinol (delta-9-THC)
and cannabidiol (CBD) are of most interest due to their unique properties (Morgan et al.
2010b). Of particular interest is delta-9-THC as it is believed to be primarily responsible
for the various psychoactive effects typically associated with the use of cannabis. In
contrast, CBD is considered to possess anxiolytic and potentially antipsychotic
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properties (Bhattacharyya et al. 2010) and therefore likely to offset some of the adverse
psychoactive effects. Laboratory studies examining the influence of both substances
have demonstrated opposing behavioural and pharmacological effects (e.g., Campos and
Guimaraes 2008; Guimaraes et al. 2004; Long et al. 2010; Malone et al. 2009;
O'Tuathaigh et al. 2010). There has been some debate within the literature as to what the
implications may be of varying delta-9-THC concentrations relative to levels of CBD,
particularly with some evidence that delta-9-THC levels may be increasing and CBD
decreasing in the pursuit of more psychoactively potent varieties, with this particularly
the case with hydroponically-grown plants (Knight et al. 2010; Mehmedic et al. 2010;
Morgan et al. 2010a; Morgan et al. 2010b). Given the lack of consistency in varieties
and growing methods of cannabis though, the implications of this currently cannot be
easily measured, particularly when examining exposure effects over very lengthy time
periods.
The specific receptors that respond to the introduction of exogenous
cannabinoids are known as cannabinoid receptors. Diversely distributed throughout the
body, research has identified two main types of cannabinoid receptors, cannabinoid 1
(CB1) and cannabinoid 2 (CB2) (Elphick and Egertova 2001; Pertwee 2008). CB1
receptors are most densely populated within the central nervous system and peripheral
neurons and have been observed to be particularly prevalent within the cerebral cortex,
hippocampus, cerebellum and basal ganglia (Elphick and Egertova 2001; Pertwee and
Ross 2002). CB1 receptors are involved in a wide range of neurological processes and
have been observed to respond primarily to the action of the endogenous cannabinoids,
anandamide and 2-arachidonoylglycerol (Pertwee 2008; Pertwee and Ross 2002).
Functions that are implicated in CB1 receptor functioning include memory, attention,
inhibitory control, time estimation, set shifting, decision making, appetite, reward, and
balance (Pattij et al. 2008; Ranganathan and D'Souza 2006; Sewell et al. 2010; Solowij
1998; Solowij and Battisti 2008; Solowij and Pesa 2010). It is because of the distributed
nature of CB1 receptors throughout the brain that such a wide range of functions are
associated. CB2 receptors have been observed to be largely located within immune cells
and respond also to anandamide and 2-arachidonoylglycerol (Pertwee 2008; Rieder et
al. 2010). Activation of CB2 receptors has been found to trigger the release of cytokines
from immune cells with some evidence for impacts upon immune system functioning by
modulating immune cell migration both within and outside the central nervous system
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(Pertwee 2008). CB2 receptors have consequently been implicated in auto-immune
response, including cell apoptosis (i.e. cell death) and inflammatory responses (Rieder
et al. 2010).
Particular interest in cognitive changes associated with the use of cannabis has
largely focused on its role in relation to the functioning of CB1 receptors. As discussed
above, delta-9-THC is believed to be responsible for the various psychoactive effects
associated with cannabis exposure, with this due to its apparent affinity for CB1 (and
CB2) receptors (Pertwee 2008). It is only considered a partial agonist though, exhibiting
lower efficacy than specific CB1/CB2 synthetic receptor agonists (Childers 2006;
Howlett et al. 2004), which may explain the relatively smaller effects of cannabis use in
comparison to that of other drugs of abuse such as heroin or methamphetamine, which
are believed to have a high affinity for their respective receptor sites within the brain
(Carson et al. 2010; Gabilondo et al. 1994; Nguyen et al. 2005). Unlike endogenous
cannabinoids though, delta-9-THC targets CB1 receptors in a very non-selective
manner, explaining the multiple effects observed during acute intoxication (Kreitzer
2005; Pertwee 2008). In addition to its action upon CB1 receptor functioning, delta-9THC has been observed to mediate the release of several other neurotransmitters,
including dopamine, glutamate and acetylcholine. This is believed to be via blocking of
the release of inhibitory neurotransmitters on dopamine-, glutamate- or acetylcholinereleasing neurons (Gardner 2005; Pertwee and Ross 2002; Pisanu et al. 2006; Pistis et
al. 2002). It is these non-specific actions that may explain impacts upon appetite and the
experience of mild euphoria following acute exposure and may contribute to the reasons
that people use cannabis.
Estimates place regular (near daily) cannabis consumption at approximately
16% of the population within Australia (AIHW 2005), with a similar statistic in the
United states of 14% of Americans aged 12 years or older estimated to be using neardaily to daily in 2007 (SAMHSA 2008). Among younger individuals, recent evidence
suggests an increase in the level of regular cannabis use despite an overall decline in the
number of users (AIHW 2008). Given these prevalence statistics, it is increasingly
necessary to examine what the chronic effects of cannabis may be, as well as the
relationship between early adoption of cannabis use and subsequent effects into later
life.
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There has been relatively little research, until recently, on chronic cannabis use
effects, with acute exposure studies, being much more straightforward and less
complicated by potential confounds, more often the focus of research (for review, see
Ranganathan and D'Souza 2006). What has been established though, is evidence of
enduring impacts upon memory and attention processes, as well as associations with
altered brain function and structure (for review, see Solowij and Pesa 2010). Many of
the chronic use studies though, have been confounded by participant sampling issues
with problems associated with other substance misuse, the presence of psychiatric
diagnoses, varying patterns in the frequency and quantity of cannabis used, and poorly
matched control samples. A need is therefore present for more tightly controlled studies
that are able to produce more conclusive results.
Alterations in cognitive ability associated with the chronic use of cannabis are
often quite subtle and not always apparent during tasks where complexity and/or level
of task demand are low (Sewell et al. 2010). The need for tasks that tap into previously
identified areas of functional deficit therefore provides a logical next step in furthering
the evidence base for associated impacts. Additionally, while there has been some
evidence for alterations in brain function associated with chronic use (e.g. Block et al.
2002; Jacobsen et al. 2004; Jacobsen et al. 2007; Jager et al. 2006), the already stated
subtle changes that accompany cannabis use may confound the detection ability of
many brain imaging measures. Psychophysiological measurement is often cited as being
more sensitive to alterations in brain function that may not easily be detectable by other
methods of brain imaging. This is due to its ability to measure, via use of the
electroencephalogram (EEG), with high temporal accuracy, fluctuations in brain
electrical activity. A derivative of the EEG is the event-related brain potential (ERP).
ERPs allow, with a similar resolution to EEG, examination of discrete sensory and
cognitive stimulus processing stages within a wide-range of processing contexts, e.g.
memory encoding, retrieval, sensory registration of stimuli and attentional control,
among other processes (Lew et al. 2006). ERPs are a highly viable and appropriate tool
for better understanding alterations in the underlying neural activity of cognitive
processes associated with chronic cannabis use.
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1.2.

AIMS AND OBJECTIVES
1. This thesis investigated the relationship between chronic heavy use of cannabis
and cognitive and psychological functioning, particularly as they relate to the
domain of memory, but also attention and inhibitory control. This was achieved
via addressing the following aims:
2. Review available research data and identify the current evidence for enduring
cognitive impairment associated with long-term cannabis use, particularly
within the domain of memory (chapter 2).
3. Review available research data of event-related brain potential (ERP)
psychophysiological studies of cannabis use to identify key ERP component
biomarkers that are influenced by cannabis exposure and may be a target for
further research.
4. Based upon the outcomes from aims 1 and 2, to conduct several studies of
cognitive ability in chronic users of cannabis during the unintoxicated state
while recording live psychophysiological measures (i.e. electroencephalogram;
EEG) for the offline generation of ERPs and examination of component
biomarkers (see chapters 4, 5, 6 and 7). These addressed the following research
questions:
a. What are some of the cognitive deficits associated with the chronic use
of cannabis when measured during the unintoxicated state?
b. What are the alterations in brain psychophysiological functioning
associated with the chronic use of cannabis when measured during the
unintoxicated state, and what do these tell us about underlying changes
in brain functioning?
c. What are the relationships between characteristics of cannabis use
history and cognitive and psychophysiological variables?
This thesis represents a major contribution to the existing, limited

psychophysiological literature on chronic cannabis use effects (see chapter 3) via the
contribution of another four empirical studies. In addition, a highly select group of
cannabis users with a long history of heavy use and limited other potential confounds
(e.g. psychiatric history, neurological injury, other substance use) were matched to a
group of healthy controls. Although such a sample may not be representative of the
cannabis-using community at large, the use of such a sample has allowed for specificity
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in attributing the results from each empirical study to the chronic use of cannabis, which
has been a difficulty in a large proportion of prior research studies.
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CHAPTER 2:

THE CHRONIC EFFECTS OF CANNABIS ON
MEMORY IN HUMANS: A REVIEW

LITERATURE REVIEW

MANUSCRIPT PUBLISHED IN CURRENT DRUG ABUSE REVIEWS
SEE APPENDIX E FOR PUBLISHED VERSION

Solowij, N., & Battisti, R. (2008). The chronic effects of cannabis on memory in
humans: A review. Current Drug Abuse Reviews, 1, 81-98.

I, Nadia Solowij, certify that Robert A. Battisti made a level of contribution to the
following chapter that is equivalent to a literature review towards fulfilment of the
degree Doctor of Philosophy (Clinical Psychology). The following review was an
invited manuscript for the inaugural issue of Current Drug Abuse Reviews.

Nadia Solowij
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2.1.

ABSTRACT

Memory problems are frequently associated with cannabis use, in both the short- and
long-term. To date, reviews on the long-term cognitive sequelae of cannabis use have
examined a broad range of cognitive functions, with none specifically focused on
memory. Consequently, this review sought to examine the literature specific to memory
function in cannabis users in the unintoxicated state with the aim of identifying the
existence and nature of memory impairment in cannabis users and appraising potentially
related mediators or moderators. Literature searches were conducted to extract wellcontrolled studies that investigated memory function in cannabis users outside of the
acute intoxication period, with a focus on reviewing studies published within the past 10
years. Most recent studies have examined working memory and verbal episodic memory
and cumulatively, the evidence suggests impaired encoding, storage, manipulation and
retrieval mechanisms in long-term or heavy cannabis users. These impairments are not
dissimilar to those associated with acute intoxication and have been related to the
duration, frequency, dose and age of onset of cannabis use. We consider the impact of
not only specific parameters of cannabis use in the manifestation of memory
dysfunction, but also such factors as age, neurodevelopmental stage, IQ, gender, various
vulnerabilities and other substance-use interactions, in the context of neural efficiency
and compensatory mechanisms. The precise nature of memory deficits in cannabis
users, their neural substrates and manifestation requires much further exploration
through a variety of behavioural, functional brain imaging, prospective and genetic
studies.
2.2.

INTRODUCTION

Short-term memory problems are among the most frequently self-reported
consequences of cannabis use by individuals who use the drug and are commonly
reported reasons for seeking to quit or reduce cannabis use. The perception that
cannabis impairs short-term memory has become ingrained in the general community
and in popular culture and lay literature. Even where a perception exists that cannabis is
a relatively benign drug, when asked whether it might have any deleterious effects,
short-term memory will often be the first thing that comes to mind in the average person
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asked on the street, and memory problems are the butt of numerous jokes and anecdotes
about cannabis users. Together with amotivation or apathy, (and perhaps paranoia),
memory problems define the prototypical and caricatured image of the chronic cannabis
user.
In the general scientific literature, impairment of memory is often cited in
association with cannabis use. Over the years since cannabis rose to become the most
widely used illicit drug in the developed world, general memory function has been
investigated in acute administration studies of cannabis to humans and animals, and in
studies of long term cannabis users. Despite the apparent prominence of potential
memory deficits in cannabis users, a search of the literature revealed that no reviews
specific to this topic have been published, other than a recent welcome review of the
acute effects of cannabis on memory in humans by Ranganathan and D’Souza (2006)
and an examination of the acute effects of cannabis on verbal and episodic memory in
relation to schizophrenia by Fletcher and Honey (2006) . Reviews of the general
literature on cognitive functioning in long term cannabis users have included studies of
memory among many other cognitive functions assessed but no reviews have focused
exclusively on memory or attempted to unravel the complexity of understanding the
nature of memory deficits, if they exist. Further, the most recent of any such reviews
were published some time ago (e.g. Iversen 2003; Solowij 1998) and hence mostly
reflect the literature prior to the late 1990s. Other recent reviews have examined
cognitive deficits only within a specific context (e.g., similarity to schizophrenia;
Solowij and Michie 2007)). A meta-analysis of a small number of studies of cognitive
function in cannabis users suggested that if any deficits exist in this population beyond
the acute intoxication period, they are most likely to occur in the domain of learning and
retrieval of information (Grant et al. 2003). This overall state of affairs prompted us to
undertake to examine the recent literature toward the compilation of this review of the
long-term effects of cannabis on memory in humans.
Ranganathan and D’Souza (2006) found in their review that acute administration
of cannabis impairs immediate and delayed free recall of information, while Fletcher
and Honey (2006) also cite evidence for difficulties in manipulating the contents of
working memory, failure to use semantic processing and organisation to optimise
episodic memory encoding, and impaired retrieval performance. We sought to examine
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the extent to which similar (or other) memory dysfunction was apparent in chronic
cannabis users in the unintoxicated state and to discern whether impairment may be
associated with specific parameters of cannabis use, such as duration, frequency, dose
or age of onset of cannabis use. We defined “unintoxicated state” for the purposes of
this review as the period beyond the several hours of acute intoxication that
immediately follows cannabis use. Thus, this state may reflect subacute intoxication and
residual effects, as discussed further below, and may extend to truly long-term effects
following substantial abstinence periods. Literature searches were conducted from the
period January 2000 – June 2007 using the broad search terms: cannabis (or synonyms)
and memory using Web of Science. This strategy returned more than 250 papers of
which abstracts were examined to identify studies that investigated memory function in
human cannabis users in the unintoxicated state. Surprisingly few studies from this date
range have examined memory function in long-term cannabis users; as a result, we also
cite within this review select studies prior to 2000 that investigated memory function
and were well-controlled. The primary studies that were considered in this review are
listed in Table 1 where details are provided regarding the nature of the samples
recruited, cannabis use measures and major findings pertinent to memory. Animal
literature will not be covered in this review, other than brief reference in support of
specific concepts. Reviews of preclinical findings pertinent to memory maybe found in
Egerton et al. (2006) and Solowij & Michie (2007) and clearly demonstrate deficits in
short-term and working memory and reversal-learning after acute and chronic
administration of cannabinoids to rodents and monkeys, implicating hippocampal and
prefrontal cortical dysfunction. Studies where cannabis users formed a control group
within an investigation of effects of other substances (e.g., MDMA) were considered
separately to the primary literature, as were studies of prenatal exposure in humans. We
have organised this review into sections addressing working memory, verbal episodic
memory and other general memory processes, reflecting the focus of the recent
literature.
While cannabis users, as well as the average person on the street, may not have
the necessary insight, knowledge or vocabulary to describe their perceived memory
problems to any degree of precision, it was our aim in conducting this review to enable
us, as researchers, and the scientific community to better define the nature of memory
deficits in cannabis users.
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2.3.

THE ENDOGENOUS CANNABINOID SYSTEM AND MEMORY

Before proceeding with our review of the literature, it is important to introduce the
involvement of the endogenous cannabinoid system (eCB) in functions pertinent to
memory. Notably, cannabinoid (CB1) receptors occur in high density in brain regions
critically involved in memory functions and cannabinoids profoundly affect synaptic
plasticity underlying learning and memory (Alger 2005), disrupting long-term
potentiation in the hippocampus (Chevaleyre et al. 2006; Hampson and Deadwyler
2000; Hoffman et al. 2003). Even a single exposure abolishes retrograde signalling
(Mato et al. 2004) and can induce lasting deficits in spatial learning and memory in
mice 3-4 weeks and 4 months after exposure (Tselnicker et al. 2007).
CB1 receptors are the most abundant metabotropic receptors in the brain and are
involved in multiple important physiological and behavioural events (Alger 2005;
Wilson and Nicoll 2002). They reside on presynaptic terminals in regions involved in
cognition, particularly learning and memory, critically in hippocampus, prefrontal
cortex (PFC), anterior cingulate, basal ganglia and cerebellum. The eCB system, via its
endogenous ligands anandamide and 2-arachidonoyl-glycerol (2-AG), mediates the flow
of information in the brain through retrograde signalling, modulating inhibitory and
excitatory neurotransmitter release crucial for synaptic plasticity, depolarisation-induced
suppression of inhibition or excitation, long term potentiation, and hence learning,
memory and other higher cognitive functions (Alger 2005; Chevaleyre et al. 2006;
Howlett et al. 2004; Piomelli 2003). eCBs are synthesised on demand through cleavage
of membrane precursors and are involved in various short-range signalling processes
(Piomelli 2003). Research has demonstrated alterations in the functioning of the brain in
CB1 rich regions and in cognitively-relevant neuromodulator systems (e.g.,
dopaminergic, cholinergic, serotonergic, GABAergic, glutamatergic) as a result of
exposure to cannabinoids (Chevaleyre et al. 2006; Iversen 2003; Piomelli 2003).
Alterations in the functionality of the eCB system, such as receptor downregulation,
desensitisation and downstream effector changes accompanying the development of
tolerance, dependence and resultant regional neuroadaptations, occur following chronic
administration

of

cannabinoids

(Hoffman

et

al.

2003;

Sim-Selley

2003).

Neurobiological studies have uncovered mechanisms involving the eCB system (too
complex and detailed to review here) that may inform the neural substrates underlying
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persistent deficits in cognition following repeated exposure to cannabis (see Egerton et
al. 2006; Ranganathan and D'Souza 2006; Solowij and Michie 2007).
2.4.

STRUCTURAL BRAIN ALTERATIONS ASSOCIATED WITH CHRONIC CANNABIS USE

Evidence for structural brain changes in cannabis users has been lacking from most
studies undertaken to date. Some recent studies have reported no global or regional
changes in brain tissue volume or composition (Block et al. 2000; Jager et al. 2007;
Tzilos et al. 2005), while others have found grey and white matter density changes
globally (Wilson et al. 2000) or in parahippocampal areas (Matochik et al. 2005). Using
more sensitive measures and assessing cannabis users with far greater exposure to
cannabis than previous studies, we have recently reported significant reduction of
hippocampal and amygdala volumes in long-term very heavy cannabis users (mean age
40, mean duration of use 20 years; Yücel et al. 2008). Hippocampal volumetric
reduction was dose-related, correlating with current daily dose, and cumulatively. It
may be that only excessive daily doses of cannabis, over a prolonged period of time,
will result in structural brain changes. Age of onset of cannabis use may also be a
critical factor, with potentially greater deleterious effects to the brain when cannabis use
is commenced during significant periods of neurodevelopment, such as adolescence.
Early onset cannabis users (before age 17) were found to have smaller whole brain
volumes, lower percent cortical grey matter, higher percent white matter and increased
resting cerebral blood flow compared to later onset users (Wilson et al. 2000).
Recent evidence of diminished neuronal and axonal integrity in the dorsolateral
prefrontal cortex (DLPFC) indicated by magnetic resonance spectroscopic markers of
metabolism (the ratio NAA/tCr) was reported by Hermann et al. (2007). Dose-related
changes in this study were also found in anterior cingulate and putamen/globus
pallidum, but not in hippocampus. Strong evidence for cumulative dose-related neuronal
damage, however, comes from the animal literature where chronic cannabinoid
administration has been shown to induce neurotoxic changes within the hippocampus,
including decreases in neuronal volume, neuronal and synaptic density, and dendritic
length of CA3 pyramidal neurons (Chan et al. 1998; Landfield et al. 1988; Lawston et
al. 2000; Scallet et al. 1987). Since functional impairment is likely to precede major
structural alterations in the brain, or to manifest concomitant to more minor neural
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alterations, there is, therefore, good reason to suspect long-term effects of cannabis use
on memory function.
2.5.

STUDIES OF MEMORY IN CHRONIC CANNABIS USERS

2.5.1. Working Memory
Working memory is disrupted by acute cannabis use (D'Souza et al. 2004), including
spatial n-back (Ilan et al. 2004) and delayed matching to sample (DMTS) tasks (Lane et
al. 2005). There is a substantial animal literature reporting impaired working memory
following acute and chronic administration of cannabinoids (see Egerton et al. 2006;
Solowij and Michie 2007)), including an impaired DMTS task performance that
resembles lesions or removal of the hippocampus (Hampson and Deadwyler 2000). A
general paucity of studies investigating working memory and related functions in
chronic cannabis users in the unintoxicated state is now being rectified with a growing
recent literature.
Kanayama et al. (2004) used functional magnetic resonance imaging (fMRI) to
investigate spatial working memory in long-term heavy cannabis users employing a
relatively simple task. Users made nonsignificantly more errors on the task, although
very few errors in both groups reflected the simplicity of the task and it has been
suggested that performance deficits in chronic cannabis users are more likely to be
elicited in complex tasks (e.g., Solowij 1998) or tasks with a greater memory load
(Jager et al. 2006). However, greater and more widespread brain activation was
displayed by cannabis users in Kanayama et al.’s study, with increased activation of
regions typically used in spatial working memory tasks, such as prefrontal cortex and
anterior cingulate, and additional recruitment of areas not typically used in such tasks,
such as basal ganglia regions. The authors interpreted their findings in terms of cannabis
users experiencing subtle neurophysiological deficits for which they compensate by
working harder and calling upon additional brain regions to meet the demands of the
task. Increased activation of the anterior cingulate in particular was thought to reflect an
increased effort to overcome cannabis-induced attentional impairments and to
coordinate activity from the wide range of regions recruited to perform the task.
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An fMRI study of a small sample of adolescent cannabis users performing an nback working memory task with additional selective attention load focused analyses on
the hippocampus (Jacobsen et al. 2004). Despite a mean abstinence of 10 months, the
cannabis users performed less accurately on the task overall compared to non-smokers
and on some measures compared to tobacco smokers, with poorest performance on the
most difficult condition (selective attention load) but with no additional decrement as a
function of memory load. Further, users failed to deactivate the right hippocampus
across task conditions in contrast to both control groups, which the authors suggested
may reflect a dysfunction of inhibitory hippocampal interneurons.
In a further study of abstinent adolescent (aged 13-18) cannabis and tobacco
smokers compared to tobacco only smokers, this group (Jacobsen et al. 2007) found
fMRI evidence of altered neurocircuitry during the performance of an n-back auditory
working memory task in the cannabis group, but only during nicotine withdrawal.
Subjects were tested twice, once during an ad libitum cigarette smoking condition and
again after 24 hours abstinence from tobacco, and cannabis users were abstinent from
cannabis for at least 2 weeks prior to testing. In the tobacco abstinence condition,
cannabis users showed increased task-related activation of posterior cortical regions and
disrupted frontoparietal connectivity during a high verbal working memory load.
Performance on the n-back task deteriorated with memory load in cannabis users in both
smoking and abstinence from tobacco conditions, whereas poorer retention on the
HVLT-R (outside of the scanner) was only evident in cannabis users during withdrawal
from nicotine. Interestingly, the changes present during nicotine withdrawal were
apparent solely in cannabis users, not in tobacco smokers, and were in spite of a limited
history of cannabis use and a substantial abstention period (mean 4.8 months, range 0.5
- 24). The authors suggested that nicotine use may mask the effects of cannabis,
protecting against some of its cognitive impact in correcting performance and neural
activity. Increased regional activation in cannabis users during nicotine withdrawal may
reflect compensatory processes that are engaged in an (unsuccessful) attempt to achieve
satisfactory task performance, in accord with the Kanayama et al. (2004) study.
In a Sternberg-type working memory task administered in an fMRI study, Jager
and colleagues (2006) found no performance deficits among moderately frequent young
adult cannabis users after one week of abstinence. Few overall regional brain activation
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differences were found between users and controls, but users showed a smaller decrease
in activity in the left superior parietal cortex in response to a decrease in memory load
than did controls, and this correlated significantly with past year exposure to cannabis.
This region is known to be involved in short-term storage and retrieval of verbal
information. The authors interpreted these findings as reflecting similar activation of
working memory systems between cannabis users and controls, but with cannabis users
requiring greater activation to achieve similar performance, which may be insufficient
with more challenging tasks.
Using a very different ‘real-world functioning’ approach, one study examined
mood and cognitive performance in a sample of workers with and without recent
cannabis use, before and after work at the start and end of the working week
(Wadsworth et al. 2006). Details regarding levels of cannabis use in the sample were
scant and preclude firm conclusions. A verbal reasoning task was employed to measure
“working memory”. Other memory tasks included immediate and delayed free recall
and recognition of 20 words presented on a computer screen and a semantic processing
task measuring speed of retrieval of knowledge from general memory. Poorer
performance in verbal reasoning was apparent in cannabis users at the start of the
working week and correlated with frequency of cannabis use. This effect was
interpreted as a ‘hangover’ from weekend use of cannabis. Poorer performance in
delayed recall was found in cannabis users pre-work at the end of the working week and
was correlated with duration of cannabis use. Cannabis users also showed slower
response organisation and lower alertness than non-users generally, and slower
psychomotor speed toward the end of the week, reflecting a lack of improvement in
speed over the working week in contrast to controls, rather than a progressive slowing
by cannabis users. The findings of this study suggest that impaired performance in
cannabis users may only manifest under certain conditions, for example when tired or
under a heavy cognitive load, and the results are informative with regard to hangover
effects and impacts on real world work performance.
A recent paper by Harvey et al. (2007) reported an investigation of working
memory and other executive and attentional functions in adolescent cannabis users
using select tests from the Cambridge Neuropsychological Test Automated Battery
(CANTAB). Memory-related subtests included: Rapid Visual Information Processing
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(RVIP) – a test of sustained attention with a working memory component; Spatial
Working Memory (SWM) – assessing strategy use and memory updating ability for
different spatial locations; Paired Associates Learning (PAL) – testing associative
learning of patterns and spatial locations of increasing difficulty; and, Spatial Span –
spatial memory span for order and location. Additional CANTAB subtests included
Motor Screening and Intra/Extra Dimensional Shift (IED) – measures of visual and
motor problems, and attention and cognitive flexibility, respectively. Participants also
completed the Rey Auditory Verbal Learning Test (RAVLT), measuring verbal memory
encoding, storage and retrieval, Digit Span to assess attention and working memory, and
the Symbol Digit Modalities Test for sustained attention. Regular cannabis users
differed significantly from non-regular users on RVIP errors, SWM total errors and
strategy use, and on total words recalled on trials 1 to 5 of the RAVLT. Cannabis use
was a significant independent predictor of SWM and RAVLT performance. No
significant differences were found on PAL, Spatial or Digit Span, Symbol Digit
Modalities, or the additional, non-memory related, CANTAB subtests. The findings of
this study provide further evidence for a potentially greater impact of cannabis upon
certain aspects of memory function in the developing adolescent brain, given the
substantially more limited exposure to cannabis in this young sample.
We have preliminary data from adult long-term heavy cannabis users and
matched non-user controls on several measures from the CANTAB (Respondek et al.
2004). We found that cannabis users’ performance was poorer than non-users on most
measures but differed significantly only on SWM errors and strategy, spatial recognition
memory and the IED, which requires shifting of attention and reversal learning.
Performance on SWM worsened as a function of the duration of cannabis use. Further
analyses of these data are in progress and will enable a better comparison of similarities
and differences between our findings in adult long-term heavy cannabis users and those
in the adolescent cohort reported by Harvey and colleagues (2007).

2.5.2. Verbal episodic memory
Verbal learning and memory have been, perhaps, the most consistently impaired
cognitive functions in studies of acute cannabis administration as well as in chronic
cannabis users. In acute studies, poorer performance has been observed in immediate
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and delayed recall of words (D'Souza et al. 2004), greater intrusion errors (Ilan et al.
2004) and, at high doses, no learning whatsoever occurring over trials (Curran et al.
2002). A reduced brain event-related potential (ERP) difference between previously
studied words and new distracter words was observed in subjects most affected
subjectively by the acute intoxication, suggesting disruption of neural mechanisms
underlying memory for recent study episodes (Ilan et al. 2004). Impairment on word list
learning tasks has been consistently demonstrated in recent neuropsychological studies
of heavy or long-term cannabis users in the unintoxicated state.
Word list learning tasks, such as the RAVLT, California Verbal Learning Test
(CVLT), Hopkins Verbal Learning Test Revised (HVLT-R), Buschke’s Selective
Reminding Task (BSRT) and variants (henceforth collectively referred to as verbal
learning tasks (VLTs)), require learning and recalling a supra-span list of words (12-16)
over a series of trials (usually 3 – 6) and sometimes following an interference trial.
Words can be presented from semantic categories (as in the CVLT), which enables the
use of organisational strategies to facilitate efficient encoding. Recall and recognition
memory may also be assessed after a delay (eg. 20-30 minutes). Thus, VLTs measure
the ability to encode, consolidate, store and retrieve verbal episodic information and are
highly sensitive to neurological impairment (Lezak et al. 2004), though age, intelligence
and educational experience also impact upon performance (Schmidt 1996). Deficits in
cannabis users have been demonstrated in all VLT task measures and have variously
been attributed to duration of cannabis use (Messinis et al. 2006; Solowij et al. 2002),
frequency of cannabis use (Pope et al. 2001; Pope and Yurgelun-Todd 1996) or
cumulative dosage effects (Bolla et al. 2002). Generally, long-term heavy cannabis
users learn fewer words on each trial and overall, recall fewer words and forget more
words following interference or a delay than short-term or light cannabis users or nonuser controls. Recognition performance may also be poor, albeit less consistently, while
intrusion errors may be present but are not routinely monitored or reported in studies.
Pope and Yurgelun-Todd (1996) compared performance on the CVLT of heavy
(≥ 22 days use in the past month, median 30 days) and light (< 9 days in the past month,
median 2 days) users of cannabis, following at least 19 hours of supervised abstinence.
The duration of use of the sample was not reported, although the median age of 20-21
suggests limited years of use. Heavy and light users differed significantly, with poorer
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performance by heavy users in the number of words recalled on almost every trial, in
the sum of all five trials, following the presentation of an interference list, following
cueing and in delayed recall (40 minutes later), but there was no temporal decay of
recall in either heavy or light users. These results suggested reduced learning in heavy
cannabis users, but the ability to retain newly learned information after a delay appeared
to remain relatively intact. In a 17 year follow-up of chronic users, Fletcher et al. (1996)
found that only older long-term cannabis users differed from controls in list learning,
while young users were unaffected.
More recent studies have replicated impairment in learning, recall and delayed
recall, with some evidence of decay. We found that 17-hour abstinent long-term heavy
(near daily) cannabis users (mean 24 years of use) recalled fewer words than shorterterm heavy users (mean 10 years of use) and non-user controls over all learning trials of
the RAVLT and lost significantly more words following a 20 minute delay (Solowij et
al. 2002). Recognition performance was also significantly poorer in long-term users and
measures of recall and recognition correlated significantly and inversely with the years
of cannabis use, after controlling for age and IQ. Despite near daily use also in the
shorter-term users, they did not differ from controls, supporting a greater impact of long
duration of cannabis use rather than frequency of use. Long-term users also showed a
smaller primacy effect, but groups did not differ in recency or words recalled from the
middle of the list. Messinis et al. (2006) essentially replicated these findings in a sample
of long-term (10 or more years of use) and short-term (5-10 years of use) cannabis users
with a substantially longer duration of abstinence prior to testing (a mean 122.8 hours),
compared to controls (with a very limited history of use). They found poorer
performance by long-term users on most trials of the RAVLT and on delayed recall and
recognition. In this study, however, the short-term users’ performance was also
significantly poorer than controls on trials 5, 6, delayed recall and recognition, whereas
in our study short-term users did not differ from controls on any measure from the
RAVLT. Both long- and short-term users in the Messinis et al., study differed from
controls on the Trail Making Test Part A (processing speed) and Part B (executive
functioning including working memory). Multiple measures from the RAVLT were also
found to correlate inversely with the duration of cannabis use. The authors interpreted
these findings as indicative of a generalised memory deficit, as verbal learning,
retention and retrieval were all impaired.
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Both our study (Solowij et al. 2002) and that of Messinis et al. (2006), employed
rigorous criteria for inclusion of cannabis users in the study to eliminate potential
confounds. While most results from these two studies are consistent and show that longterm heavy use of cannabis impairs verbal learning and memory, it is not clear why
differences were found with regard to short-term cannabis users. The larger sample size
(n=51 vs. n=20), relatively greater duration (mean 10.2 vs. 6.95 years) and frequency
(28.3 vs. 20.7 days/month) of cannabis use in our short-term users cohort, as well as the
significantly shorter period of abstinence prior to testing (median 17 hours vs. mean
122.8 hours), might have predicted a greater probability of cognitive deficits occurring
in the short-term users of our study. Further, our cohort may have used a significantly
greater quantity of cannabis per day (an average 2 joints), whereas Messinis et al.’s
threshold for entry to the study was 4 joints per week, but actual quantities used were
not reported. The only other differences between the two cohorts were that Messinis et
al.’s subjects were slightly younger (24.25 vs. 28.7 years) and less educated (10.8 vs.
14.1 years), with several points lower IQ (101.1 vs. 105.1). Perhaps this combination of
factors confers a greater vulnerability to cognitive deficits following heavy cannabis
use.
Other studies have investigated the persistence of cognitive deficits or recovery
of function following much longer periods of abstinence from cannabis. Bolla and
colleagues (2002) found a significant dose-related response on delayed recall from the
RAVLT in 28-day abstinent former heavy cannabis users: the number of words recalled
diminished as a function of the number of joints smoked per week but performance was
unrelated to duration of cannabis use. The mean duration of use in the sample, however,
was only 4.8 years (range 2 – 15 years). Heavy users were not impaired in recognition
performance in contrast to light users, leading the authors to speculate that heavy
cannabis use is associated with difficulty in recalling information, rather than with
acquisition or retention of information. However the sample size of this otherwise wellcontrolled study was exceedingly small (n=22 users in total, only 7 classified as heavy
(mean 94 joints per week)), which may have lead to insufficient power to detect
recognition deficits. Alternatively, recognition performance may be more amenable to
recovery following abstinence. Despite the small sample size, the strength of this study
is in its assessment of cognition beyond the wash-out period for the majority of
cannabinoid residues, with cannabis users residing on an inpatient clinical research ward
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for 28 days. This may rule out the attribution of any deficits found to the residual effects
of acute cannabis intoxication (although up to 4 months abstinence may be required to
eliminate all remaining accumulated cannabinoid metabolites in some users). Bolla and
colleagues showed a trend toward persistent poorer performance by heavy users than
light users on all measures of verbal learning and memory in their study (including
Logical Memory and Digit-Symbol Paired Associate Learning which also showed a
dose-related decrement), with a large magnitude of difference between heavy users and
light users (1.0 – 3.3 SD units) and poorer performance than age-matched norms on
some tests (e.g., Rey Complex Figure Copy and Delayed Recall). They suggested that
the pattern of results was characteristic of subcortical, prefrontal involvement and
normal aging, implying that heavy use of cannabis may result in premature cognitive
decline. Further, they also found that IQ interacted with dose on several measures (e.g.,
Symbol-Digit Paired Associate Learning, but not RAVLT performance) whereby lower
IQ individuals were significantly more impaired with increasing number of joints
smoked per week. This suggests that perhaps higher IQ individuals are better able to
compensate for cannabis-related cognitive impairment.
Similar deficits in recall of word lists from the BSRT was found by Pope and
colleagues (2001) in heavy cannabis users (at least 7 uses per week and at least 5000
lifetime episodes of use) who were abstinent for 0, 1 or 7 days at testing, but these
deficits appeared to recover after 28 days of supervised abstinence with no significant
differences evident between former heavy users or controls at that time. Performance on
delayed recall was significantly worse in heavy users still on day 28, but not after
controlling for IQ. No associations were found between performance on day 28 of
abstinence and lifetime episodes of cannabis use, but some association was apparent
with levels of the urinary cannabinoid metabolite taken at baseline (day 0). The authors
interpreted their data to suggest that cannabis-associated memory deficits may be
reversible phenomena associated with recent drug exposure. This contrasts with our
analyses (Solowij et al. 2002) showing that impaired performance was not a
consequence of recent use prior to testing (hours of abstinence) or cannabinoid residues
(urinary cannabinoid metabolite level on the day of testing), and while recency of use
was also a predictor of performance, duration of use was generally a superior predictor.
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Pope et al.’s (2001) findings also contrast with Bolla et al.’s (2002) with regard
to the persistence of cannabis-related effects after 28 days of abstinence. It is possible
that the repeat-measures, and hence practice, inherent in Pope et al.’s study enabled
cannabis users to overcome persistent deficits, particularly since they were of a
significantly higher IQ than the users of Bolla et al.’s study, but they were also
significantly older (36 vs. 20 years) and may have consumed less cannabis over time
than did those of Bolla et al.’s study. Pope et al., report a median 18,720 lifetime
episodes of cannabis use (episodes being separated by at least one hour) but no quantity
measures are provided and less than one joint may be used per episode. Bolla et al.’s
heavy users were using approximately 94 joints per week at the time of admission to the
study and had used cannabis for a mean 5.3 years, which could extrapolate to 25,906
lifetime joints, although this heavy pattern of use may well have not been consistent
over the duration of their lifetime cannabis use. Nevertheless, it would appear that four
critical factors could explain the persistence of deficits in Bolla and colleagues’ study in
contrast to that of Pope and colleagues: a significantly greater amount of cannabis was
consumed by Bolla et al.’s sample over a significantly shorter period of time by
significantly younger users of significantly lower IQ. Thus, excessively heavy use in
young adults of lower IQ may result in persistent impairment of memory (and other
cognitive functions) that may require a much longer period of abstinence to recover.
This is in line also with our findings of structural brain alterations in excessively heavy
users (albeit in much older users) and earlier work of ours showing greater cognitive
impairment in lower IQ users (Solowij 1998). The young age of Bolla et al.’s sample
also raises concern regarding possibly greater deleterious effects in the young adult or
adolescent brain: age of onset was not reported but can be calculated as being 14 – 15
years in the heavy users.
Interestingly, in a re-analysis of their data, Pope’s group found that deficits on
the BSRT, and in particular on 30 minute delayed recall, were more likely to persist
after 28 days abstinence among those who had commenced cannabis use prior to age 17
(Pope et al. 2003). Although the authors sought to explain this in terms of potential
“cultural divergence”, the finding accords with several other studies that have also
found evidence for greater adverse effects among those commencing cannabis use
earlier during adolescence as opposed to young adulthood, most often before versus
after the age of 17. Early onset cannabis use was shown to impair attentional processes
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measured by reaction time during visual scanning (Ehrenreich et al. 1999), visual search
and short-term memory (Huestegge et al. 2004; Huestegge et al. 2002), and result in the
most reduced P300 amplitudes in an attention task (Kempel et al. 2003). Early onset
effects on brain volume, grey and white matter, and cerebral blood flow (Wilson et al.
2000) were reported above. That the adolescent brain may be more vulnerable to the
impairing effects of cannabis on memory (among other attentional and executive
functions) is evident from the few studies that have now been conducted on adolescent
samples of cannabis users. Attention to this specific population has been slow to
translate into the research arena; Schwartz et al. (1989) were the first to observe
persistent short-term visual memory impairment in 6-week abstinent adolescent
cannabis users. The study by Harvey et al. (2007) discussed above, shows evidence of
impaired performance on the RAVLT in regular adolescent cannabis users (mean age
16.1, range 13-18), with additional evidence for impaired working memory in
adolescents in this study and the fMRI studies of Jacobsen et al. (Jacobsen et al. 2004;
2007) (mean age around 17 years; age of onset around 13.6 years). Recently, Medina
and colleagues (2007a) reported poorer story memory (Logical Memory from the
Wechsler Memory Scale III (WMS-III)), as well as poorer planning and sequencing
ability, complex attention and slower psychomotor speed in a neuropsychological study
of adolescent cannabis users after a minimum 23 days monitored abstinence. These
measures were significantly associated with lifetime episodes of cannabis use after
controlling for lifetime alcohol use. Lifetime cannabis use was marginally associated
with CVLT performance, although this did not differ markedly from controls. Several
other studies of adolescent cannabis users are further discussed below (Fried et al.
2005b; Medina et al. 2007b; Schweinsburg et al. 2005).
A further investigation of the potential persistence of cognitive deficits in
cannabis users comes from a study of monozygotic twins discordant for cannabis use.
Lyons and coauthors (2004) administered an extensive neuropsychological test battery
assessing a broad range of cognitive functions. The cannabis-using twins had not used
cannabis for at least one year, but the last regular cannabis use had occurred almost 20
years ago in this cohort. The mean age of participants at the time of testing was 46.3, the
mean age of last regular use of cannabis was 27.1, the mean age of initiation 21.3 and
the mean duration of use was 5.8 years, with an estimated mean 916 days of use over
the lifetime. Memory assessments included the CVLT, subtests of the WMS–Revised
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(WMS-R), and the Rey-Osterrieth Complex Figure Test. Cannabis-using twins differed
significantly in general intelligence and not in the composite scores across the memory
domain. However, long delay free recall on the CVLT was significantly poorer in the
cannabis users in univariate tests, with a trend apparent also for long delay cued recall,
and these measures together with Block Design and non-dominant Finger Tapping were
the only significant findings from the entire battery, with the largest effect sizes. There
was no relation between performance and lifetime days of cannabis use. The authors
downplayed their findings, concluding that their study did not support the existence of
meaningful long-term effects of previous cannabis use in long-abstinent individuals, and
reasoned that the CVLT findings would have been more meaningful had there been
evidence of similar trends toward impairment on the other CVLT measures and on the
Logical Memory subtest of the WMS. It should be noted that the minimal extent and
duration of cannabis use in this sample, and commencement of use at a relatively older
age, may have lessened the extent of development of memory impairment in contrast to
other studies, but indices of deficient memory functioning were nevertheless detected 20
years after regular cannabis use. Poorer performance on precisely the measures that
other studies of both current and abstinent cannabis users have found to be impaired,
and in general intelligence, in otherwise genetically- and environmentally-matched
twins speaks to cannabis-related effects and further prospective studies of much heavier
cannabis users, perhaps who had commenced at an early age, with similarly long
abstinence periods would be informative.
One study has used functional brain imaging to investigate verbal memory
processes in cannabis users. Block and colleagues (2002) used positron emission
tomography (PET) to examine memory-related regional cerebral blood flow in frequent
users after a minimum 26 hours supervised abstinence. Subjects learned a list of words
(from the RAVLT) over multiple trials to a criterion of two perfect recalls, using
Buschke’s selective reminding technique, one day prior to the scanning session.
Cannabis users required significantly more trials than controls to achieve the learning
criterion but then performed the task in the scanner as well as controls. However, upon
introduction of a novel list of words, users showed an increased recency effect, recalling
more words than controls from the end of the word list and fewer from the middle,
suggesting a greater reliance on short-term or working memory and poorer encoding
ability. This pattern of altered distribution of memory processes would contribute to
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poor list learning over trials. Cannabis users showed decreased memory-related blood
flow in the PFC, increased flow in memory-relevant regions of the cerebellum, and
altered lateralisation in the hippocampus relative to controls, with the greatest
differences apparent in episodic encoding during new list learning (i.e., differences in
brain activation were less evident for the well-learned list than for the novel one).

2.5.3. Other memory processes
Hippocampal-dependent associative memory has been assessed in an fMRI study of one
week abstinent moderate cannabis users (median 1900 lifetime joints) compared to nonuser controls using a pictorial memory task (Jager et al. 2007). Performance on the task
did not differ between groups but recall accuracy decreased as a function of past year
and lifetime estimates of cannabis use. Decreased activation in cannabis users was
observed in left and right parahippocampal regions and in the right DLPFC during
associative learning, but no differences were apparent during recognition and activation
differences did not correlate with cannabis use or voxel-based morphometric measures
of parahippocampal volume. For this reason the authors surmised that lower brain
activation may not reflect neurocognitive impairment but may be related to some other
covariate of frequent cannabis use, but this is difficult to reconcile with their
performance data indicating deterioration in recall accuracy to be progressive with
extent of cannabis exposure. In contrast to other studies that found increased activation
during memory-related tasks and interpreted these as compensatory mechanisms
(reviewed above), this study found lowered activation, which accords with the
hypoactivity observed in other studies that have utilised Stroop and decision-making
tasks in fMRI studies of cannabis users (Bolla et al. 2005; Eldreth et al. 2004). Results
are likely to reflect differing tasks, regions of brain activation investigated and methods
of analysis, as well as differing extent of exposure to cannabis and abstinence periods.
Hermann et al. (2007) found significant deficits in neuropsychological tests of
visual short-term memory (Benton Visual Retention Test) and auditory verbal shortterm memory in a small sample of near-daily cannabis users (mean age 22, duration of
use around 5 years). Further, performance on the Wisconsin Card Sorting Test and Trail
Making Test (both of which depend on efficient working memory) varied as a function
of delta-9-tetrahydrocannabinol (delta-9-THC) or cannabidiol detected in hair analysis,
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as did magnetic resonance spectroscopic metabolite ratios in anterior cingulate and
putamen/globus pallidum, while, as reported above, a ratio indicative of diminished
neuronal and axonal integrity in DLPFC was significantly lower in cannabis users.
2.6.

STUDIES OF OTHER SUBSTANCE USERS WITH CANNABIS USERS AS A COMPARISON

GROUP

Cannabis users often use other substances, most commonly alcohol and tobacco, but
polydrug use of other illicit substances is also frequent. Most of the studies reviewed
above have excluded other substance use as a confound and have sought to recruit
cannabis users who are relatively free of regular use of illicit drugs in order to isolate
effects associated with cannabis use itself. It is possible that the effects of smoking
tobacco and drinking alcohol may be additive or synergistic with cannabis in the
induction of memory or other cognitive impairment, and some studies have sought to
examine these potential interactions (e.g., Jacobsen et al. 2007 as reviewed above,
others below). Other studies have not sought specifically to investigate the cognitive
effects of cannabis itself, but have employed cannabis users as control groups in
investigations of the memory impairing effects of other substances (largely those
investigating the effects of Ecstasy (3,4-methylenedioxymethamphetamine (MDMA)).
Recent studies of these types, where some inferences may be made with regard to
specific effects of cannabis, are reviewed in this section.
Schweinsburg et al. (2005) used fMRI to compare SWM performance in
adolescent (aged 15-17) cannabis and alcohol abusers, with solely alcohol abusers, and
non-user controls. The cannabis users had been abstinent for approximately one week.
There were no significant performance differences between any of the groups on the
SWM task but brain activation differences were apparent between all three groups. The
cannabis users showed lower activation in inferior frontal and temporal regions and
greater activation in prefrontal regions than non-user controls. Lower inferior frontal
and temporal, but greater medial frontal activation, was observed in the cannabis and
alcohol user group compared to the alcohol abusers, which the authors interpreted as
reflecting compensatory mechanisms. These observations were not present between the
alcohol and non-user control groups. Given that the cannabis and alcohol groups were
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equivalent in alcohol, and other drug use history, differences were attributed to cannabis
exposure, despite this being quite limited in this young sample.
Similar groups to those in the Schweinsburg et al. (2005) study were recruited
by Medina et al. (2007b) in a neuropsychological and structural MRI study. Examining
the combined effects of alcohol and cannabis on cognitive function and hippocampal
volume, cannabis and alcohol-abusing participants did not differ from alcohol only
abusers or controls on assessments of vocabulary or verbal memory (CVLT). No overall
group differences were found in hippocampal volumes, although cannabis and alcohol
users had larger left than right hippocampal volumes, with the reverse for alcohol only
users. A clear functional relationship between verbal learning and hippocampal
asymmetry was found in non-user controls, but appeared abnormal in cannabis and
alcohol users. Further investigation of brain function and morphology in adolescents,
and adults, who use cannabis and alcohol is clearly warranted.
Ecstasy or MDMA is a popular recreational drug that produces feelings of
euphoria and increased energy, with cannabis used frequently to offset withdrawal
(Croft et al. 2001). Cognitive deficits, and particularly memory impairment, are
associated with ongoing use of MDMA (Parrott et al. 2001; Rodgers 2000), and thus it
may be reasoned that combined use with cannabis may result in further deficits.
However, inconsistent findings within the literature suggest that the interaction is not
straightforward, and indeed there have been suggestions that cannabis use may be
neuroprotective against MDMA-related memory deficits due to differing actions acutely
with regard to oxidative stress and other mechanisms (e.g., dopaminergic; Croft et al.
2001; Gouzoulis-Mayfrank and Daumann 2006; Parrott et al. 2001).
Rodgers (2000) compared the performance of MDMA/cannabis users and
cannabis-only users with non-user controls on the WMS-R and found that both
MDMA/cannabis and cannabis-only users performed worse than controls on the Logical
Memory I and II subtests. Self-reported abstinence from cannabis was for 1 month
(unverified). The authors posited that logical memory problems may have been
associated more with cannabis use, whereas MDMA use impaired delayed recall and
visual and verbal paired associate task performance. An additional study by Rodgers et
al. (2001) investigated memory problems associated with cannabis versus MDMA in a
large sample of respondents (n=488) to a web-based assessment. Drug use was assessed
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by a web-modified-version of the University of East London Recreational Drug Use
Questionnaire and memory was assessed by the Everyday Memory Questionnaire
(EMQ) - a measure of common memory lapses, and the Prospective Memory
Questionnaire (PMQ) - a measure of short-term habitual memory, episodic memory,
internally cued memory, and strategies used to aid memory. The authors used regression
techniques to isolate the contribution of each substance to variance in the cognitive
measures and found a double-dissociation. Cannabis use was significantly and uniquely
associated with everyday memory problems (as measured by the EMQ), and poorer
short-term and internally cued memory (as measured by the PMQ), and these effects
were dose-related, increasing with monthly frequency of cannabis use. Greater
frequency of MDMA use, on the other hand, significantly and uniquely predicted longterm memory scores on the PMQ, relating to storage and retrieval mechanisms, and also
predicted more errors in completing the online assessments. Use of strategic techniques
to aid memory correlated negatively with use of both substances, but significantly more
for cannabis. While there are limitations regarding validity and reliability in web-based
research of this kind and the lack of objectivity of most of the measures, this study was
the first to demonstrate a dissociation between self-reported memory effects associated
with cannabis versus MDMA and has intrinsic value in quantifying the nature of
memory problems that users perceive themselves to be experiencing. The methodology
of this study may have resulted in the recruitment of a more highly educated sample, but
this may have served to provide greater insight and better self-evaluation of memory
problems. The interesting findings are worthy of further exploration.
Comparing groups of non-user controls, cannabis only and cannabis/MDMA
users, Croft et al. (2001) found few differences in memory function between cannabis
only and cannabis/MDMA users, but moderate memory and processing speed
impairment was evident when comparing cannabis/MDMA users with non-user
controls. This was across a battery of memory assessment instruments, including a VLT
(Coughlan list and design learning), digit span, Warrington recognition memory,
associative learning, as well as tests of other cognitive domains. While cannabis only
and non-user control groups were not examined separately, (not being the primary
groups of interest), the authors argued that the lack of difference between the two drugusing groups implied deficits to be cannabis-related and not due to MDMA, since
cannabis use was common to both groups. Where minimal differences were found on
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memory tests between these groups (eg. working memory for design learning), these
were, however, in the direction of better performance by the combined
cannabis/MDMA group. It is noteworthy that this group had a more extensive history of
cannabis use (estimated mean lifetime joints 10964.9) compared to the cannabis-only
using group (7762.4), and the authors posited a complex interaction between these
substances whereby cannabis use may have attenuated MDMA-specific deficits.
Simon and Mattick (2002) recruited cannabis-only and MDMA users with
similar exposure to cannabis (around 65 joints per month) and equivalent IQ to examine
the effects of MDMA on memory. The WMS-III was used to assess memory deficits.
No significant group differences were detected, although frequency of cannabis use
showed a trend toward predicting performance on visual immediate memory. The lack
of a non-drug using control group in this study and limited variability within the cohorts
to examine dose-response relationships may have limited the potential to detect specific
substance-related memory effects (Parrott and Milani 2003).
In a study of verbal memory using a German version of the RAVLT, MDMA
users with concomitant cannabis use, but not cannabis-only users, differed on most
performance measures from non-user controls (Quednow et al. 2006). In contrast to the
Croft et al. (2001) study, cannabis use was lower among MDMA users than cannabisonly users (estimated mean lifetime episodes of use 547.1 vs. 1033.4 respectively). The
cannabis-only users of this study were relatively young (mean age 23.42) and were not
heavy users: they had used cannabis for a mean 6.55 years, thus averaging about 13
joints per month (or less than 4 times per week as reported by the authors). This small
sample also had a relatively higher IQ than the comparison groups of this study. These
factors may explain the lack of significant impairment in RAVLT performance.
2.7.

STUDIES OF PRENATAL/PERINATAL EXPOSURE

A long-standing concern that potential neurotoxic effects of drugs may affect critical
periods of neurodevelopment has prompted investigation of the effects of substance use
during pregnancy on outcomes in offspring. To date, there have been a limited number
of investigations of prenatal exposure to cannabis, with memory-specific findings even
more sparse. Two large cohort investigations have been following the cognitive and
psychosocial development of offspring of cannabis-using and non-using women over
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many years: the Ottawa Prenatal Prospective Study (OPPS; Fried et al. 2002); and the
Maternal Health Practices and Child Development Study (MHPCD; Richardson et al.
2002)). Both of these studies assessed mothers on a range of demographic variables and
have sought to account for numerous potential confounds to determine any effect of
prenatal exposure to cannabis.
Since 1978 the OPPS has assessed their low-risk – Caucasian and predominantly
middle-class – cohort every few years (Fried and Watkinson 2001), with the most recent
published findings examining offspring at ages 18 to 22 (Smith et al. 2006). During
pregnancy, mothers were reported to have used either: no cannabis; less than six joints
per week; or greater than or equal to six joints per week. The MHPCD, commenced in
1982, contrasts with the OPPS in that the cohort comprises high-risk individuals – of
both Caucasian and African American parentage (47% and 53%, respectively), of a low
socio-economic background and raised mostly by single mothers – who are thus less
protected by potentially ameliorating demographic variables (Leech et al. 1999).
Multiple longitudinal observations have been made with the most recent published from
the MHPCD examining offspring at the age of 10 (Goldschmidt et al. 2004). Level of
cannabis use during pregnancy was assessed in the MHPCD during each trimester with
mothers classified into three categories: no use; less than one joint per day; or greater
than or equal to one joint per day. These levels of use are comparable to the OPPS with
children in both studies being classified as having been exposed prenatally, to
potentially no, light-to-moderate, or high levels of cannabis.
Evidence of memory impairment across both samples has been minimal with a
review of both these cohorts describing prenatal cannabis exposure as impacting upon
memory inconsistently over repeated measurements of the same individuals (Huizink
and Mulder 2006). At age 4, decreasing memory performance on memory subscales of
the McCarthy Scales of Children’s Ability was observed with increased prenatal
marijuana exposure in the OPPS cohort (Fried and Watkinson 1990). This effect was
not maintained among 9 to 12-year-olds, with increasing impairment with increased
prenatal exposure holding true solely for aspects of executive functioning related to
visual analysis, visual hypothesis testing and impulse control. Memory performance, as
assessed by subtests of the WISC-III, the Auditory Working Memory Test, and the
Gordon Diagnostic Delay and Vigilance Tasks, was not impaired (Fried et al. 1998).
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Lack of impairment could be accounted for by the fact that some memory-related
executive processes do not develop until several years later. At ages 13 to 16 memory
impairment became evident when memory-related processing speed was taken into
account, something not considered in previous analyses (Fried et al. 2003). Performance
on both Abstract Designs and Peabody Spelling tests were poorer for children of heavycannabis-using mothers. These tests rely on visual memory, analysis and integration and
are sensitive to poorer processing speed capabilities. The authors cited evidence for this
argument from unpublished data from the cohort on a motor tracing task where
significantly slower latencies, but not fewer errors, were present. This suggests that
compensatory processes may augment accuracy at the cost of speed.
By the ages of 17-18, some of the OPPS cohort had themselves commenced
cannabis use and Fried, Watkinson and Gray (2005b) compared non-user controls (those
with little to no personal use), to regular light (current use of less than 5 joints per week)
and heavy users (five or more joints per week) and to a group of former regular users
(no regular use for three or more months and less than two joints per week within the
past two months). Greater prenatal exposure had occurred in the heavy user group. The
authors were able to compare individual results with those from an earlier age, allowing
adjustments for pre-drug performance. Assessments included the use of the WAIS-III,
as well as multiple memory measures from the WMS-III: immediate memory index;
general memory index; and working memory index. Immediate and delayed memory
was found to be poorer for the heavy using group, as was visual processing speed, in
comparison to controls. A lack of deficits in the former regular users (with a mean
history of just over 2 ½ years and an estimated 4800 lifetime joints smoked, in contrast
to current heavy users with also 2 ½ years experience and 1900 lifetime joints) was
posited as evidence for neurocognitive recovery. An fMRI investigation of a sample of
this cohort at ages 18-22 (Smith et al. 2006) found differential brain activation patterns,
particularly within the PFC, evident for prenatally exposed individuals in the absence of
overt performance differences during a response inhibition task. These differences
between the prenatally exposed and non-exposed groups were maintained after
controlling for prenatal nicotine, alcohol and caffeine exposure as well as current
personal cannabis use in the sample, which was greater in the prenatally exposed group
(6.36 vs. 0.93 joints per week). The authors interpreted their findings as suggesting that
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prenatal exposure to cannabis is related to changes in neural activity that last into young
adulthood.
Similar findings to the OPPS have been observed among the MHPCD cohort.
Short-term memory impairment, as assessed by the Stanford-Binet Intelligence Scale,
was observed for 3-year old MHPCD children, although moderated by pre-school
educational experience for those of Caucasian parentage (Day et al. 1994). Limited
impact was found upon memory at age 10 with first trimester heavy cannabis use by
mothers found to weakly predict poorer performance on the Design Memory subtest of
the Wide Range Assessment of Memory and Learning (Richardson et al. 2002).
Determination of impact at older ages has not yet been published for the MHPCD
cohort, so further changes during the adolescent years are as yet unknown. As with the
OPPS study, findings have been suggestive of executive functioning deficits, with
academic achievement related to such functioning at age 10 indicative of problems in
this domain (Goldschmidt et al. 2004).
In contrast, prenatal (or neonatal) exposure to cannabinoids has unequivocally
been shown to be harmful in animal studies, (e.g., Fride 2004a; b; Mereu et al. 2003).
Mereu et al. (2003) found that in utero exposure to cannabinoids disrupted retention in a
passive avoidance task in 40- and 80-day-old rats and this was accompanied by
decreased hippocampal long-term potentiation and glutamate release, suggesting longlasting, if not permanent, impairment of memory processes and their neural substrates.
The authors surmised that these mechanisms may explain the observations of cognitive
impairments in humans exposed to cannabis in utero, as have been discussed above.
Given that there has been some evidence of cognitive dysfunction in the human cohorts,
independent of their own cannabis use, enduring effects as a result of prenatal exposure,
while possibly not severe, are likely. Whether these are specific to memory processes,
or more closely tied with executive functioning and memory-related processing speed,
remains unclear. It is possible that while younger individuals may be able to compensate
for cognitive deficits at the cost of efficiency, the impact of prenatal exposure may
become more evident later in life interacting with age-related cognitive decline.
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2.8.

PARAMETERS OF CANNABIS USE AFFECTING NEUROCOGNITION AND PERSISTENCE

OF DEFICITS

As highlighted above in relation to verbal learning tasks (and here more broadly),
neurocognitive deficits in adult cannabis users have variously been attributed to
duration of cannabis use (Fletcher et al. 1996; Messinis et al. 2006; Solowij 1998;
Solowij et al. 2002), frequency of cannabis use (Pope et al. 2001; Pope and YurgelunTodd 1996; Solowij 1998) or cumulative dosage effects (Bolla et al. 2002; Bolla et al.
2005; Chang et al. 2006). There is evidence that the effects of frequency and duration of
use may be dissociable, as shorter lasting and potentially reversible effects on
information processing, versus more enduring effects reflecting neural alterations that
may be less amenable to recovery (Solowij 1998). However, duration of use is
necessarily confounded with increasing age and increasing cumulative dose of
exposure. Frequency of use alone may not be a sufficiently good indicator without
consideration of quantity used per occasion and cumulatively. Dose can usually only be
estimated from self-report and, with significant variation in actual quantity of cannabis
consumed in different sized smoking implements (eg. joints, bongs, cones, blunts, etc)
or estimated gram consumption, together with significant variation in the potency of
cannabis consumed, only very imprecise estimates may be obtained. This is an
impediment that continues to plague research in this field, which must continue to rely
largely on self-report. Recommendations for future studies include obtaining as much
detailed information as possible on each of these parameters, with corroborating
evidence from sources such as hair analysis, which may be able to provide
quantification of exposure over at least the few past months (e.g., Hermann et al. 2007).
A significant source of variability in the studies reviewed above, and as evident
from the summary information in Table 1, is the duration of participant abstinence from
cannabis use prior to testing. This has ranged from a minimum 3 (but mean 29) hours in
one study (Hermann et al. 2007) to a mean 20 years in another (Lyons et al. 2004). We
have considered all of these diverse studies within our review as they met our definition
of “unintoxicated” state and most studies attempted to ensure that participants were not
acutely intoxicated at the time of testing. Clearly, the closer the assessment occurred to
the last use of cannabis, the more likely any impairment found might potentially be
attributed to cannabinoid residues that may still be present within the brain, and might
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therefore be considered a subacute effect. Some studies have, however, used various
statistical methods to aid interpretation of effects as being due to recent cannabis use
versus longer-lasting deficits associated with other parameters of cannabis use, as
mentioned above. That similar impairments have been found across studies with short
abstention periods and in some of those with abstinence of over one month, suggests
enduring residual effects that may last well beyond any period of acute intoxication. It
may be, however, that following years of heavy cannabis use, the resultant effects of
accumulated cannabinoids on altered neural functioning may induce a state of chronic
intoxication that requires a significantly longer period to resolve, even beyond the
elimination of cannabinoids from the body. Truly long-lasting deficits for months and
years after cannabis use, if not accounted for by other confounds related to a propensity
to use cannabis, and if shown to be dose-related, are likely to reflect long-term
alterations to the functioning of the brain that may or may not be reversible. A close
examination of the literature reviewed here failed to differentiate in any simplistic or
clear manner specific memory deficits that are associated only with brief abstinence
periods from cannabis (and hence subacute effects) from others that may be more
apparent following prolonged abstinence. Further research, and ideally long-term
prospective studies, are required to shed light on shorter-lasting versus longer-lasting
effects and the persistence of deficits following abstinence from cannabis.
The prevailing investigations of recovery of cognitive function with prolonged
abstinence from cannabis have produced conflicting results with some studies
suggesting full recovery after 28 days abstinence (Pope et al. 2001), others showing
partial early recovery and after a mean 2 years abstinence (Solowij 1998) and others still
finding no recovery after 25-28 days abstinence (Bolla et al. 2002; Bolla et al. 2005;
Eldreth et al. 2004). Some evidence of impaired memory was apparent even 20 years
after last regular cannabis use in the twin study of Lyons et al. (2004). The reasons for
these differences are unclear but may be due in part to varying tasks and methodologies
and differing characteristic populations. Few studies have assessed very long term users
with histories of 20 – 30+ years of use as in some of our previous studies, or users with
extreme heavy use.
Enduring deficits have been shown to be more likely to persist beyond cessation of
cannabis use when use commenced prior to the age of 17 (Pope et al. 2003). These

51

findings suggest that age of onset may be a critical factor in the development and
persistence of neurocognitive deficits and that the adolescent brain may be more
vulnerable to the insult of even low-level cannabis use. Indeed, there is growing
evidence for greater adverse cognitive outcomes when use is commenced during
adolescence (e.g., prior to age 16 or 17) as opposed to young adulthood (Ehrenreich et
al. 1999; Pope et al. 2003; Wilson et al. 2000). Early-onset cannabis use confers the
greatest risk of developing psychosis, either in its own right (e.g., Stefanis et al. 2004),
or as a gene by environment interaction (Caspi et al. 2005). Thus, individuals who begin
to use cannabis when the brain is still developing may be most vulnerable to its
deleterious effects. There is a growing recognition that substances affect the brain in
different ways during adolescence versus adulthood (e.g., White and Swartzwelder
2004) and insufficient research has investigated the unique effects of cannabis during
this neurodevelopmentally vulnerable period. Animal studies have also demonstrated
greater adverse consequences when cannabinoids are administered to adolescent rats
(e.g., O'Shea et al. 2004; Pistis et al. 2004; Schneider and Koch 2003; 2005) and effects
on other critical neurodevelopmental periods (prenatal or perinatal) have been discussed
above. Since adolescence is a critical period of structural and functional brain
maturation (Paus 2005), further investigation of the neurocognitive impact of cannabis
use during this unique neurodevelopmental period is clearly warranted.
2.9.

MEMORY DYSFUNCTION, VULNERABILITIES AND NEURAL INEFFICIENCY

The cumulative evidence from the above-reviewed research suggests that cannabis use
does, in some fashion, impact negatively upon memory function. Greater memory
deficits may be apparent in more complex tasks and among heavier cannabis users. The
nature of memory deficits in chronic cannabis users is not dissimilar to that observed
under acute intoxication. Chronic cannabis users in the unintoxicated state also show
impaired immediate, but moreso delayed free recall of verbal information, poor retrieval
of information from memory, and difficulties manipulating the contents of working
memory. Recognition memory is inconsistently reported to be impaired. Organisational
strategies within memory have not been sufficiently well researched. There is limited
evidence for poor strategy use in spatial working memory. Several studies employed the
CVLT and found similar impairment in cannabis users in learning, on measures of
immediate and delayed recall, and sometimes in cued recall and recognition, to studies
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where other verbal learning tests have been administered to cannabis users. This
suggests that providing word lists that were amenable to better organisation to facilitate
encoding and recall, did not improve memory performance in cannabis users; either
they failed to employ efficient organisational strategies or did not benefit from attempts
to do so. Specific encoding manipulation studies, for example that systematically vary
depth of encoding or the organisation of stimulus material, have yet to be conducted in
chronic cannabis users. In the few studies where primacy/recency effects have been
reported, cannabis users have tended to recall fewer words from the beginning of a word
list and more words from the end, suggesting a greater reliance on short-term or
working memory and poorer encoding. Cumulatively, there is evidence in support of
encoding, storage and retrieval deficits in chronic cannabis users. The extent to which
attentional and motivational factors may influence memory function has not been well
established.
The overall similarity between the acute and chronic effects of cannabis on
memory function speaks to potential residual effects associated with a state of chronic
intoxication. Dose-, frequency- and recency-related impairment may reflect such a state
due to the accumulation of cannabinoids. Where effects have been shown to be related
to duration of cannabis use, or to persist beyond a period during which most
cannabinoid residues would be eliminated, it is more difficult to ascribe these to a
chronically intoxicated state but may reflect alterations to the functioning of the brain
that require substantial time to revert to normality. A common theme that has emerged
in the literature is a distinct lack of commonality in cataloguing the parameters of
cannabis use among participants to obtain adequate estimates of the extent of exposure.
A goal of future studies should be to document as much detailed information as possible
regarding recent and historical use of cannabis, quantifying the frequency of episodes of
smoking and quantifying dose in terms of a more standardised measure such as cigarette
sized joints. Large variation in the potency of cannabis smoked precludes any more
precise estimation of actual dose of delta-9-THC delivered.
There is likely to be a wide range of individual differences in the propensity to
develop memory dysfunction associated with long-term heavy cannabis use. The
influence of multiple interpersonal factors on resilience to and susceptibility to
cognitive impairment deserves greater attention. Such factors may include personality
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and differing genotypes (e.g., Agrawal and Lynskey 2006; Lynskey et al. 2006; Solowij
and Michie 2007). A predisposition to substance use in general may also confer greater
vulnerability to cannabis-related cognitive sequelae (Yücel et al. 2007) and requires
further attention in prospective studies. While most recent studies have sought to match
groups or otherwise covary potential confounds, and have done so in far better
controlled ways than earlier research in this field, greater attention may need to be
devoted to factors such as nicotine use and age of onset of cannabis and other substance
use. One study has suggested that the use of nicotine may mask cannabis-related
impairment (Jacobsen et al. 2007), but interactions between cannabis use and tobacco,
or indeed alcohol, have not been well studied and may be additive, synergistic or
interact via potential neuroprotective mechanisms (e.g., Medina et al. 2007b; Parrott et
al. 2004). While determining the extent of neurocognitive dysfunction that may be
attributed to cannabis alone is necessary to inform the mechanism of cannabis effects,
this requires exclusion as much as possible of other substance use and the results of
such studies may therefore not inform the nature of potential interactions in the general
population where use of other substances is common among cannabis users. A similar
argument may extend to investigations of very heavy cannabis users, who represent
only a proportion of the wider cannabis-using population. As such, continued studies at
both the extreme end of the cannabis-use spectrum together with studies of more
moderate users and polydrug users are equally worthy, as long as the study designs
enable investigation of appropriate questions and precision in hypotheses postulated.
The interactive effects of various substances are also well placed for testing in
preclinical studies, albeit extrapolation from animal studies to long-term use in humans
is problematic.
Most studies have sought to match cannabis users and controls on IQ or else
have used IQ as a covariate to determine cannabis-related memory-specific effects by
accounting for confounding that may be due to differing cognitive reserves. Where
possible, true measures of premorbid IQ obtained prior to the commencement of any
cannabis use enable a more direct means of ensuring that later observed memory
deficits are not due to poor intellectual functioning independent of subsequent substance
use. In the absence of similar memory tests having been also administered premorbidly,
memory deficits that are shown to be dose-related (or otherwise associated with
cannabis use parameters) may then be interpreted as cannabis-specific sequelae. Few
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studies have been able to obtain such premorbid measures, however estimates of
premorbid IQ and measures of current IQ require further examination in light of
evidence suggesting potential interactions between cannabis effects and IQ.

For

example, cognitive impairments have been found to be greater in cannabis users of
lower IQ than in higher IQ users in several studies (e.g., Pope and Yurgelun-Todd 1996;
Solowij 1998) and where differences between cannabis users and controls have tended
to be of lower magnitude these have tended to be in cohorts of higher IQ (literature
reviewed above and in (literature reviewed above and in Solowij 1998). Suggestions
that individuals with borderline or low IQ might be even more susceptible to cannabisinduced deficits, particularly of short-term or recent memory have been posited for
some time (e.g., Schwartz et al. 1989), as have suggestions that individuals of higher IQ
may be able to compensate for detrimental effects of cannabis use (e.g., Solowij 1998),
but these factors continue to be under-investigated. Differences between the 28 day
abstinence studies of Pope et al. (2001) and Bolla et al. (2002) were highlighted above
with regard to IQ differences: it is possible that neurocognitive deficits in cannabis users
with lower IQ may also be less amenable to recovery following prolonged abstinence.
A general tendency across most studies of cannabis users to recruit participants
with above average IQ, possibly due to ease of access to such individuals, in some
instances may result in near ceiling performance in both cannabis users and controls,
preventing the separation of groups on performance measures. Utilising tasks of
sufficient complexity to discriminate between higher-IQ users and controls may be
required for a more thorough examination of the impact of cannabis at this top end of
intellectual capacity. Higher IQ individuals may be more capable of adopting alternate
strategies or of engaging neural circuitry more efficiently during cognitive task
performance, and this may either explain or confound some of the neuroimaging
findings in cannabis users.
In general, findings of altered brain activation from imaging studies of cannabis
users suggest compensatory processes activated to ameliorate cognitive deficits (e.g.,
Block et al. 2002; Eldreth et al. 2004; Jacobsen et al. 2007; Jager et al. 2006; Jager et al.
2005; Kanayama et al. 2004; Schweinsburg et al. 2005). More effortful processing
appears to be engaged in an attempt to produce equivalent behavioural outcomes to
normal cognitive functioning, sometimes successfully, other times not. Cannabis users
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may recruit additional brain regions or increase the activation of the same brain regions
as controls, thus “working harder” (Kanayama et al. 2004), at a “higher
neurophysiological cost” (Jager et al. 2006) to meet the demands of the task, until the
demands of this cost or of the task exceed their available resources, at which point,
performance deficits would likely become apparent.
Where decreased regional brain activation has also been observed in cannabis
users (e.g., Bolla et al. 2005; Eldreth et al. 2004; Jager et al. 2007), this is generally
accompanied by increased activity in other regions, and the hypoactivity is interpreted
not as reflecting greater neural efficiency, but as impaired activation of regions known
to be involved in performing the task, regions that may include areas of high density
cannabinoid receptors. Our knowledge regarding the complex effects of cannabis on
resting state brain physiology, perfusion and chemistry is still far from complete, as is
the knowledge required for accurate interpretation of brain activation in neuroimaging
studies, both normative and of multiple other clinical populations. As such, any
simplistic or mechanistic interpretation of increased versus decreased brain activation in
neuroimaging studies is not appropriate and further deciphering or speculation is
beyond the scope of this review. Further examination of the efficiency of neural
connectivity in cannabis users is warranted, with particular attention to interactions
between under-activated and over-activated regions involved in specific tasks.
The engagement of compensatory mechanisms involving increased brain
activation and recruitment of additional regions may be at the cost of neural and taskrelated efficiency. Lower efficiency may manifest in terms of longer latency measures
and slower processing speed, which are evident in some of the studies of cannabis users
reviewed above (e.g., Bolla et al. 2002; Fried et al. 2003; 2005b; Harvey et al. 2007;
Medina et al. 2007a; Messinis et al. 2006; Wadsworth et al. 2006), but have perhaps not
always been sufficiently considered within memory tasks. Cannabis users tend to
produce longer latencies during tasks that they may nevertheless complete just as
successfully as controls. Individuals with slower processing speed have been shown to
activate PFC regions more than those with faster processing speeds, with a greater need
for PFC executive control mechanisms to enable successful task performance, reflecting
neural inefficiency (Rypma et al. 2006). Slowed processing speed is thought to underlie
age-related cognitive decline, with individuals taking progressively longer to perform
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most cognitive operations as they age (Sliwinski et al. 1994). Some suggest that the
nature of impairments associated with cannabis may reflect premature age-related
cognitive decline (e.g., Bolla et al. 2002; Solowij 1998). It is also possible that greater
cannabis-related memory deficits could manifest with the onset of age-related cognitive
decline. The evidence with regard to age-effects interacting with cannabis-effects is
convoluted. Some studies find greater impairment in older cannabis users, suggesting
that young adults may draw upon greater cognitive reserve to overcome cannabisrelated impairment, while other work suggests greater adverse consequences during
adolescence. There may be a U-shaped relationship between age and cognitive-effects
of cannabis, which would interact with the age of onset of cannabis use.
A recent study (van den Heuvel et al. 2006) found that an increase in the volume
of white matter hyperintensities as individuals age correlated strongly with decreases in
processing speed. Slower processing speed was considered to be due to a loss of neural
efficiency in long association fibres as a result of the progression of periventricular
white matter hyperintensities. These fibres connect distal cortical regions in the
recruitment of cognitive function. Cognitive decline in other areas, such as memory, is
not typically observed until shorter-association fibres (operating within cortical regions)
are disrupted (Tisserand and Jolles 2003). Evidence of white and grey matter changes in
cannabis users has been reported in adult and adolescent cannabis users (Matochik et al.
2005; Wilson et al. 2000) including greater regional density of white matter which could
reflect early cognitive decline. Findings in older populations of cannabis users have
attributed deficits to the greater years of cannabis exposure (e.g., Solowij et al. 2002)
but aging may well interact with the cumulative dose of exposure to cannabis.
Insufficient attention has been given to investigating gender differences in the
neurocognitive sequelae of cannabis use. Pope and colleagues (1997; Pope and
Yurgelun-Todd 1996) found some evidence of gender-specific cognitive effects of
heavy cannabis use in their generally high-IQ sample: female heavy users remembered
fewer items and made more errors than female light users in a visuospatial memory
task, whereas male heavy users were more impaired in attentional/interference tasks and
in delayed recall. Neubauer et al. (2005) found task- and sex-specific lower regional
brain activation among higher-IQ individuals; for males in a test of spatial ability and
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for females in a test of verbal ability. Females continue to be greatly under-represented
in studies of cannabis users.
The involvement of the cannabinoid system in processes of critical importance
to memory function and the effects of acute and chronic administration of cannabinoids
on memory-relevant neural substrates are beyond the scope of this paper but have been
described elsewhere (Ranganathan and D'Souza 2006; Solowij and Michie 2007). That
long-term and heavy cannabis use may impact deleteriously upon the neural substrates
of efficient memory processing is certainly conceivable, as is a potentially greater
impact during critical neurodevelopmental periods. Even transient changes to
neurotransmitter systems during such periods have been shown to cause lasting effects
in the adult brain that can translate to neurological and psychiatric disorders (e.g.,
Ansorge et al. 2004). It is up to future research to continue to isolate more specifically
precisely which components of the memory system are most affected, when and how.
2.10.

CONCLUSION

Sufficient evidence has accumulated from recent studies of cannabis users in the
unintoxicated state to conclude that long-term heavy cannabis use is associated with
impaired memory function, associated being the key operative, given the wide range of
studies reviewed in this paper. Our central tenet is that impaired memory function
persists beyond the period of acute intoxication and is related to a variety of cannabis
use parameters. Deficits have been shown to increase as a function of frequency,
duration, dose and age of onset of cannabis use, but the precise parameters of cannabis
use that result in memory deficits remain to determined. A number of studies of
cannabis users abstinent for reasonably long periods suggest that dysfunctional memory
may persist for some time after the acute intoxication, but whether this reflects the
action of drug residues causing a state of chronic intoxication or whether a potential
alteration of neural function requires a longer period of time to normalise, also remains
to be determined. We have discussed a need to better characterise the nature of memory
impairment, the specific parameters of cannabis use that are critical in its manifestation,
and the propensity for memory deficits to persist. If memory function is impaired for
hours or weeks following last use of cannabis, this is important public health
information for the millions of cannabis users who operate in such “unintoxicated
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states” for substantial periods of their daily lives. As such, this impairment of memory
function is just as critical to understand as is the very important question of whether
recovery of function occurs following prolonged abstinence.
Recent research has made a number of advances in methodology and is
beginning to ask pertinent questions but the field is still wide open for further, more
detailed investigation. The precise nature of memory deficits in cannabis users has not
been fully elucidated: there is evidence for impaired encoding, storage and retrieval.
Much can be borrowed from cognitive neuroscience approaches to manipulating
memory paradigms to understand more about each of these stages of memory function
and how these may be impacted by cannabis use. Further functional neuroimaging
studies could be greatly informative in determining the neural substrates underlying
memory impairment and the efficiency of neural connections in cannabis users
performing memory tasks, and ERP studies of memory and other cognitive functions
may provide fine temporal resolution to examine the specific cognitive processes that
are impacted by cannabis use and may manifest in terms of memory impairment. A
closer consideration of the memory deficits associated with specific parameters of
cannabis use and interactions with age, IQ, personality factors, genetics and neural
substrates including the endogenous cannabinoid system, will better inform our
understanding of the effects of cannabis on memory, general cognition and brain
function and the potential for recovery with abstinence. Combined multidisciplinary
research approaches, including cognitive, neuroimaging, neurochemical and genetic,
hold much promise for future research in this field.
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Table 2-1. List of studies reviewed with use parameters, abstinence period, estimated IQ, tests used and memory findings.
Cannabis Use
Parameters

Abstinence
Period

Estimated IQ
(Mean)

Memory (& Imaging)
Tests

CAN(7/17.4);
TOB(7/17.1);
CON(7/16.8)

CAN(24-1460 days of
use; Mean 282.8);
TOB(0-1; Mean 0.6);
CON(nil)

CAN(1.5-24 mo;
Mean 10)

CAN(97);
TOB(91.4);
CON(103.2

n-back WM task with
Selective Attention Task
Load; CPT; fMRI

CAN<CON on accuracy WM;
Can<CON on % correct CPT;
CAN<CON & CAN<TOB in
deactivation of right hippocampus

Kanayama et al.
(2004)

CAN(12/37.9);
CON(10/27.8)

CAN(6-36 hrs)

na

SWM - perception &
short-delay; PET

CAN<CON on accuracy ns; CAN>CON
activation in PFC/ACC/Basal Ganglia

Jager et al. (2006)

CAN(10/22.7);
CON(10/22.8)

CAN/CON(Mini
mum 1 wk)

CAN(104.9);
CON(106.1)

Sternberg; fMRI

No group differences on Sternberg;
CAN>CON for activation in SPC

Harvey et al. (2007)

CAN(34/16.1);
CON(36/16.4)

Min 12 hrs

CAN(95.9);
CON(103.4)

CANTAB - RVIP, SWM,
PAL, Spatial Span;
RAVLT; Digit Span

CAN>CON on RVIP, SWM errors;
CAN<CON on SWM strategy use;
CAN<CON on RAVLT Total Words
Recall

Jacobsen et al.
(2007)

CAN(20/17.1);
TOB(25/17)

CAN(5100-54000
occasions; Mean
19200); CON(no
history of
abuse/dependence)
CAN(mean 7.1 yrs; 217 j/wk); CON(0-15 life
j)
Over 28-days:
CAN(2.2-84.8 j; Med
11.3; 1st use age 7-16);
CON(0-6 j; Med 0; 1st
use age 5-17)
CAN(62-2799 life use;
Med 351); TOB(0-40
life use; Med 6)

CAN(0.5-24 mo;
Mean 4.8 mo);
TOB(1-40 mo;
Mean 9.2 mo)

CAN(92.6);
TOB(95.1)

n-back WM task with
Selective Attention Task
Load; HVLT-R

CAN<TOB on Delayed Recall during
nicotine withdrawal; CAN>TOB in PC
activation; disrupted F-P connectivity for
CAN

OCAN(Mean 34 yrs;
5.2 j/day, 2-7
times/wk);
YCAN(Mean 8 yrs; 3.8
j/day, 2-7 times/wk)

72 hrs

OCAN(110.33);
OCON(115.50);
YCAN(113.78);
YCAN(115.33)

12-trial Spanish SRT +
Free Recall; Sorting task;
Story Episodic Memory

OCAN<OCON on SRT Accuracy &
Free Recall

Author(s)
Working Memory

Groups (n/Mean Age)

Jacobsen et al.
(2004)

Memory Findings

Verbal Episodic
Memory
Fletcher et al.
(1996)

O(17/45.31);
O(30/45.64);
YCAN(37/29.29);
YCON(49/27.28)
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Pope & YurgelunTodd (1996)

HVY(65/Median 20);
LGT(64/Median 21)

HVY(22-30 days/mo);
LGT(0-9 days/mo)

Min 19 hrs

HVY(100.6);
LGT(104.8)

WMS, CVLT, ROCF

HVY<LGT on Imm Recall, Total Recall,
Post-Interference, & Delayed Recall (ns)

Pope et al. (2001)

CAN(63/36);
EXCAN(45/41);
CON(72/39.5)

CAN(15-24 yrs; 1170027000 eps; Mean
11700); EXCAN(11-19
yrs; 8400-16000 eps;
Mean 11000) CON(525 eps; Mean 5)

0, 1, 7 & 28 days

CAN(106);
EXCAN(115);
CON(115)

Assessed repeatedly over
3-4 days: BSRT; Benton
Revised Visual Retention
Test; WMS

After IQ-adjustment, CAN<CON on
Day 7 Total Recall & Consistent LongTerm Retrieval

Pope et al. (2002)

CAN(77/36);
CON(87/40)

CAN(Min 5000 times;
current daily); CON(150 times)

0, 1, 7 & 28 days

CAN(108);
CON(115)

Assessed repeatedly over
3-4 days: BSRT; Benton
Revised Visual Retention
Test; WMS

After IQ-adjustment, CAN<CON on
Day 7 Consistent Long-Term Retrieval

Bolla et al. (2002)

HVY(7/20.7);
MOD(8/21.9);
LGT(7/24.6)

HVY(3-10 yrs; 78-117
j/wk); MOD(2-15 yrs;
18-70 j/wk); LGT(2-6
yrs; 2-14 j/wk)

HVY/MOD/LGT(
28 days)

HVY(91);
MOD(95);
LGT(101.9)

RAVLT; Logical Mem
(WMS-R); Rey Osterreith
Complex Figure; Symbol
Digit PAL

-ve r with RAVLT Delayed Recall &
Symbol Digit PAL

Block et al. (2002)

CAN(18/na);
CON(13/na)

CAN(2+ yrs, Mean3.9
yrs; 7+ times/week);
CON(0-2 life use)

CAN(Min 26 hrs;
Mean 27.8 hrs)

na

BSRT; Novel Word List;
PET

CAN<CON on learning/relearning in
BSRT; CAN>CON for word recency in
Novel list; CAN<CON for middle list
words in Novel list; CAN<CON in PFC
activation; CAN had absence of
hippocampal Lateralization

Solowij et al.
(2002)

LT(51/42.1);
ST(51/28.7);
CON(33/34.8)

LT(17.3+ yrs/Med 27.9
days/mo); ST(2.7-17
yrs/Med 28.3 d/mo);
CON(limited history)

LT/ST(7-240 hrs;
Med 17 hrs)

LT(105.7);
ST(105.1);
CON(107.9)

RAVLT; Omitted
Numbers

LT<ST/CON on Total Recall; LT<Con
on RecogA/B; LT/ST<CON on
RecogA/B

Lyons et al. (2004)

Twins:
CAN/CON(54/46.3)

CAN(Mean 5.8 yrs;
Mean 916 days)

CAN(Mean 20
yrs; 1 yr Min)

CAN(107.98);
CON(108.13)

WMS-R; CVLT; ROCF

CAN<CON on CVLT long delay free
recall & long delay cued recall (ns)
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Wadsworth et al.
(2006)

CAN(34/24.03);
CON(85/26.79)

CAN(Mean 7.63 yrs,
3.35 days/wk)

na - implied
heavier use on
weekends

CAN(113.28);
CON(113.22)

Imm/Delayed Free Recall;
Delayed Recog; Verbal
Reasoning; Semantic
Processing

CAN<CON on Verbal Reasoning &
Delayed Recall pre-work day 1

Medina et al.
(2007)

CAN(31/18.07);
CON(34/17.86)

CAN(Mean 2.91 yrs;
Mean 540.64 life use);
CON(<5 life use)

CAN(Min 28
days)

Vocab. T:
CAN(55.7);
CON(57.3)

CVLT; ROCF; Logical
Mem (WMS-III)

CAN<CON on CVLT Trial 1 & Verbal
Story Mem composite score, WMS-III
Logical Mem measures

Other Memory
Processes
Hermann et al.
(2007)

CAN(13/22);
CON(13/23)

CAN(Mean 719 g/day
for 5.6 yrs; Mean 25
days/mo); CON(nil)

CAN(3-84 hrs;
Mean 29); Hair
Analysis

CAN(124);
CON(124)

HAWIE-F/B; TME,
BVRT; MRS

CAN<CON in BVRT STM Accuracy;
CAN>CON in errors for BVRT, TME &
Errors; CAN<CON on neuronal &
axonal integrity in DLPFC

CAN(20/24.5);
CON(20/23.6)

CAN(Med 1900 life j;
Med 332.5 j last yr);
CON(Med 0 life j; Med
0 j last yr)

1 wk

CAN(107);
CON(103)

Pictorial Memory
paradigm; fMRI

-ve r for Recall Accuracy with extent of
last yr & life cannabis use; CAN<CON
brain activation in bilateral
parahippocampal & right DLPFC

Rodgers et al.
(2000)

MDMA/CAN(15/31);
CAN(15/30);
CON(15/32)

1 mo

na

WMS-R

MDMA/CAN & CAN<CON on Logical
Mem I/II; MDMA/CAN<CAN & CON
on Verbal/Visual Paired Assoc. II

Croft et al. (2001)

CAN(18);
MDMA/CAN(11);
CON(31)

48 hours

CAN(115.2);
MDMA/CAN(116.2
); CON(115.2)

Warrington Recog Mem
Test; F/B-DS; Coughlan
List & Design Learning

CAN & MDMA/CAN<CON on
Coughlan Total Recall & F/B-DS

Rodgers et al.,
(2001)

MDMA/CAN &
CON(488/21-25 Modal
Age)

MDMA/CAN(Mean 4
days/wk over 10 yrs);
CAN(Mean 4 days/wk
over 11yrs); CON(nil
history)
CAN(7762.4 life
Mean);
MDMA/CAN(10964.9
life Mean); CON(0.5
life use)
MDMA/CAN(1-4, 520, or 20+ times/mo)

na

na

EMQ, PMQ, UEL

+ve r for level of cannabis use with
errors in EMQ, PMQ short-term & PMQ
internally cued

Jager et al. (2007)

Cannabis
Comparison Group
Studies
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Simon & Mattick
(2002)

MDMA/CAN(40/25.3);
CAN(37/23.2)

MDMA/CAN(Mean
67.9 j/mo; n=25 regular
use); CAN(Mean 62.6
j/mo)
CANALC(Mean 3.37
yrs; Mean 309.87 life
eps); ALC(Mean 3.03
yrs; Mean 11.33 life
eps); CON(Mean 1.46
yrs; Mean 1.47 life eps)

Minimum 24
hours

MDMA/CAN(105.6
); CAN(107.6)

WMS-III

No group differences. Frequency of use
(ns) predicting visual memory
performance

Schweinsburg et al.
(2005)

CANALC(15/16.91);
ALC(15/16.77);
CON(19/16.50)

CANALC(Mean
7.64 days);
ALC(Mean 79.67
days); CON(Mean
145 days)

Vocab. Scaled:
CANALC(11.77);
ALC(12.53);
CON(12.21)

SWM; fMRI

No differences on SWM;
CANALC>CON for activation in
DLPFC; CANALC<CON for activation
in inferior frontal & temporal regions;
CANALC<ALC in activation in inferior
frontal & temporal regions;
CANALC>ALC in activation in medial
frontal area

Quednow et al.
(2006)

CAN(19/25.42);
MDMA(19/24.21);
CON(19/23.42)

CAN(Mean 6.55 yrs;
Mean 3.89 times/wk);
MDMA(Mean 3.95 yrs;
Mean 1.63 times/wk);
CON(nil)

Minimum 3 days:
CAN(Mean 7.1);
MDMA(Mean
11.1)

CAN(109.7);
MDMA(100.6);
CON(105.7)

RAVLT

MDMA<CON on Imm Recall, Total
Recall, Retroactive Interference,
Delayed Recall, Recog

Medina et al.
(2007)

CANALC(26/17.6);
ALC(16/16.9);
CON(21/17.5)

CANALC(Mean 402.3
life eps; Mean 14.2
days/mo over last 3
mo); ALC(Mean 11.9
life eps; Mean 0.8
days/mo over last 3
mo); CON(nil)

CANALC(Mean
31.4 days; Min 2);
ALC(419.9);
CON(951.9)

Vocab. T:
CANALC(55.3);
ALC(59.2);
CON(56.7)

CVLT; structural MRI

No CVLT or hippocampal volume group
differences. Hippocampal asymmetry
correlated with CVLT performance in
CON; abnormal in CANALC and ALC

ACC - Anterior Cingulate Cortex, ALC - Alcohol only group, BSRT - Buschke’s Selective Reminding Task, BVRT - Benton Visual Retention Test, CAN - Cannabis group, CANALC –
Cannabis and alcohol group, CON - Control group, CPT - Continuous Performance Task, DLPFC - Dorsolateral Prefrontal Cortex, eps – Episodes, EXCAN - Formerly Heavy Ex-Cannabis User
group, F/B-DS - Forward/Backwards Digit Span, EMQ – Everyday Memory Questionnaire, fMRI – Functional magnetic resonance imaging, F-P – Fronto-Parietal, HAWIE – Hamburg Wechsler
Intelligenztest für Erwachsene, hrs – Hours, HVY – Heavy User group, IED – Intra/Extra Dimensional Shift, Imm – Immediate, LGT – Light User group, LT – Long-Term User group, MDMA –
MDMA/Ecstasy group, Med – Median, Min – Minimum, mo – Month(s), MOD – Moderate User group, MRI – Magnetic resonance imaging, MRS – Magnetic resonance spectroscopy, na – Not
Available, ns – Non-Significant, OCAN – Older Cannabis User group, OCON – Older Non-Users group, PAL – Paired Associates Learning, PC – Posterior Cortex, PFC – Prefrontal Cortex,
PMQ – Prospective Memory Questionnaire, RAVLT – Rey Auditory Verbal Learning Test, Recog – Recognition, ROCF – Rey-Osterreith Complex Figure Test, RVIP – Rapid Visual Information
Processing, SRT – Selective Reminding Task, ST – Short-Term User group, SWM – Spatial Working Memory, TME – Tempoleistung und MerkFähigkeit Erwachsener, TOB – Tobacco User
group, wk – Week(s), WM – Working Memory, WMS – Wechsler Memory Scale, YCAN – Younger Cannabis User group, YCON – Younger Control group
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CHAPTER 3:

ADDITIONAL BRIEF REVIEW OF THE ERP

LITERATURE PERTINENT TO CANNABIS

LITERATURE REVIEW
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3.1.

EVENT-RELATED POTENTIAL (ERP) STUDIES OF CANNABIS USE

The review paper of chapter 2 detailed the impacts associated with the chronic use of
cannabis as it pertains to predominantly memory, but also attentional control and
inhibition. While ERP-based studies of cannabis effects were reviewed as they pertained
to these cognitive processes, the following section explores these in more detail given
the focus of the present dissertation. To date, the electrophysiological components that
have been examined include: the auditory sensory gating P50; the N100, an index of
exogenous stimulus characteristics as well as attentional demand; the mismatch
negativity (MMN), a pre-attentive index of auditory processing and sensory memory;
the processing negativity (PN), an index of selective attention; and, the late P300, a
positive post-attentional component related to stimulus salience, direct attentional
control, and contextual updating. The following section outlines those preclinical animal
and human studies that have examined these components under both acute and chronic
exposure to cannabinoids.
3.2.

THE AUDITORY SENSORY GATING P50

Believed to be an index of central nervous system capacity to register salient stimuli, the
P50 is a positive-going pre-attentive ERP component that occurs approximately 50 ms
following the discrete presentation of auditory stimuli (Grunwald et al. 2003). The P50
has been observed to habituate (i.e. reduce in amplitude) to repeated stimuli, indicating
it to be a biomarker for the brain’s ability to filter out redundant sensory information; a
process known as sensory gating (Grunwald et al. 2003; Luntz-Leybman et al. 1992).
Deficits in the P50, observable by a smaller/lack of reduction following repeat
presentation of stimuli, are hypothesised to more overtly manifest as perceptual
overloads (Sewell et al. 2010).
Cannabinoid receptors are densely populated within structures that are implicated in the
generation of the P50, i.e. hippocampus, tempoparietal region and prefrontal cortex
(Eggan and Lewis 2007; Grunwald et al. 2003; Luntz-Leybman et al. 1992). Therefore,
exposure to exogenous cannabinoids will likely affect its expression, indicating
potential disruption to the sensory gating process. To date, only four human studies
have reported an effect of cannabis on P50 expression, all of which have been with
chronic users of cannabis. A reduction in the P50 gating response was observed in all
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studies for the cannabis users relative to controls (Edwards et al. 2009; Patrick et al.
1999; Patrick and Struve 2000; Rentzsch et al. 2007) with more frequent use (Edwards
et al. 2009; Patrick et al. 1999) and a longer history of use (Rentzsch et al. 2007) related
to reduced gating. Examining participants during the non-intoxicated state, the reduced
gating observed was still present in Rentzsch et al.’s 28-day abstinent sample (Rentzsch
et al. 2007), indicating a persisting effect that was unlikely due to sub-acute levels of
exogenous cannabinoids. Whether this effect is particular to chronic cannabis use or not
remains unclear as there have been no human studies of acute exposure. Preclinical
studies with rats have though, observed reduced gating in an animal analog of the P50
following administration of a cannabinoid agonist (Dissanayake et al. 2008; Hajós et al.
2008; Zachariou et al. 2008), suggesting an effect of acute exogenous cannabinoid
exposure is likely.
3.3.

THE PERCEPTUAL/ATTENTIONAL N100

The N100 (or N1) is typically related to auditory stimuli and has a centro-parietal
maximum. This component has been related to the differential activation of featuresensitive neural elements during the stages of basic perceptual processing (Horvath et
al. 2008; Naatanen and Picton 1987). Given its early occurrence within the ERP
waveform (approximately 100 ms post-stimulus), the N1 is believed to be relatively
independent of overt cognitive processes, although it shows some evidence of being a
measure of attentional allocation towards stimuli, in that an enhancement is observed
with increased attention (Bubic et al. 2010).
There has been a single study that incidentally examined the N100 alongside
acute cannabis exposure. Ilan et al. (Ilan et al. 2004) observed reduced N100 following
administration of delta-9-THC, with this linked to attentional processing. There have
been three studies to date specifically investigating chronic cannabis use effects on the
N100, all of which have been from the same Indiana research group. A reduction in the
visual N160 (a visual analog of the auditory N100) was observed among a group of
chronic cannabis users in comparison to healthy controls (Skosnik et al. 2006b). Given
that this was a frontally maximal component, the authors argued that it was an index of
attentional processes, observed to be impaired among cannabis users (e.g. Kempel et al.
2003; Solowij et al. 1995b). A later study by Edwards et al. (Edwards et al. 2008)
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replicated these findings but in the auditory modality, although a similar study failed to
show this effect (Skosnik et al. 2008a). Edwards et al. argued that their differing results
to the Skosnik et al. (2008a) study were due to their own study requiring recruitment of
frontal top-down attentional mechanisms, as illustrated in the earlier work by Skosnik
(2006b). Given these findings, the N100 appears to be sensitive to chronic use effects,
particularly when targeting attentional mechanisms.
3.4.

THE MISMATCH NEGATIVITY (MMN)

The mismatch negativity (MMN) is the brain electrical response to a deviant within a
sequence of regular stimuli. The mismatch is specifically the difference in amplitude
between the two responses, characterised by a negative-going ERP component
occurring approximately 100 to 200 milliseconds after the presentation of an auditory
stimulus. It is an index of early auditory processing and sensory memory. The amplitude
and latency of the MMN alter with deviations in the frequency and/or duration from a
sequence of standard stimuli (Naatanen and Alho 1995; Rinne et al. 2000).
There has been one study of the acute effects and one of the chronic effects of
cannabis upon the expression of the MMN in humans. Juckel et al. (2007) compared the
acute effects of an oral cannabis extract containing both delta-9-THC and cannabidiol
(CBD) with delta-9-THC alone and an additional placebo control among healthy
volunteers. They observed greater MMN in the cannabis extract condition in
comparison to the delta-9-THC and placebo conditions but no differences between the
latter two. The authors argued that this was indicative of the cognitive-enhancing effects
of the CBD that buffered against the deleterious effects of the delta-9-THC and that a
single oral dose of delta-9-THC alone is insufficient to elicit MMN disturbances.
Another study by the same research group examined chronic users of cannabis and the
MMN (Roser et al. 2008b). A reduction in MMN amplitude was observed for the
frequency deviant among cannabis users measured at the vertex with heavier and
longer-term users showing reduced amplitude at frontal and central sites in comparison
to lighter and shorter-term users, respectively. The authors suggested that long-term
heavy cannabis use may impact upon auditory sensory memory and information
processing and indicated this ERP component as a possible target for future research
with cannabis users.
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3.5.

THE N400

The N400 (or N4) is a negative-going component often associated with semantic
processing and memory processing (Dunn et al. 1998; Fernandez et al. 1998). Most
evident at frontal locations, this component is believed to be particularly sensitive to
brain insult, particularly in the verbal domain (Ceballos et al. 2005). Verbal memory
deficits are commonly associated with the use of cannabis (Ranganathan and D'Souza
2006; Solowij and Battisti 2008).
There have been only three studies, all from scientists from the same research
team (Hart et al. 2010; Ilan et al. 2005; Ilan et al. 2004), that have investigated acute
cannabis effects upon the N400. Examining memory processes, the authors observed a
reduced N400 during recognition memory performance after the administration of
smoked delta-9-THC, with this enhanced at a higher dose. This effect though was only
observed in two of the studies (see Hart et al. 2010; Ilan et al. 2005). This component
may therefore be a useful target for studies of memory processing associated with
cannabis use although further research is needed and additionally with chronically-using
populations.
3.6.

PROCESSING NEGATIVITY (PN)

Among auditory studies of directed attention, processing negativity (PN) is defined as a
negative shift in the ERP waveform that may be observed as early as 60-80 ms poststimulus, but can also be evident as late as 600 ms post-stimulus (referred to as late PN).
PN is commonly examined as an electrical marker of selective attention (Solowij 1998).
Three studies of PN have all observed an increased negativity (indicative of impairment
in PN) to target tones in chronic cannabis users compared to healthy controls (Solowij
1998; Solowij et al. 1991; 1995b), with greater impairment of this component related to
an increased duration of use (Solowij et al. 1995b). The authors argued that this was
indicative of cannabis users engaging in unnecessary processing of stimuli related to
difficulties in selective attention and filtering. In a single case study of a chronic user,
Solowij et al. additionally observed normalization of the PN following acute exposure
to cannabis in comparison to the unintoxicated state (Solowij et al. 1995a). These
studies indicate that the PN is sensitive to the effects of cannabis use and hence a
biomarker for future investigations.
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3.7.

THE P300 AND OTHER LATE POSITIVITIES

By far one of the most frequently examined ERP components, strongly related to overt
cognitive processing, is the P300 (also known as P3). A late positive-going component
in the ERP waveform, the P300 is a reliable index of directed attention and overt
stimulus processing and is often used to measure stimulus salience, importance, novelty,
and memory processes (Polich and Criado 2006).
The majority of cannabis use and ERP studies to date have been an investigation
into effects on the P300 and other late positive components. Alterations in P300
amplitude have been observed in studies of both acute exposure as well as chronic use
of cannabis, indicating that this component has high utility as a cognitive biomarker of
cannabis use influences. Findings though, have often been inconsistent, including in
opposite directions, with large differences in participant samples cited as a major
confound (Sewell et al. 2010). Acute studies of the P300 and late slow waves (known as
“memory evoked shift” in tasks of memory processing) have largely found a decrease in
amplitude with an increased dose of delta-9-THC (e.g. Hart et al. 2010; Ilan et al. 2005;
Ilan et al. 2004; Roser et al. 2008a). Studies of chronic users of cannabis have produced
the most mixed findings. A reduction in P300 amplitude amongst regular, unintoxicated
cannabis users has been observed in studies by Solowij (1998), Solowij et al. (1991) and
Kempel et al. (2003). A study by Patrick et al. (1995) observed a reduction in P300
amplitude but found this to be confounded by age and psychiatric diagnoses.
Differences in P300 latency, but not amplitude, were observed in a study by Solowij et
al. (1995b), with increased latency related to more frequent use of cannabis. A study by
de Sola et al. (2008) failed to show any differences in P300 amplitude amongst users of
cannabis in comparison to controls, and, a study by Skosnik et al. (2008b) observed an
increase in P300 amplitude. As already stated, sample differences have been considered
a major confound with varying participant characteristics including level, frequency and
duration of cannabis use, the presence of other substance use and/or psychiatric
diagnoses, and non-matched control groups on key characteristics of age and premorbid
intellectual functioning. Additionally, the nature of the cognitive load required of
participants during electrophysiological measurement has varied considerably with the
use of more simple tasks such as oddball paradigms producing null results (see de Sola
et al. 2008; Patrick et al. 1995), other than the study by Solowij (1998). Differences
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were observed on more complex tasks including tasks of selective attention being
related to decreased P300 amplitude and delayed latency (see Kempel et al. 2003;
Solowij et al. 1991; Solowij et al. 1995b), and increased amplitude observed on a verbal
processing task (see Skosnik et al. 2008b). These findings indicate that the P300 is quite
sensitive to the influence of cannabis and that the nature of P300 morphological changes
differ with task used and participant characteristics.
3.8.

PSYCHOPHYSIOLOGICAL STUDIES: CONCLUDING REMARKS

Although very few psychophysiological studies have been conducted examining effects
of cannabis exposure, with even fewer specific to chronic cannabis use, they do indicate
the viability of such recording methods for the measurement of cannabis use effects.
The prior review (chapter 2) very strongly showed that the effects of chronic cannabis
use are often very subtle, if not undetectable by overt outcome measures. There is a
need for more highly sensitive measures and the use of psychophysiological recording
may fill this role. In particular, the use of event-related brain potentials (ERPs),
generated from the electroencephalogram (EEG), have great utility in their ability to
examine often subtle processing differences that may be present in a cannabis-using
sample as well as the underlying impacts upon related cognitive processes.
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CHAPTER 4:

CHRONIC USE OF CANNABIS AND POOR NEURAL

EFFICIENCY IN VERBAL MEMORY ABILITY

EMPIRICAL STUDY 1

MANUSCRIPT PUBLISHED IN PSYCHOPHARMACOLOGY (BERLIN)
SEE APPENDIX F FOR PUBLISHED VERSION

Battisti, R. A., Roodenrys, S., Johnstone, S. J., Respondek, C., Hermens, D. F., &
Solowij, N. (2010). Chronic use of cannabis and poor neural efficiency in verbal
memory ability, Psychopharmacology, 209, 319-330.
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4.1.

ABSTRACT

The endogenous cannabinoid system is sensitive to the introduction of exogenous
cannabinoids such as delta-9-tetrahydrocannabinol (delta-9-THC), which are known to
impact upon memory functioning. We sought to examine the impact of chronic cannabis
use upon memory-related brain function via examination of the subsequent memory
effect (SME) of the event-related potential (ERP). The SME is predictive of recall
outcome and originates in structures that are dense with cannabinoid receptors
(hippocampus and parahippocampus). The SME and performance on a verbal memory
task were compared between 24 cannabis users (mean 17 years of near daily use) in the
unintoxicated state and 24 non-using controls. The task involved the presentation of
word lists, each with a short delay before recall. ERPs were recorded during encoding
and later averaged by outcome (correctly recalled/not recalled). Cannabis users showed
poorer recall and altered patterns of SME activation: specifically, attenuation of the
negative N4 and an increase in the late positive component (LPC). Duration of cannabis
use and age of initial use correlated significantly with SME amplitudes. A longer history
of use also correlated with greater recall that was related to N4 expression. The results
indicate that, relative to non-using controls, chronic users of cannabis have altered
memory-related brain activation in the form of dysfunctional SME production and/or
poorer neural efficiency, which is associated with deficits in memory recall. Greater
alteration was associated with a longer history of cannabis use and an earlier onset of
use. Neuroadaptation to the effects of chronic exposure may additionally play a role.
Keywords: Cannabis,
neuroadaptation, N4.

ERP,

subsequent

memory

effect,

neural

efficiency,
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4.2.

INTRODUCTION

Short-term memory impairment is regularly reported as a common side-effect of
cannabis use and it is the perceived persistence of this impairment outside of acute
intoxication that can encourage discontinuation of use. Even among those who regularly
use cannabis and have little or no intention of ceasing use, memory problems are
recognized as an impediment that is experienced on an ongoing basis. Within the
literature, cannabis-related short-term memory loss has been well documented in the
context of acute exposure (for review, see Ranganathan and D'Souza 2006) and,
recently, in relation to chronic use (for review, see Solowij and Battisti 2008).
delta-9-tetrahydrocannabinol

(delta-9-THC),

the

primary

psychoactive

constituent of cannabis plant matter, binds to receptors that are abundant within frontal
cortical regions of the brain, as well as the hippocampus, substantia nigra and
cerebellum (see Ranganathan and D'Souza 2006). The frontal cortex and hippocampus
are critical to sustained attention, working memory and long-term memory functions.
The introduction of exogenous delta-9-THC is therefore likely to disrupt the normal
functioning of these receptors, and hence the function of these brain regions. During
acute intoxication with delta-9-THC, memory impairment is most frequently
documented for immediate and delayed free recall of information (see Ranganathan and
D'Souza 2006). Impairment also includes manipulating the contents of working
memory, failure to use semantic processing and organization to optimize episodic
memory encoding, and impaired retrieval performance (e.g., Fletcher and Honey 2006).
While memory impairment during acute exposure to cannabis may be quite marked
(Ranganathan and D'Souza 2006), chronic effects of cannabis (i.e. during the
unintoxicated state following long-term use) appear to result in more subtle impairment
that can consequently be harder to detect (Grant et al. 2003). A recent review by
Solowij and Battisti (2008) sought to clarify the extent to which impairments may
persist beyond acute intoxication; the literature showed overall impaired encoding,
storage, manipulation and retrieval mechanisms in long-term or heavy cannabis users.
The findings were indicative of persistent impairment suggesting underlying brain
changes associated with cannabis use. Research has increasingly focused on chronic
use-related impairment and, in particular, verbal memory ability. Verbal memory tasks
involving the learning of word lists, and providing measures of immediate and delayed
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recall, as well as rate of learning and error intrusion, have typically been used due to
their sensitivity for detecting brain injury and dysfunction (e.g., Bolla et al. 2002;
Messinis et al. 2006; Pope et al. 2001; Pope and Yurgelun-Todd 1996; Solowij et al.
2002). Poorer learning and word recall, as well as increased susceptibility to
interference, has been observed to occur for chronic cannabis users in comparison to
non-using healthy control participants.
Structural brain changes associated with chronic use of cannabis have recently
been observed (Solowij et al. 2009), as have functional brain activation differences
during the execution of verbal and spatial working memory tasks (e.g., Block et al.
2002; Jacobsen et al. 2004; Jacobsen et al. 2007; Jager et al. 2006). Such brain imaging
methods, however, lack the temporal resolution required to examine at the millisecond
level the processing of discrete cognitive events, a subtle dysfunction of which may be
evident with chronic cannabis exposure. Event-related potentials (ERPs) are able to
provide this level of precision.
To date, there have been a limited number of neurophysiological studies of
cannabis users specifically utilizing ERPs, and fewer still examining chronic use.
Alterations in brain electrical activity have been observed for both early and late ERP
components. In studies of acute administration, Roser et al. (2008b) have recently
shown that delta-9-THC modulates the amplitude of the mismatch negativity
component, an early index of sensory memory, Leweke et al. (1998) found enhanced
positivity from 250ms onwards following the presentation of previously learned words
in an emotional word recognition task, while Ilan et al. (2005; 2004) found attenuated
ERP amplitudes, including a reduced N400, in spatial working memory and word
recognition tasks. In studies of chronic users during the unintoxicated state, Patrick et al.
(1999) showed a reduced P50 auditory gating response and Rentzsch et al. (2007)
determined that this P50 deficit was also evident in 28 day abstinent chronic cannabis
users, and correlated with the duration of cannabis use. Kempel et al. (2003) found
evidence of altered selective attention processes indexed by the N2 and P3 components,
which were associated with early onset cannabis use. Skosnik and colleagues found
larger P300 amplitudes to unpleasant trait words in an affect processing task in one
study (2008b), and altered steady state visual evoked potentials in another (2006b).
Wölfling et al. (2008) found a larger late positivity in visual ERPs to drug-related cues.
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Solowij et al. (Solowij et al. 1991; 1995b) and Solowij (1998) observed differential
effects of duration versus frequency of cannabis use in a selective attention task. Frontal
processing negativity to irrelevant stimuli increased with the duration of exposure to
cannabis in current users and in ex-cannabis users (mean abstinence 2 years), suggesting
persistent changes in the brain. P300 latency increased with increasing frequency of use
in current users only, suggesting a short-term effect potentially associated with a
buildup of cannabinoid residues in the brain. While far from exhaustive, these studies
do indicate ERPs are a useful, and under-utilized measure in the identification of altered
brain activation associated with cannabis exposure that manifests as disruption to the
normal electrophysiological signatures elicited during a range of different tasks.
ERP studies in normal populations have established reliable components related
to memory processes. An electrophysiological complex, labeled the subsequent memory
effect (SME), is thought to index successful memory encoding. Characterized by
differences in brain electrical response amplitude to encoded versus non-encoded items,
the SME includes a negative peak occurring approximately 400 ms post-stimulus (N4 or
N400) and a late positive component (LPC) emerging approximately 500 ms poststimulus. For memory encoding tasks the N4 has been suggested to originate in the
parahippocampus (Friedman and Johnson Jr 2000). Evident frontally, a reduced N4
indicates successful storage of to-be-encoded items (Dunn et al. 1998; Fernandez et al.
1998). Recent evidence suggests the N4 to be sensitive to brain dysfunction, in
particular verbal processing (e.g., Ceballos et al. 2005) and memory deficits at older
ages (e.g., Olichney et al. 2008). The LPC is thought to originate within the
hippocampus for memory tasks (Friedman and Johnson Jr 2000). Maximal parietally,
greater positivity is apparent for successfully encoded items (e.g., Blanchet et al. 2007;
Dunn et al. 1998; Fernandez et al. 1998; Otten et al. 2007). Disruption of the structures
that subserve either component would be expected to be reflected in the morphology of
SME components.
Since the underlying brain structures of the SME, as well as related memory
processes, are densely populated with cannabinoid receptors (Felder et al. 1996),
exogenous cannabinoids may disrupt their expression. Chronic administration may
potentially lead to more enduring disruption, such as interference within the brain’s
reward circuitry and desensitization of cannabinoid receptors (e.g., Hoffman et al. 2003;
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Sim-Selley 2003). As delta-9-THC can become concentrated in adipose tissue (fat), the
liver, lung and spleen with regular use, and is then slowly released back into the blood,
it has quite a long terminal half-life (Musshoff and Madea 2006; Onaivi et al. 2006).
This persistence of delta-9-THC within the body may result in regular users
experiencing chronic mild intoxication with corresponding altered brain function. Such
effects may be apparent in association with measures of recency and frequency of
cannabis use and/or cannabinoid residues (for example, as measured by urinary
cannabinoid metabolites), and would be expected to dissipate once residues were
eliminated from the body. Effects associated with the duration of exposure or the
cumulative dose of exposure to cannabis, suggest more enduring effects on brain
function, which may or may not recover upon cessation of use. There is mixed evidence
in the literature regarding the persistence of cognitive deficits following cessation of
cannabis use (e.g., Bolla et al. 2002; Pope et al. 2001; Solowij 1995; Solowij 1998;
Solowij et al. 1995a). Recent research has demonstrated significant dose-related
reduction of hippocampal volume in chronic cannabis users who also showed memory
deficits (Yücel et al. 2008). This suggests that long-term heavy exposure to cannabis
may indeed result in changes to brain structures. There is also growing evidence that a
younger age of onset of cannabis use may be associated with greater adverse cognitive
outcomes (see Solowij and Battisti 2008). As such, a thorough investigation of multiple
parameters of cannabis use on specific cognitive processes inherent within memory
function is warranted.
Given the potential of ERPs as a measure of subtle brain dysfunction, and the
relatively reliable presence of SME components during memory encoding, this study
sought to address the possible impact of chronic cannabis use on these measures.
Evidence linking cannabis use with impaired verbal memory performance indicates the
utility of this line of research. By combining well-established behavioral performance
measures with electrophysiological measures, this study sought to identify SME as a
biomarker for quantifying the effects of long-term cannabis use.
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4.3.

METHODS AND MATERIALS

4.3.1. Participants
Twenty four long-term users of cannabis (13 males) and 24 controls (11 males) were
recruited from the general community via advertisement in newspapers and posters. A
30-minute telephone screening interview was conducted with each potential participant,
to determine eligibility for the study.
For all participants, inclusion required being between the ages of 18 and 55, no
history of diagnosis with any psychiatric disorder or neurological injury, and a native
English speaker. For substances other than cannabis, alcohol or nicotine, no participant
had any more than a limited history of recreational use (less than 10 times for any
particular substance and no more than 3 times in the past year). To qualify for inclusion
as a cannabis user, participants must have been using cannabis at least 4 days per month
(n = 23 participants used 15 or more days per month) for a minimum of 3 years. Control
participants were selected to match cannabis users on key demographics (i.e. sex, age,
and educational experience).

4.3.2. Procedure
The study was approved by the University of Wollongong Human Research Ethics
Committee and all participants gave written informed consent. Each individual received
$50 for participating in the study.
Suitable participants were invited to attend a 3 hour test session at the University
of Wollongong where a more detailed history was taken via structured interview and
neurocognitive ability tests were administered. Cannabis users were required to abstain
from use for at least 12 hours prior to the test session and tobacco smokers from either
group were allowed to smoke cigarettes up until its commencement and then not until
the completion of the session. Urine samples were obtained from cannabis users from
the night prior and on the day of testing, and from controls on the day of testing, to test
for illicit drug use and for corroboration of self-reported abstinence from cannabis.
While 2 participants tested positive for sympathomimetic amines, this was corroborated
by prior self-reported use of cold and flu medication. Consequently, no participant was
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required to be excluded based upon the toxicology screen. Participants underwent a
face-to-face structured interview of between 60 and 75 minutes. Information collected
included age, handedness, educational, medical, and mental health (both personal and
family) histories, as well as detailed questioning regarding any type of substance use
(including alcohol and tobacco). Age of first use of cannabis, as well as the age of onset
of regular use (at least twice/month) were determined as measures of the duration of
cannabis use. A questionnaire assessing withdrawal symptoms was also used to
determine the potential impact of at least 12 hours abstention. This consisted of 8 items
rated on a 0 – 4 Likert scale reflecting symptoms of overall withdrawal, cravings,
headaches, agitation, irritability, concentration and coordination difficulties, low or sad
mood, and anxiety. This produced a total withdrawal score out of 40. An estimate of
Wechsler Adult Intelligence Scale 3rd Edition Revised (WAIS-III-R) Full Scale IQ was
obtained from the National Adult Reading Test (NART; Nelson and Willison 1991), as
a measure of premorbid intellectual functioning.
Following completion of these tasks, participants were fitted with an electrode
cap and were seated in a dimly lit, electrically shielded, sound-attenuated and airconditioned booth. They then completed the verbal memory task and were assessed on
their strategy use at the conclusion of the task.

4.3.3. Verbal Memory Task
The verbal memory task consisted of 11 administration trials of lists of 14 words
(including a practice list) that were presented in the centre of a computer screen in front
of the participant. Words in each list all came from the same semantic category (e.g.
fruits, animals). The order of lists and words within lists was randomised for each
participant. On each trial the category name appeared for 3000 ms (e.g. ‘FLOWERS’),
followed by a fixation arrow pointing upwards and indicating the location of the list
words. The arrow persisted for the remainder of the trial. Following a 5000 ms interval,
list words (e.g. ‘DAISY’, ‘ORCHID’, ‘ROSE’) appeared successively for a 2000 ms
duration with no inter-stimuli interval. A 10 second retention period followed the
presentation of the list items, after which a 1400 Hz tone sounded for 250 ms, indicating
the start of the recall phase. Participants had been pre-instructed to recall aloud as many
of the words from the list that they could remember. They were not explicitly instructed
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to recall the words in the order presented. If this was queried, the instruction of “just
recall as many words as you can” was given. At the conclusion of the task, participants
were given a questionnaire assessing their use of memory strategies. They were first
asked an open-ended question about whether they used any conscious strategies to help
them remember the words. To determine the degree to which participants used
categories for retention and/or encoding, at the conclusion of the task they were asked to
choose from the following strategies which they used most often to help them remember
the words: visual imagery, making up stories or sequences of events, chunking words
together, using categories, or rote repetition. Finally, they were asked to rate how
difficult it was to use their primary strategy on a 1-5 Likert scale.

4.3.4. Physiological Measures
Scalp electroencephalogram was recorded using an Electro Cap from 19 electrode sites
(Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, T4, T5, T6, Pz, P3, P4, O1 and O2) using the
international 10-20 system with a ground electrode located between Fpz and Fz. The
electro-oculogram was measured vertically by electrodes placed 1 cm above and below
the left eye. All electrodes were referenced to linked ears. Impedance was below 3 kΩ
for EOG and reference electrodes, and below 5 kΩ for scalp electrodes. EEG was
recorded at 500 Hz via a NuAmps system and Scan software and amplified 19 times
with a bandpass filter of 0.1 Hz and 30 Hz. The use of amplification via a 32-bit A/D
converter allowed for high resolution sampling of small voltages.

4.3.5. Data Extraction and Statistical Analysis
In order for all data to be included in parametric comparisons, statistical normalization
(transformation) of those behavioral and substance use variables that violated normality
assumptions was carried out according to procedures recommended by Tabachnick and
Fidell (2000). Procedures used are cited within Table 1. Word recall performance and
the primary strategy use difficulty rating were subjected to independent samples t-tests,
and chi-square analysis was used to compare primary strategy use between groups.
ERP epochs were generated 100 ms pre-, and 900 ms post-presentation of each
word list item. Baseline correction used the 100 ms pre-stimulus period. Post-list
participant free recall allowed classification of each epoch as representing either a
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correctly recalled (CR) or not recalled (NR) word. Vertical EOG was calculated
averaging the two eye channels, and used for the ocular artifact reduction procedure
(Semlitsch et al. 1986) to remove the effects of blink and other eye-movements from the
EEG. Remaining epochs containing amplitudes exceeding ±100 µV (considered
artifacts) were excluded from analysis. As the number of available epochs varied
between and within subjects (for correctly recalled, CR, and, not recalled, NR trials), the
number of epochs included in an average was calculated for each participant according
to the trial type with the fewest epochs. An equal number of epochs from the other trial
type were selected randomly. This procedure was used to ensure comparability within
subjects as per our standard laboratory practice (e.g., Johnstone and Clarke 2009). Thus,
if for example, a participant had 80 CR and 60 NR epochs available, all 60 NR epochs
were used and a random 60 CR epochs chosen. This process was performance driven
and also took into account rejected epochs due to excessive artefact. Consequently, a
minimum of 30 epochs were included for any given condition or participant.
ERP amplitudes were measured at nine sites (F3, Fz, F4, C3, Cz, C4, P3, Pz, and
P4) using site-based analyses within each region (i.e. midline: Fz, Cz, Pz; frontal: F3,
Fz, F4; central: C3, Cz, C4; and parietal: P3, Pz, P4) with grand average ERPs inspected
for prominent positive and negative peaks. Two major components consistent with the
SME literature were identified, i.e. the N4 and LPC. Maximal at Fz, a 365 – 445 ms
latency range was used for measuring the N4. N4 latency and amplitude were compared
between groups for correctly recalled (CR) and not recalled (NR) epochs. LPC was
examined in line with the method used by Paller et al. (1987), with NR epochs
subtracted from CR epochs for the 445-900 period post-stimulus (from the end of the
N4 latency window to the end of the ERP epoch). This differential parietal-maximum in
brain activity was labelled ‘Dm’ for difference in subsequent memory.
A 2 (group) x 2 (condition) x 3 (site) repeated measures analysis of variance
(ANOVA) using planned contrasts was used to examine differences between groups
(control vs. user), for each condition (CR vs. NR), between sites for each region (e.g.
frontal: F3, Fz, F4) as factors for N4 amplitude. Although N4 tends to be observed
frontally and the LPC parietally, all regions were examined in order to better examine
possible alterations in topography associated with cannabis use. N4 latency was
examined from the site of maximum amplitude (Fz) between conditions (CR vs. NR)
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and group (control vs. user) in a 2 x 2 repeated measures ANOVA. A 2 x 3 repeated
measures ANOVA using planned contrasts was applied to the LPC Dm data examining
differences between groups (control vs. user) within each region. Cohen’s d (d) was
calculated as a measure of effect size for all significant effects involving a comparison
of means.
Following quantitative comparisons, Pearson’s product-moment correlations
were performed between ERP amplitude and latency measures, and performance,
demographic and cannabis use variables for each group separately. As the N4 is largely
a frontally-observed component, and also to better distinguish it from the parietallylocated LPC, the mean of the three frontal sites (F3, Fz, F4) was used for correlational
analyses for CR and NR trial types. The mean of the parietal sites (P3, Pz, P4) was used
for LPC Dm.
4.4.

RESULTS

4.4.1. Demographic and Cannabis Use Variables
Table 1 presents the mean values and statistical comparisons for demographics and
substance use measures. All comparisons were made using independent samples t-tests
unless otherwise specified. There were no differences between groups in gender
distribution, age, educational experience or NART-estimated WAIS-III-R Full Scale IQ.
Cannabis users self-reported abstaining from cannabis for a mean 20 hours and
Table 1 shows levels of cannabinoid metabolites (11-nor-delta-9-tetrahydrocannabinol9-carboxylic acid, creatinine normalized) detected in urine samples from the night
before and day of testing. The high levels of metabolites observed are consistent with
the reported heavy use of the sample, and the overall drop in levels suggests truthfulness
in requested abstention. No control subject tested positive for cannabinoid metabolites.
No participant met the criteria for alcohol or substance abuse or dependence (other than
for cannabis). Cannabis users and controls did not differ in levels of current alcohol
consumption. There were more tobacco smokers within the cannabis-using group and
all but 4 users mixed their cannabis with tobacco. For cannabis use history, additional
information was collected about patterns and duration of use and methods of use (i.e.
via ingestion, or smoking via pipes, water pipes, joints or inhalers). The median days of
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use per month was 30 and therefore total cones per month, rather than frequency, was
selected for subsequent analyses. The majority of users preferred to use a water pipe
(bong) - a cylindrical device with a water chamber and recess for a cone. A cone is a
small receptacle where cannabis and/or tobacco may be placed and upon burning, the
smoke inhaled in a single inhalation. Without loss of sidestream smoke, one cone is
thought to deliver delta-9-THC equivalent to smoking 1/3 of a standard cigarette sized
joint (Yücel et al. 2008). Additionally, few users indicated any other than very mild
symptoms that may be related to cannabis withdrawal.
Table 4-1. Demographic and substance use measures. Mean (SD) or Median [Range] is
included for each group.

1

Gender (% females)
Age
Education
WAIS-III-R FSIQ
Age of first cannabis use 2
Duration since first cannabis use (years)
Age of regular cannabis use 2
Duration of regular cannabis use (years)
Frequency of cannabis use (days per month) 3
Quantity of cannabis use (cones per month) 2
Hours since last cannabis use 2
Withdrawal 2
Urinary metabolites (ng/mg) evening before 2
Urinary metabolites (ng/mg) day of testing 2
Standard alcoholic drinks per week 2
Cigarettes per day 1,4

Controls (n = 24)

Users (n = 24)

P

54.2
35.5 (11.5)
14.4 (2.0)
106.2 (6.2)
2.3 [0-15]
0 [0-15]

45.8
36.4 (11.2)
13.2 (2.9)
101.3 (12.0)
15 [12-25]
20.2 (9.7)
17 [13-42]
17.0 (9.3)
30 [4-30]
435 [30-1500]
13 [9-108]
3.5 [0-19]
1034.5 [109-4696]
988 [126-2935]
6.5 [.30-59]
0 [0-30]

.564
.791
.118
.080
.343
.002

1

Pearson chi-square analysis.

2

A Log10 transformation was applied to the data to correct for normality violations.

3

This variable was not used in analyses due to a lack of variability (75% of cannabis users were using 25 days
or more per month).

4

This variable was not used in subsequent analyses due to a low number of tobacco smokers in both groups (n =
11 cannabis users (other than for mixing with cannabis) and n = 1 controls smoked tobacco weekly).

4.4.2. Behavioural Data
Cannabis users recalled significantly fewer words than controls across all word lists
presented (proportion recalled words users (mean 49.1 [SD 10.9]) vs. controls (mean
56.7 [SD 9.6]): F[1,46] = 2.57, P = .013, d = .74). As a proportion, this represents an
average reduction of 13.5% in correct recall for users in comparison to controls. The
mean words recalled per list by users was 6.87 [SD 1.52], and for controls 7.94 [SD
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1.34]. Percentage of correctly recalled words also correlated marginally significantly
with duration of regular cannabis use (r = .399, P = .053). A longer history of regular
use was associated with a greater number of correctly recalled words.
Groups did not differ in the nature of the primary encoding strategy used (χ2 = 4.881, P
= .181), although controls appeared more likely to use visual imagery and less likely to
use rote learning strategies than users, and both groups relied heavily upon
categorization. Cannabis users rated strategy use as significantly more difficult than
controls (mean difficulty rating: users 3.83 [SD 1.17]; controls 2.88 [SD 1.36], T[1,46]
= 2.618, P = .012).

4.4.3. ERP Results
Grand mean ERPs to word presentations at each of the 3 midline scalp sites are
displayed for the control and user groups in Figure 1 for correctly recalled (CR) and not
recalled (NR) words. Differences between groups appear to begin from the onset of the
frontal N4 window (approximately 350 ms) and continue through the parietal LPC (445900 ms) with an overall shift to greater positivity (i.e. reduced N4 and increased LPC)
among users.
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Figure 4-1. Grand average ERPs for controls (left) and users (right) for correctly
recalled (CR; thick line) and not recalled (NR; thin line) trials at the time of encoding at
midline frontal (Fz; top), central (Cz; middle) and parietal (Pz; bottom) sites. Time (ms)
is indicated on the x-axis and amplitude (µV) on the y-axis, where by convention
negative is up.
4.4.3.1.

N4 Latency

N4 latency at Fz differed marginally significantly between groups, F[1,46] = 3.789, P =
.058, with users showing a shorter latency than controls (mean difference = 13.88 ms).

4.4.3.2.

N4 Amplitude
There was a marginally significant group by condition by site interaction for

midline N4 amplitude, F[1,46] = 3.724, P = .060, d = .74. Figure 2 shows that although
the overall pattern of larger N4 for frontal (Fz) relative to parietal (Pz) locations exists
for both groups, user N4, relative to controls, is attenuated particularly on CR trials
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frontally and on NR trials parietally. There was a significant group by region interaction
for N4 amplitude at central sites, F[1,46] = 4.467, P = .040, d = 2.19. User N4 was
greater within the left compared to the right sites, whereas the difference was minimal
for controls. This pattern varied significantly with condition, F[1,46] = 4.748, P = .034,
d = 2.24. Users had greater overall variability between sites with this particularly
evident on NR trials. This pattern was not evident for controls. These results can be seen
in Figure 2.
There was a significant group by site interaction for N4 amplitude frontally,
F[1,46] = 4.154, P = .047, d = 1.70, as well as parietally, F[1,46] = 8.936, P = .004, d =
2.14, as seen in Figure 3. Controls showed increased N4 at Fz relative to the lateral
sites, with this enhancement of N4 at Fz absent in users. A pattern of reduced N4 for the
parietal right (P4) relative to the left hemisphere (P3) was present for users but not
controls. These effects did not vary with condition, P > .05.

4.4.3.3.

LPC Dm (Differential Maximum) analyses

Evident centrally and parietally, the LPC Dm did not vary between groups at frontal
sites, P > .05. Figure 4 shows the significant group by site interactions at central,
F[1,46] = 8.836, P = .005, d = 4.43, and parietal sites, F[1,46] = 4.691, P = .036, d =
4.18. Users showed a larger difference at Cz relative to controls, and at Pz relative to
lateral sites (P3, P4). Controls showed a general linear decrease from left hemisphere
(C3, P3) across midline (Cz, Pz) to the right hemisphere (C4, P4).
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Figure 4-2. N4 amplitude for control and user participants on CR and NR trials at midline (a) and central
(b) sites. As the N4 is a negative-going component, reverse values are shown for amplitude (µV) on the yaxis. Vertical lines show the standard error of the mean (SEM).
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4.4.4. Correlational analyses
Table 2 shows correlations between SME components and participant demographic and
cannabis use variables. Controls showed a single correlation only with age and N4
amplitude on correct trials, whereas users had significant correlations for age, IQ and
percentage of correctly recalled words with N4 amplitude on both trial types. Higher
scores on these variables were related to attenuated N4 (i.e. more positive as this is a
negative-going component). Positive correlations were observed between N4
amplitudes and age of first cannabis use and age of regular use, and with duration of
use, although there were no observed relationships with quantity of exposure per month
nor with levels of cannabinoid metabolites or measures of recency of use or withdrawal
scores. Controlling for age resulted in a loss of significance for cannabis usage history
variables with N4, P > .05. However, controlling for duration since first use and
duration of regular use on CR and NR trials, respectively, resulted in a loss of
significance for the N4 correlation with age, P > .05, thus indicating relationships to be
jointly explainable by age and usage variables. There were no significant correlations
with N4 latency, P > .05 (not included in the table), or the LPC.
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Table 4-2. Significant correlations for SME components with participant demographic
and cannabis use variables.
N4 CR1

N4 NR1

LPC1

Controls
Age
Education
IQ
% of words recalled

2

Drinks per week

.520**

.217

.258

.173

.039

.339

.179

-.149

.198

-.089

-.131

.147

-.201

-.052

-.091

.777**

.549**

.218

.188

.101

.209

Users
Age
Education
WAIS-III-R FSIQ

.405*

.434*

.019

% words recalled 2

.520**

.541**

-.085

Age of first use

.447*a

.457*a

-.016

.344

.110

Age of regular use
Duration since first use

.624**
.730**

a

b

a

a

.258

b

.088

.452*

Duration of regular use

.476*

Quantity of use (cones/month)

-.180

.442*
.067

.024

Withdrawal

-.276

.182

-.118

Urinary metabolites (ng/mg) evening before

.268

.121

-.141

Urinary metabolites (ng/mg) day of testing

.195

.073

-.113

Hours since last use

.046

.122

.040

Drinks per week

-.033

.017

-.098

1

Correlations were performed using mean amplitudes for regions of interest for SME components (i.e.
mean of frontal sites for N4 and mean of parietal sites for LPC).
2
% of words recalled did not correlate significantly with any demographic or cannabis use parameter (p
> .05), other than a marginally significant correlation for users (r = .399, p = .053) with duration of
regular cannabis use.
* p < .05
** p < .01
a
Correlation lost significance after controlling for age.
b
Relationship due to both variable and age.
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4.5.

DISCUSSION

Reliable differences in memory-related neurophysiological functioning were observed
for cannabis users compared to controls within this study. An overall shift to positivity
and changes to variability within regions was observed for users on both SME
components of interest, with N4 earlier and attenuated and LPC increased. Altered
activation of the N4 occurred on correctly recalled versus not recalled trials between the
two groups, with a longer history of cannabis use related to attenuated N4. Behaviorally,
users showed significantly poorer performance in verbal memory, although poorer word
recall performance appeared to correlate with a shorter history of regular use. These
findings represent evidence that chronic use of cannabis is related to altered patterns of
brain function that underlie poor memory performance and that possible neuradaptation
occurs with an increased history of regular use. Notably, the first 350 ms of the ERPs
were similar; however, the critical N4-LPC window showed marked differences across
groups and conditions. In particular, the overall shift to greater positivity may be due to
N4 peaking earlier for users and interpreted as a general failure to efficiently activate
memory-related brain structures, and the overall pattern of results as demonstrating
poorer neural efficiency and use of compensatory structures.
The behavioral results suggest that chronic use of cannabis affected either the
encoding, retention or recall of study items. The level of poorer performance observed
is largely consistent with other studies of short-term verbal memory ability among
chronic cannabis users (see Solowij and Battisti 2008). The data on strategy use
indicates both groups used the pre-list category label to aid recall. While it cannot be
ruled out, the use of categories likely served to reduce the effect of interference from
other lists and therefore findings observed here can be specifically related to memory
encoding, retention and recall processes. The extent of potential disruption to other
memory processes within the retention and recall phases though cannot be determined
in the present study due to their lack of suitability for ERP analysis. Given the trend for
greater accuracy being related to an increased history of regular use, within the context
of overall poorer group performance, there may be some recovery of functioning
occurring. Specifically, regular use of cannabis causes poorer performance on tests of
verbal memory with continued exposure resulting in neuroadaptation via the recruitment
of compensatory processes and/or structures that is behaviourally evident by an
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approach to normal (although still likely impaired) level of function. Unlike the
mechanisms underlying the development of tolerance, those that may underly longerterm neuroadaptation have yet to be determined. We propose that these most likely
involve the alteration of function of brain structures underlying memory function with a
resultant shift toward recruitment of additional compensatory regions that facilitate task
performance. This is consistent with a recent study by Ramaekers et al. (2009) that
observed a reduced response to the cognitively impairing effects of acute delta-9-THC
exposure among heavy users of cannabis relative to that of occasional users. Having not
examined short-term heavy users in our study, identifying a reliable increase in
impairment following onset of regular use could not occur here. However, a longer-term
neuroadaptation process may explain the increased performance among longer-, relative
to shorter-term users during the unintoxicated state. Our significant correlations
between N4 amplitude with accuracy and IQ only among cannabis users add weight to
the possibility of neuroadaptation following chronic exposure to exogenous
cannabinoids with a likely interaction with available cognitive resources. During verbal
memory encoding processes, the N4 may have utility as an index of neuroadaptation
following brain insult.
Prior

research

has

indicated

altered

functioning

of

memory-related

neurophysiological components with exposure to cannabinoids. In their study of the
acute effects of cannabis upon brain electrical markers of memory processes, Ilan et al.
(2004) observed, during the recognition memory component, an attenuated slow wave
(equivalent to our LPC) with no change in a component equivalent to our N4. Although
not directly comparable to ours given that retrieval, as opposed to encoding, processes
were examined, their findings were largely in opposition to our own. If the assumption
is made that N4 and LPC to encoded items are expressed similarly at the point of
encoding as well as recognition, there are two likely explanations for the lack of
similarity in findings. Firstly, Ilan et al. (2004) administered an acute dose of delta-9THC, whereas our participants had all temporarily abstained from cannabis for a period
of at least twelve hours, resulting in an unintoxicated state (or chronic mild intoxication
due to the persistence of delta-9-THC residues). Secondly, participants in the Ilan et al.
(2004) study were classified as “casual” users, with levels of use varying from one day
per month to one day per week. While Ilan and colleagues did not report mean days of
use across the group, our participants used a median 30 days per month and had a mean
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of seventeen years of regular use. A subsequent similarly constructed study by Ilan et al.
(2005) replicated their original findings with the additional observation of attenuated
N400, as observed in our task. Although not definitive, this contrast in findings between
their studies may indicate that while the LPC shows an altered response for chronic
exposure measured during the unintoxicated state in comparison to acute exposure
among casual users, N400 is less reliable in its expression following acute intoxication.
It has recently been demonstrated that heavy chronic users of cannabis show evidence
of reduced response and neuroadaptation to delta-9-THC compared to occasional users
(e.g., Ramaekers et al. 2009). As long-term heavy smokers, our participants are
therefore likely showing some form of neuroadaptation as a result of their long term
heavy exposure to cannabis. Our finding of increased attenuation of the N4 with a
longer history of use supports this notion. Due to a relative paucity of
neurophysiological studies of chronic users, additional comparisons cannot easily be
drawn. A recent review by Ceballos et al. (2009) has indicated both a high likelihood of
neurophysiological disruption from chronic use as well as a distinct need to examine
this further.
The concordance of our control participant SME morphology with the findings
of earlier investigations into this electrical complex (for review, see Friedman and
Johnson Jr 2000) implicates the expression of parahippocampal and hippocampal
functioning in our results; as these are believed to be the generators of the SME N4 and
LPC, respectively. The altered functioning of SME components among the cannabis
users suggests the possibility that the functioning of these particular structures, that are
dense with cannabinoid receptors, may be disrupted. As discussed above, the overall
shift to positivity and the more widespread brain activation reflects a less efficient brain
response. The tendency for users to have a shorter latency may indicate that it is peaking
earlier for this group. This may represent inadequate activation of the structures
subserving the N4 and consequently contribute to the pattern of overall increased
positivity (or reduced negativity) observed also for the LPC as well as the apparent need
for alternate structures. Consequently, our findings indicate a need for greater
recruitment of resources within the parahippocampus and hippocampus during the
performance of a verbal memory task, as well as possible use of additional structures, to
compensate for disruption to optimal brain signaling brought about by chronic exposure
to cannabis. This interpretation accords also with the evidence for reduced hippocampal
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volumes in chronic cannabis users (Yücel et al. 2008), which may translate to impaired
hippocampal function and require the recruitment of additional compensatory brain
structures in an attempt to achieve successful performance. Evidence of neuroadaptation
among longer-term users of cannabis (e.g., Ramaekers et al. 2009) suggests that the
changes observed here may be enduring.
While not easily explainable, the altered relationship observed within our study
of the N4 with age for users compared to controls suggests that chronic use of cannabis
may result in an altered pattern of brain aging. Comparing the general ERP profile of
cannabis users in our study to the normative literature reveals similarities with findings
associated with aging. Nielsen-Bohlmen and Knight (1995) observed both attenuated
N4 and increased LPC-like positivity among older adults and Olichney et al. (2008)
suggested that disruption of the N4 and P600 (possibly similar to our LPC) may be
indices of conversion to dementia. Although utilizing recognition memory tasks, and
thus making direct comparisons difficult, these studies do suggest that late
neurophysiological components, such as the N4 and LPC, are likely to be predictive of,
or at least related to, increased dysfunction in later life. Examination of this hypothesis
within the current study is not possible due to a lack of power. A larger sample size in
future research would be better position to gain insight into this phenomenon.
A difficulty within our study was an inability to rule out the influence of residual
levels of cannabinoids within the body and/or withdrawal from cannabis. However,
neither recency of use, metabolite levels, nor self-reported withdrawal symptoms
correlated with accuracy or SME measures. Additionally, the high probability of
neuroadaptation within our cannabis using sample would make it unlikely that residual
levels would be related to substantive alterations. Of possible influence to the findings
of this study are the effects of nicotine withdrawal within the cannabis-using group.
With a median 0 cigarettes per day and tobacco smokers being allowed to smoke up
until approximately 1½ hours prior to our ERP recording, it is unlikely that many, if
any, participants were experiencing serious nicotine withdrawal. However, measuring
nicotine withdrawal in future studies would ensure that any influence of this potential
confound was accounted for.
In conclusion, our study demonstrates that chronic exposure to cannabis impacts
upon verbal memory processes. This is evident both at the behavioural and
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neurophysiological level through the use of measures of recall and brain electrical
response. Alterations in SME components were indicative of disruption in optimal brain
functioning and poorer neural efficiency. The more widespread activation observed
indicates altered neural signaling and possible recruitment of compensatory mechanisms
(i.e. neuroadaptation via use of adjacent/alternate brain structures). In addition, the N4
proved to be particularly sensitive to the duration of cannabis use and performance on
the verbal memory task, and therefore has utility as a biomarker in future investigations.
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CHAPTER 5:

CHRONIC CANNABIS USE IS ASSOCIATED WITH

DEFICITS IN THE PSYCHOPHYSIOLOGICAL OLD/NEW EFFECT
IN MEMORY RECOGNITION

EMPIRICAL STUDY 2
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5.1.

ABSTRACT

Tests of recognition memory are believed to be highly sensitive to changes in memory
and brain function and so may be likely to detect often subtle effects associated with
long-term cannabis use. We tested chronic (near daily) users of cannabis during the
unintoxicated state (n=21) and matched healthy non-using controls (n = 22) on a
measure of delayed recognition memory while event-related brain potentials (ERPs)
were recorded. ERPs have been demonstrated to be highly sensitive to changes in brain
functioning that may not be easily detected. Cannabis users showed a reduced ability to
discriminate previously seen from unseen words in comparison to controls as well as
alterations in early attentional (N1) and the later OLD/NEW effect present in N4 and P3
ERP components, indicative of poorer neural efficiency and use of compensatory
mechanisms. A longer duration of use and earlier age of use onset were related to
recovery of behavioural performance and alterations in brain activity, respectively,
indicating the presence of neuroadaptation. Factors related to current cannabis
consumption patterns also differentially affected outcome measures indicating that both
long and short-term factors influence brain electrical functioning and overt behavioural
performance.
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5.2.

INTRODUCTION

Memory-related impairment following acute use of cannabis is well documented (see
Ranganathan and D'Souza 2006) with recent studies showing effects that persist outside
of acute intoxication among long-term heavy users (see Solowij and Battisti 2008). The
ability of delta-9-tetrahydrocannabinol (delta-9-THC), the primary psychoactive
ingredient of cannabis, to impact upon these functions is related directly to the
distributed network of cannabinoid 1 (CB1) receptors that bind delta-9-THC. Located
throughout the brain, these receptors are particularly dense within the memory functionimplicated frontal cortex and hippocampus (Eggan and Lewis 2007; Iversen 2003;
Quickfall and Crockford 2006). Given the near constant exposure to exogenous
cannabinoids or their metabolites with long-term high levels of use, there is potential for
enduring functional changes within these memory structures.
Functional magnetic resonance imaging and positron emission tomography have
provided evidence of functional changes associated with chronic use of cannabis during
memory tasks (e.g., Block et al. 2002; Jacobsen et al. 2004; Jacobsen et al. 2007; Jager
et al. 2006), with evidence of structural changes more recently observed using magnetic
resonance imaging (e.g., Yücel et al. 2008). Although informative, such measures
provide limited insight regarding the subtle deficits associated with chronic cannabis
use. Since event-related brain potentials (ERPs) are highly sensitive to minor
fluctuations in brain neurological activity that can be mapped to particular cognitive
functions, ERPs have high utility for examining memory impairment in cannabis-using
populations. ERP studies examining both acute exposure to cannabis (e.g., Ilan et al.
2005; Ilan et al. 2004; Leweke et al. 1998; Roser et al. 2008a; Roser et al. 2008b) and
chronic use during the unintoxicated state (e.g., Battisti et al. 2010b; Patrick et al. 1995;
Rentzsch et al. 2007; Skosnik et al. 2006a; Skosnik et al. 2006b; Solowij 1998; Solowij
et al. 1991; 1995b; Wölfling et al. 2008) have reliably detected alterations in brain
electrical activity, highlighting the suitability of ERPs for the study of cannabis-related
effects on the brain.
Tests of memory ability also may be able to detect the subtle changes associated
with exogenous delta-9-THC exposure (see Zuurman et al. 2009). Verbal memory tasks
may be particularly advantageous due to their sensitivity for the detection of brain
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injury and dysfunction. In support of this, chronic cannabis use has been associated with
poorer verbal memory in terms of rate of learning, recall/recognition and susceptibility
to interference (e.g., Battisti et al. 2010b; Bolla et al. 2002; Messinis et al. 2006; Pope et
al. 2001; Pope and Yurgelun-Todd 1996; Solowij et al. 2002; Wagner et al. 2010).
Among ERP studies of verbal memory recognition, the OLD/NEW effect is considered
to be a robust finding, identified by a reduced (i.e. less negative) fronto-central N4 (a
negative-going ERP component approximately 400 ms post-stimulus presentation) and
larger (i.e. more positive) parietally-located P3 component (a positive-going component
present within the 300-800 ms range) for previously studied words in comparison to
new words (Friedman 2000; Friedman and Johnson Jr 2000; Kayser et al. 2009;
Mecklinger 2000). As an index of item familiarity and explicit recollection, alterations
in the expression of the OLD/NEW effect indicate dysfunction in the processes
underlying these components.
Recent studies have shown evidence indicative of neuroadaptation following
chronic and/or frequent use of cannabis, suggesting a gradual reorganisation of function,
and possibly structure, with continued use (e.g., Battisti et al. 2010b; Hart et al. 2010;
Hart et al. 2001; Mata et al. 2010; Ramaekers et al. 2009), as well as greater change
and/or greater impairment associated with an earlier age of onset (e.g., Battisti et al.
2010a; Battisti et al. 2010b; Harvey et al. 2007). We previously observed a greater
change in ERP alterations in a verbal memory task to be associated with a longer history
of use (Battisti et al. 2010b). These findings highlight the need to examine such usage
factors in detail, and as they relate to other measures of memory function, including
behavioural performance and brain activity measures.
Given the promise of tests of memory performance as biomarkers for
examination of the effects of cannabis use, the present study combined a recognition
memory task with ERPs. It was anticipated that the sensitivity of both measures,
specifically changes in overt behavioural responding as well as alterations in the
expression of the ERP-based OLD/NEW effect, would facilitate the examination of both
gross and more subtle effects associated with the chronic use of cannabis during the
unintoxicated state, as well as relationships with usage history factors.
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5.3.

MATERIALS AND METHODS

5.3.1. Participants
Current users of cannabis (n = 24) and healthy controls with a limited history of
substance use (n = 24; less than 10 times of use of any illicit substance and less than 4
times in the past year) were recruited from the general community via advertisement in
newspapers and posters. A 30-minute eligibility screening telephone interview was
conducted with each potential participant. Inclusion required being between the ages of
18 and 55, no history of diagnosis with any psychiatric disorder or neurological injury,
and a native English speaker. For inclusion in the present study, cannabis users were
required to have used cannabis at least 15 days per month for a minimum of 5 years.
Control participants were selected to match cannabis users on key demographics (i.e.
sex, age, and educational experience). While meeting inclusion criteria was based upon
an assumption of truthfulness in participant self-reporting, inclusion/exclusion criteria
(other than for cannabis use) were never revealed to participants. Additionally, selfreport is generally considered to be valid and reliable in the substance use literature (Del
Boca and Darkes 2003). Demographic data from some of the participants included in
the present study was previously published in Battisti et al. (2010a; 2010b) alongside
outcome measures from other experiments.

5.3.2. Procedure
The study was approved by the University of Wollongong Human Research Ethics
Committee and all participants gave written informed consent. Each individual received
$50 for participating in the study.
Suitable participants were invited to attend a 3 hour test session at the University
of Wollongong where a detailed history was taken via structured interview designed
specifically for the study, and neurocognitive tests were administered. Cannabis users
were required to abstain from use for at least 12 hours prior to the test session and
tobacco smokers from either group were allowed to smoke cigarettes up until its
commencement and then not until the completion of the session. The specified period of
abstinence from cannabis was used to minimise any potential effects of withdrawal and
to more accurately represent the day-to-day substance use profile of the sample. That is,
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we aimed to assess cannabis users in the state in which they might operate on a daily
basis when not acutely intoxicated. Urine samples were obtained from users from the
night prior and on the day of testing, to test for illicit drug use and for corroboration of
self-reported abstinence from cannabis (i.e. immunoassays for benzodiazepines,
sympathomimetic amines, opiates, cocaine and cannabis, and gas chromatography-mass
spectrometry to quantify the cannabinoid metabolite THC-COOH (carboxy-THC,
creatinine normalised)). No control subject tested positive for cannabinoid metabolites.
While 2 participants tested positive for sympathomimetic amines, this was corroborated
by prior self-reported use of cold and flu medication. Consequently, no participant was
required to be excluded based upon the toxicology screen. The face-to-face structured
interview went for 60-75 minutes and information collected included age, educational,
medical, and mental health (both personal and family) histories, as well as detailed
questioning regarding any type of substance use (including alcohol and tobacco). Given
the very light levels of other (non-cannabis) substance use, we did not formally assess
for past other substance abuse/dependence but no participant reported ever having been
in treatment for, having been dependent on, or regularly having used any other
substance. Handedness was assessed using the Edinburgh Handedness Inventory
(Oldfield 1971) with 92% of users (n = 22) and 88% of controls (n = 21) classified as
right-handed. Determination of cannabis usage history included assessing age of onset
of initial and regular (at least twice/month) cannabis use, to allow determination of
duration of use. Average days of use per month, average number of occasions of use per
day and average number of cones per occasion of use were additionally determined as
measures of frequency and quantity of use. Withdrawal symptoms, due to at least 12
hours abstention, were assessed via a self-report questionnaire based on an adaptation of
the Marijuana Withdrawal Checklist (adapted from Budney et al. 1999; Vandrey et al.
2005). This consisted of 8 items rated on a 0 – 4 Likert scale reflecting symptoms of
overall withdrawal, cravings, headaches, agitation, irritability, concentration and
coordination difficulties, low or sad mood, and anxiety. This produced a total
withdrawal score out of 40. An estimate of Wechsler Adult Intelligence Scale Revised
(WAIS-R) Full Scale IQ was obtained from the National Adult Reading Test (NART)
(Nelson and Willison 1991), as a measure of premorbid intellectual ability; i.e.
insensitive to brain injury and a likely measure of pre-cannabis use intellectual ability
(Solowij 1998).
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Following completion of these tasks, participants were fitted with an electrode
cap and were seated in a dimly lit, electrically shielded, sound-attenuated and airconditioned booth approximately 1.4 m in front of a computer cathode-ray-tube
monitor. They then completed several additional neurocognitive tasks while EEG was
recorded, including the word recognition task (WR), the focus of the present study.
Details of a test of verbal memory encoding, which was the source of word stimuli
subsequently tested in the present task, can be found in Battisti et al. (2010b).

5.3.3. Experimental Task
Approximately 45 minutes prior to the WR task, participants had completed a verbal
memory task that included the presentation and recall of ten 14-item word lists with
each list containing words all of the same category (e.g. flowers, drinks or animals). For
the WR task, 100 words were randomly selected for each participant from these word
lists (10 from each list of 14). These words were classified ‘old’ (OLD) as participants
had viewed and been required to encode them earlier. An additional 50 words, classified
as ‘related’ (REL), were selected from the same categories as the lists in the verbal
memory task, with 5 words included from each category. A final list of 50 words,
classified as ‘novel’ (NOV), were randomly selected from an additional 5 categories (10
from each) that had not been used in the verbal memory task. These three word types
formed the three levels of Condition examined in the present study. The order of the 200
words was randomized for each participant with the WR task consisting of 4 blocks of
50 words with a preceding practice block of 10 words. Words were presented in white
on a black background in the centre of a computer screen above an upwards pointing
white fixation arrow. Blocks began with the appearance of the arrow, which persisted
for the entire block, and 9.5 seconds later the first word appeared. Each word was
presented for 1500 ms and there was a variable 2250-2750 ms from the offset of the
preceding word to the onset of the next. Participants were instructed to indicate a ‘Yes’
or ‘No’ response as to whether they had seen the word during the verbal memory task
by pressing as quickly and accurately as possible the appropriate button on a 2-button
button box. They were instructed to use either thumb to respond. The left/right yes/no
response was counterbalanced across participants.
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5.3.4. Physiological Measures
Scalp electroencephalogram was recorded using an Electro Cap from 19 electrode sites
(Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, T4, T5, T6, Pz, P3, P4, O1 and O2) with a ground
electrode located halfway between Fpz and Fz. The electro-oculogram was measured
vertically by electrodes placed 1 cm above and below the left eye. All electrodes were
referenced to linked ears. Impedance was below 3 kΩ for EOG and reference electrodes,
and below 5 kΩ for scalp electrodes. EEG was recorded at 500 Hz via a NuAmps
system and Scan software and amplified 19 times with a bandpass filter of 0.1 Hz and
30 Hz.

5.3.5. Data Extraction and Statistical Analysis
In order for all data to be included in parametric comparisons, statistical normalization
(transformation) of those behavioural and substance use variables that violated
normality assumptions was carried out according to procedures recommended by
Tabachnick and Fidell (2000). Procedures used are cited within Table 1. Group
comparisons of demographic data were made using independent samples t-tests unless
otherwise specified.
The ERP epoch was defined as 100 ms pre-stimulus to 900 ms post-stimulus.
Baseline correction used the 100 ms pre-stimulus period. Vertical EOG was calculated
averaging the two eye channels, and used for the ocular artefact reduction procedure
(Semlitsch et al. 1986) to remove the effects of blink and other eye-movements from the
EEG. Remaining epochs containing amplitudes exceeding ±100 µV (considered
artefacts) were excluded from analysis. Epochs were classified by Condition (and not
correct or incorrect response) for the grand averages in order for sufficient epochs to be
available for analyses. A minimum of 40 epochs were included for each Condition for
each participant. Excessive artefact at multiple sites resulted in too few epochs and thus
exclusion of 2 control and 3 user participants. A total of n = 22 controls and n = 21
users were available for analyses.
ERP amplitudes were measured at nine sites (F3, Fz, F4, C3, Cz, C4, P3, Pz, and
P4) using region-based analyses (i.e. midline: Fz, Cz, Pz; frontal: F3, Fz, F4; central:
C3, Cz, C4; and parietal: P3, Pz, P4). Based upon visual inspection of the ERP
waveforms (see Figure 2 for grand averages), and consideration of the relevant
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electrophysiological literature, the N4 and P3 were identified for examination of the
OLD/NEW effect. An additional component, the N1, was also examined due to its
consistent prominence across conditions within the waveforms as well as apparent
group differences. The N1, observed maximally at Fz was the most negative peak in the
50-150 ms latency range, the N4 was the most negative peak maximal at Cz and
examined within the 300-500 ms latency range, and the P3 was the most positive peak
maximal at Pz in the 500-700 ms latency range. The site of maximum amplitude was
used for peak selection within the stated latency range.
A 2 x 3 repeated measures analysis of variance (ANOVA) was used to examine
differences between groups (control vs. user), for each WR condition (OLD, REL,
NOV) on response time (RT). Planned contrasts were used to examine differences
between and within conditions for each group on this measure. Signal detection
analyses (i.e. D-Prime (d’) and beta) were conducted to assess participants’ ability to
discriminate the previously seen (OLD) words from the REL and NOV conditions (i.e.
d’) as well as any response bias (i.e. tendency for a participant to say “no” or “yes”;
beta). As there were two conditions of distracter words (REL, NOV), d’ and beta were
calculated for both. Use of SDT also yielded scores on hit rate for the target (OLD)
words and false alarms (FA) rates for the two distracter conditions (REL, NOV).Signal
detection analyses were subjected to independent samples t-tests. False alarm (FA) rate
and hit rate were also examined using For component amplitudes, 2 x 3 x 3 repeated
measures analyses of variance (ANOVA) were used to examine differences between
groups for each WR condition for the three sites (e.g. Fz, Cz, Pz) within regions of
interest (ROI). ROI was determined via identification of the site of maximum amplitude
using planned contrasts along the midline (e.g. most negative site for N4 and most
positive site for P3). Follow-up analyses for the three lateral sites (e.g. F3, Fz, F4 for a
frontally maximal component) within a ROI were examined across the 3 conditions for
each group. Planned contrasts were used to identify differences between and within
conditions for each group. Peak latencies were examined from the site of maximum
amplitude between conditions in a 2 x 3 repeated measures ANOVA. Planned contrasts
were used for site amplitude comparisons (e.g. linear contrast, F3 vs. F4; quadratic
contrast, Fz vs. mean of F3/F4). Greenhouse-Geisser corrections were applied for all
violations of sphericity with corrected p and normal degrees of freedom reported where
applicable. Only significant main effects of condition, site and interactions involving
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group are reported. Due to a significant difference in the number of cigarettes consumed
per day between groups, this variable was used as a covariate for those significant
interactions involving group.
So as to explore the effects of key demographic and cannabis usage variables on
behavioural outcome measures and individual ERP components, Pearson’s productmoment correlations were performed for each group separately for ERP amplitude and
latency measures with demographic and cannabis use variables. ERP amplitudes were
averaged for each ROI (e.g. the mean of F3, Fz and F4 for frontal sites) prior to
inclusion in analyses. In those cases where duration and/or age of use onset and the
participant’s current age correlated with outcome measures, partial correlations were
used to rule out the effect of aging.
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5.4.

RESULTS

5.4.1. Demographic and Cannabis Use Variables
Table 1 presents the mean values and statistical comparisons for demographics and
substance use measures. There were no differences between groups in gender
distribution, age, NART-estimated WAIS-R Full Scale IQ or educational experience.
Number of standard alcoholic drinks per week and cigarettes consumed per day were
significantly higher for cannabis users.
Cannabis users self-reported abstaining from cannabis for a median of 13 hours
and

Table

1

shows

levels

of

cannabinoid

metabolites

(11-nor-delta-9-

tetrahydrocannabinol-9-carboxylic acid, creatinine normalized) detected in urine
samples from the night before and day of testing. The high levels of metabolites
observed are consistent with the reported heavy use of the sample. A paired samples ttest on the transformed metabolite levels showed a significant drop from the evening
before to the day of testing (t(20) = 1.7, p = .044), indicating truthfulness to selfreported abstention. There were more tobacco smokers within the cannabis-using group
and all but 3 users mixed their cannabis with tobacco. For cannabis use history,
additional information was collected about patterns and duration of use and methods of
use (i.e. via ingestion, or smoking via pipes, water pipes, joints or inhalers). The
majority of users preferred to use a water pipe (bong) - a cylindrical device with a water
chamber and recess for a cone. A cone is a small receptacle where cannabis and/or
tobacco may be placed and upon burning, the smoke inhaled in a single inhalation.
Without loss of sidestream smoke, one cone is thought to deliver delta-9-THC
equivalent to smoking 1/3 of a standard cigarette sized joint (Yücel et al. 2008).
Additional correlations were performed within the user group, specifically
examining the severity of withdrawal symptoms. Both age of first use (r = -.680, p =
.001) and age of regular use (r = -.524, p = .015) correlated significantly with
withdrawal scores, indicating that a younger age of onset of cannabis use was related to
increased withdrawal scores. Withdrawal scores also significantly correlated with age (r
= -.539, p = .012), although not with any other demographic variable (p > .05).
Controlling for age resulted in a loss of significance for the relationship between
withdrawal and age of regular use (r = -.272, p = .246) but not for the relationship
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between withdrawal and age of first use (r = -.475, p = .034), suggesting the latter to be
a robust observation. The correlation of withdrawal and age was non-significant when
controlling for age of regular use and age of first use (r = -.338, p = .145; and r = -.273,
p = .244, respectively). These findings indicate that relationships with withdrawal are
jointly explainable by age of first use, age of regular use and age, however the first of
these has the strongest relationship.
Table 5-1. Demographic and substance use measures: Mean (SD) or Median [Range] for each group.
Controls (n = 22)
Gender (% females)

1

Age

Users (n = 21)

p

50.0

42.9

.435

36.5 (11.6)

36.9 (10.9)

.918

Education

14.3 (2.0)

13.4 (3.0)

.298

WAIS-R FSIQ

106.0 (6.4)

103.1 (10.8)

.293

-

15 [12-25]

-

Age of first cannabis use

2

Duration since first cannabis use (years)

-

21.1 (9.6)

-

Age of regular cannabis use 2

-

17 [13-42]

-

Duration of regular cannabis use (years)

-

17.5 (9.3)

-

Frequency of cannabis use (days per month) 2

-

30 [15-30]

-

-

450 [30-1500]

-

-

13 [9-60]

-

-

4 [0-19]

-

-

1035 [109-4696]

-

-

988 [126-2935]

-

3 [0-15]

7 [0-59]

.058

0 [0-15]

0 [0-30]

.005

Quantity of cannabis use (cones per month)

2

Hours since last cannabis use 2
Withdrawal

2

Urinary metabolites (ng/mg) evening before 2
Urinary metabolites (ng/mg) day of testing
Standard alcoholic drinks per week

2,3

Cigarettes per day 2,3

2

1

Pearson chi-square analysis.
A Log10 transformation was applied to the data to correct for normality violations.
3
Mann-Whitney statistic calculated on non-transformed data. There were a low number of tobacco smokers in
both groups (n = 9 cannabis users (other than for mixing with cannabis) and n = 1 controls smoked tobacco at
least weekly.
2

5.4.2. Behavioural Analyses
Accuracy analyses compared Group within Condition and can be seen in Table 2. Users
had significantly greater false alarms (FA) than controls (mean difference, MD = .07;
F(1,41) = 4.580, p = .038), although no interaction with Condition was present. A
significant main effect of Condition showed higher FA scores on REL than NOV trials
(MD = .42; F(1,41) = 272.865, p < .001). Users’ REL d’ scores were significantly lower
than controls (t(41) = 2.193, p = .034), while the difference on NOV trials did not reach
significance (p=.156). Groups did not differ on hit rate or beta scores and there was no
Condition main effect for beta.
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Table 5-2. Mean(SD) hit rate, d’, beta and false alarm (FA) rate scores for each group.

Control
User

Hit rate

FA rate
REL

FA rate
NOV

d’ REL

d’ NOV

beta REL

beta NOV

.83(.09)
.82(.08)

.42(.19)
.52(.16)

.03(.04)
.07(.10)

1.23(.43)
.93(.46)

3.03(.46)
2.75(.79)

.71(.27)
.67(.21)

6.43(4.17)
4.39(3.33)

A 2 x 3 repeated measures ANOVA with planned comparisons compared the
two Groups across the three levels of Condition for response time. Users had overall
significantly slower RT (F(1,41) = 9.9, p = .003) with no interaction with Condition and
Group present. There was a main effect of Condition for RT on correct trials (F(2,82) =
142.8, p < .001). Planned contrasts showed responses to REL distracter trials to be
significantly slower than both NOV and OLD trial types (p < .001) and NOV trials
slower than OLD trials (p = .021). RT results can be seen in Figure 1.

Response Time (ms)

1400

Controls
Users
1200

1000

800
OLD

REL

NOV

Figure 5-1. Response time for correct responses for cannabis users and controls across each of the three
Conditions. Vertical bars show standard error of the mean (SEM). Response time is in milliseconds (ms).

5.4.2.1.

Behavioural Correlations

Table 3 shows correlations for behavioural data with demographic and cannabis use
parameters. Pearson’s r is reported for each Group and Condition where a value greater
than ± 0.3 was present in at least one instance (i.e. for at least one condition or either
group). There were no significant correlations among users or controls for d’, beta or
response time with age or IQ. Among cannabis users, more regular, longer duration of
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use and lower withdrawal, were associated with reduced response bias (beta) and a
greater ability to discriminate targets from distracters (d’) on the more difficult REL
trials. On the less difficult NOV condition, a longer duration of use was associated with
increased response bias (beta), lower withdrawal was associated with a greater ability to
identify targets from distracters (d’), and a longer duration of use was associated with
faster responding (RT).
Table 5-3. Correlations for SDT and RT with behavioural and cannabis use parameters. All correlations
for a given variable are reported for each Condition and Group if one or more of these exceeded ± 0.3.
SDT
d’ (REL)
.041

beta (REL)
.131

d’ (NOV)
.148

beta (NOV)
.201

WAIS-R FSIQ

.095

.049

.193

.158

Users
Age

.380

-.144

.332

.253

WAIS-R FSIQ

.160

-.221

.315

-.081

Duration since 1st use (years)

.374

-.038

.292

.371

Duration of regular use (years)

.469*

-.125

.343

.452*

Cones/day

-.157

.335

-.271

.096

Frequency of use (days/month)

.256

-.526*

.379

-.195

Hours since last use

.123

.310

.045

.322

Withdrawal

-.394

.470*

-.517*

-.091

Controls
Age

Response Time
Controls
Age

OLD
.210

REL
-.121

NOV
-.173

Users
Age

-.121

-.075

-.351

Duration since 1st use (years)

-.058

-.116

-.362

Duration of regular use (years)

-.144

-.331

-.486*

Cones/day

.032

-.326

-.130

Quantity of use (cones/month)

-.005

-.320

-.151

Withdrawal

.338

.084

.271

* p < .05
** p < .01

109

5.4.3. ERP Results

Amplitude ( µV)

-4

REL

OLD

NOV

-2
0
2
4

Controls
Users

N1

6
0

200

400

600

800

Time (ms)

N4

P3

Figure 5-2. Grand average ERPs for controls (dotted line) and users (solid line) at midline frontal (Fz;
top), central (Cz; middle) and, parietal (Pz; bottom) sites for REL (left panel), NOV (middle panel) and,
OLD trials (right panel). Time (ms) is indicated on the x-axis and amplitude (µV) on the y-axis (where
negative is up). Shaded areas represent the latency ranges used for peak selection.

5.4.3.1.

N1

Measured at Fz, N1 latency did not differ between Conditions or Groups. Planned
contrasts for midline N1 amplitude showed a significant effect of Site with a frontocentral maximum illustrated by enhanced Fz relative to Pz (MD = 1.68 µV; F(1,41)
=47.905, p < .001) and Cz maximal in comparison to the mean of Fz/Pz (MD = .39 µV;
F(1,41) = 17.112, p < .001).
ROI analyses of N1 amplitude within frontal sites showed a significant Group
by Site interaction for the linear comparison (F(1,41) = 5.540, p = .023). Figure 3 shows
users to have overall reduced N1 amplitude relative to controls that was maximally
different within the right hemisphere (MD = 0.41 µV). A significant effect of Site was
also present with a centro-left N1 maximum illustrated by greater N1 at F3 than F4 (MD
= .30 µV; F(1,41) = 11.841, p = .001) and enhanced N1 at Fz relative to the mean of
F3/F4 (MD = 0.21 µV; F(1,41) = 22.243, p < .001). There were no significant effects
involving condition.
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Controls
Users

Amplitude (µV)

-2.0

-1.5

-1.0

Left

Midline

Right

Figure 5-3. N1 amplitude at left (F3), central (Fz) and right (F4) frontal sites for cannabis users and
controls. Negativity is up for this negative-going component. Amplitude is in microvolts (µV).

5.4.3.2.

N4

Measured at Fz, N4 latency did not differ between Conditions or Groups. A significant
effect of Site for N4 amplitude showed a fronto-central maximum illustrated by
enhanced N4 at Fz relative to Pz (MD = 1.05 µV; F(1,41) = 3.962, p = .053) and at Cz
relative to the mean of Fz/Pz (MD = 2.11 µV; F(1,41) = 121.710, p < .001).
ROI analyses for N4 amplitude were conducted at central sites. Condition
interacted significantly with Group (F(2,82) = 3.946, p = .023), an effect that was
independent of tobacco use (F(2,80) = 3.481, p = .036), with planned contrasts (see
Figure 4) showing groups to differ in the magnitude of the REL vs. NOV (MD control =
.225 µV; MD user = 1.70 µV; F(1,41) = 6.617, p = .014) and NOV vs. OLD differences
(MD control = .75 µV; MD user = 2.13 µV; F(1,41) = 4.384, p = .043). Although nonsignificant (p=.443), the REL vs. OLD difference appeared larger for controls (MD
control = .977 µV; MD user = .427 µV). There was a significant effect of Site with a
central (Cz) N4 maximum relative to the mean of C3/C4 (MD = .772 µV; F(1,41) =
15.734, p < .001) and no difference between lateral sites. There was a significant main
effect of Condition (F(2,82) = 8.322, p = .001) with planned contrasts showing
enhanced N4 on NOV compared to REL (MD = .71 µV; F(1,42) = 4.034, p = .051) and
OLD trials (MD = 1.42; F(1,42) = 17.42, p < .001).
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Figure 5-4. Central N4 amplitude for cannabis users and controls for each level of Condition. Negativity
is up for this negative-going component. Amplitude is in microvolts (µV).

5.4.3.3.

P3

Measured at Pz, P3 latency did not differ between Conditions or Groups. P3 amplitude
was maximal in the posterior region, being larger at Pz relative to Fz (MD = 5.06 µV;
F(1,41) = 71.601, p < .001) and reduced at Cz relative to the mean of Fz/Pz (MD = .43
µV; F(1,41) = 4.835, p = .034)..
ROI analyses of P3 amplitude were conducted at parietal sites. A significant
Group by Site interaction was found for P3 with a centro-right maximum for users and a
midline maximum for controls (shown in Figure 4). This was evident from the P3 vs. P4
(F(1,41) = 4.735, p = .035) and Pz vs. the mean of P3/P4 differences (F(1,41) = 3.960, p
= .053). A significant effect of site was present with a central (Pz) positivity maximum
illustrated by greater amplitude at Pz compared to the mean of P3/P4 (MD = .92 µV;
F(1,41) = 42.311, p < .001), with no P3 vs. P4 difference (MD = .14 µV). There was a
significant main effect of Condition (F(2,82) = 7.636, p = .001) with planned contrasts
showing greater P3 amplitude on OLD compared to REL (MD = 1.62 µV; F(1,42) =
26.024, p < .001) and NOV trials (MD = 1.24 µV; F(1,42) = 6.971, p = .012).
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Figure 5-5. P3 amplitude parietal left (P3), central (Pz) and right (P4) sites for cannabis users and
controls. Amplitude is in microvolts (µV).

5.4.3.4.

ERP Correlations

Table 4 shows correlations for N1, N4 and P3 amplitude with component latencies, key
demographic and cannabis use variables. Groups differed in their pattern of N1
correlations between latency or amplitude and relationships with age. There was an
effect of semantic content and duration of use such that greater N1 amplitude was
highly significantly related to a longer history of use for semantically alike conditions
(the REL and OLD conditions involving previously seen categories), but not novel
categories (NOV). A similar trend relationship for older age and longer duration of use
was seen for with OLD trial N4 amplitude, and increased NOV trial N4 amplitude was
related to a greater number of hours since last use. A greater number of hours since last
cannabis use significantly correlated with increased P3 amplitude in all Conditions. A
trend for higher withdrawal scores being related to increased P3 amplitude for REL
trials was present. An earlier age of regular use onset was related to increased NOV P3
amplitude.
As age significantly correlated with N1 amplitude on the OLD and REL
Conditions, partial correlations were used to control for the effect of this variable on the
relationships with duration since 1st use and of regular use. Both sets of relationships
(i.e. N1 OLD and REL amplitudes with duration since 1st and of regular use,
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respectively) lost significance after controlling for age. However, upon subsequently
controlling separately for the effect of each of these two variables for the OLD and REL
relationships with age, duration since 1st use was found to render the correlations nonsignificant. This indicates that both duration since 1st use and age were jointly strongly
contributing to the relationships with OLD and REL trial N1 amplitude.
Table 5-4. Correlations for N1 (mean of F3, Fz, F4), N4 (mean of C3, Cz, C4) and P3 amplitude (mean
of P3, Pz, P4) for each Group across each level of Condition with latency, key demographic and cannabis
use parameters. All correlations for a given variable are reported for each Condition and Group if one or
more of these exceeded ± 0.3.

Controls
REL latency

OLD

N1 Amplitude
REL

NOV

-.536*

-.442*

-.356

NOV latency

-.287

-.095

-.121

OLD latency

.453*

-.358

.124

Age

.248

.324

.127

-.638**

-.722***

-.468*

Users
REL latency
NOV latency

-.498-

-.584**

-.298

OLD latency

-.808***

-.693***

-.524*

.621**

.650**

.315

.319

.297

.265

.656** b

.707*** b

Age
Age of regular use (years)
Duration since 1st use (years)
Duration of regular use (years)

.469*

a

.506*

a

.292
.147

Urinary metabolites (ng/mg) evening before

.367

.393

.314

Urinary metabolites (ng/mg) day of testing

.296

.308

.299

Controls
Age

OLD

N4 Amplitude
REL

NOV

.172

.267

.114

Users
Age

.432

.413

.318

Duration since 1st use (years)

.428

.406

.289

Duration of regular use (years)

.341

.338

.338

Hours since last use

.346

.374

.489*

Users

OLD

P3 Amplitude
REL

NOV

Age of 1st use (years)

-.247

-.210

-.367

Age of regular use (years)

-.371

-.323

-.568**

Hours since last use

.604**

.501*

.526*

.387

.405

.154

Withdrawal

* p < .05
** p < .01
*** p < .001
a
Correlation lost significance after controlling for age.
b
Relationship due to both variable and age.
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5.5.

DISCUSSION

This study demonstrated that chronic use of cannabis is related to a wide range of
alterations in behavioural and neurophysiological functioning associated with
recognition memory performance. Using a highly novel paradigm, significant
differences were observed in the way that chronic cannabis users in the unintoxicated
state processed recognition memory-related information relative to matched healthy
controls. Additionally, evidence of neuroadaptation was present, demonstrated by
relationships between outcome measures and duration of cannabis use and age of use
onset, as well as changes in the withdrawal experience associated with age of use onset.
Our behavioural findings were consistent with previous findings of memoryrelated impairment (for review, see Solowij and Battisti 2008), with cannabis users in
the present study being less able to discriminate the target (OLD) words from the
distracters (NOV/REL). This was most evident for the more difficult distracter
condition (REL) that required recognition of specific items rather than just being able to
recognise that the category was wrong. Additionally, groups did not differ in response
biases, i.e. favouring a ‘yes’ or ‘no’ response, lending support to the effects present
being due to memory-related discrimination difficulties. The overall slowing of
response time across all conditions for users is consistent with the findings of another
study of ours (see Battisti et al. 2010a), indicating a general slowing of information
processing. While this effect may be present here, it is also explainable by users likely
experiencing difficulties in making accurate recognition memory judgements.
A highly novel finding within our study was users showing an altered N400
OLD/NEW effect with OLD and REL conditions appearing to be processed similarly in
contrast to controls, with the latter group evidencing a REL/NOV vs. OLD difference
indicative of accurate stimulus detection. Users’ findings were consistent with their
behavioural data showing that they were less able to discriminate the REL distracters
from the targets (OLD) than were the controls. Additionally, users showed a
pronounced OLD/NEW effect in comparison to controls, indicating that a greater
recruitment of resources were needed to successfully execute the discriminatory
response, indicative of poorer neural efficiency. The recruitment of compensatory
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structures/processes has been suggested in previous studies of ours (Battisti et al. 2010a;
Battisti et al. 2010b).
Users showed significantly altered lateral parietal topography for the P3 of the
OLD/NEW effect, specifically a more diffuse centro-right positivity maximum relative
to a control midline maximum. This is suggestive of a persistence of activation and
poorer neural efficiency and/or the use of compensatory processes. Our results may
reflect a general replication of Ilan et al.’s (2005) ‘memory evoked shift’, i.e. a broad
shift to increased positivity among their participants acutely exposed to cannabis.
Evident visually within the ERP waveforms of our chronically using sample, this effect
was not statistically significantly present and was likely confounded by variability.
Strongly related to explicit recollection processes (Friedman and Johnson Jr 2000;
Kayser et al. 2009), the lack of condition differences between groups and altered
patterns of parietal lateral activity indicates that users experience dysfunction in the way
that they activate retrieval processes relative to healthy controls, but that they are able to
engage retrieval mechanisms in a similar, but albeit less effective, fashion to controls.
Unexpected but of high interest were the N1 findings. We observed N1 to be
maximal fronto-centrally for both groups with users showing more left hemisphere
recruitment and controls more midline. Although the visual N1 is considered to be
largely a centro-parietal component related to differential activation of feature-sensitive
neural elements (Horvath et al. 2008), it has also been suggested to reflect more of an
attentional process whereby an enhancement of the N1 is related to a greater allocation
of attention toward stimuli (Bubic et al. 2010). Among users, the observed changes in
topography and level of activation suggest that they may have experienced greater
difficulty attending to stimuli, subsequently impacting upon their task performance and
the expression of later components. This is consistent with previous interpretations of
findings related to alterations in auditory (Edwards et al. 2008) and visual N1 (Skosnik
et al. 2006b) among chronic cannabis users. The pattern of correlation findings of N1
amplitude with latency suggest that early familiarity detection of the semantic category
is present (i.e. for the OLD/REL conditions) resulting in the recruitment of more
attentional resources to the task as an individual is effectively becoming prepared for a
more difficult discrimination. This explains the more consistent direction and strength
of correlations for the OLD/REL conditions in contrast to the NOV condition across
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both groups. The presence of moderately strong NOV latency/amplitude correlations for
users though suggests that they are less effective at very early semantic discrimination.
Although unexpected and quite speculative, these findings nevertheless indicate the N1
to be a useful biomarker for attentional processing differences among cannabis users
and therefore a key target for future research.
Evidence of neuroadaptation was observed within this study as shown by the
strong range of correlation findings for behavioural and neurophysiological outcome
measures. A longer history of cannabis use related to a greater ability to discriminate
between the target and distracter stimuli, and faster response times to NOV distracters.
Additionally, longer term use was related to a change in response bias; possibly
indicating recovery of function but also related to greater confidence in memory
performance. Cumulative evidence from our data suggests that longer-term users
experience decreasing levels of impairment. This is consistent with prior studies that
have shown chronic or experienced cannabis smokers to show a reduced impact upon
cognitive functioning from acute doses (Hart et al. 2010; Hart et al. 2001; Ramaekers et
al. 2009), but goes further to indicate that these effects are not simply due to tolerance,
as they increase with an increasing number of years of use (e.g., Battisti et al. 2010b).
The neurophysiological findings support the behavioural data in that longer histories of
use were related to changes in component amplitude. Additionally, we saw evidence of
an earlier age of regular use uptake being related to an increased level of subsequent
brain function alteration, as observed in an earlier study of ours (see Battisti et al.
2010a). This parallels findings in a recent study by Mata et al. (2010) where changes in
cortical gyrification among adolescent and young adult cannabis users consistent with
those found in older age were observed. This indicates a necessity to better understand
the impacts that carry into adulthood following earlier and regular exposure during the
formative years. In particular, deleterious effects that may extend beyond those
observed as part of the normal aging process. Without long-term longitudinal studies
though, such findings will at best remain speculative.
In addition, a higher frequency of cannabis use was related to lower response
bias scores on the more difficult distracter condition (REL). Changes associated with a
higher frequency of cannabis use have previously been ascribed to a buildup of
cannabinoid residues in the brain that deleteriously affect users (Solowij et al. 1995b),
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as well as changes in cerebral blood flow (Becker et al. 2010). On the surface this
indicates that more frequent users devoted greater effort to the task. However, this may
also link with our neuroadaptation hypotheses with regular use among long-term users
improving performance due to a developed need for exogenous cannabinoids.
Individuals with more frequent use are also expected to have a greater tolerance to the
effects of cannabis (Ramaekers et al. 2009) and are also more likely to require more
regular use to manage withdrawal symptoms, including cognitive deficits. It is likely
that there are both neuroadaptive and tolerance factors at play.
Findings related to withdrawal and hours since last use indicate that there are
influences of current consumption patterns on cognitive function as higher subjective
withdrawal scores were related to poorer performance and a greater number of hours
since last use related to greater alterations in neurophysiological measures.
Consequently there may be two processes operating. One is that long-term
neuroadaptation relates to global enduring shifts in the way that stimuli are processed.
The other is related to more immediate factors and represents effects associated with the
regularity of use (in terms of frequency) and recency of use (in terms of hours since last
use and withdrawal). Reviewing the strong relationship between age of first cannabis
use onset and participant subjectively reported withdrawal scores adds further detail. To
our knowledge, this has not previously been reported in the literature and indicates a
potential increase in difficulty in abstaining from cannabis use, due to an increased
withdrawal experience, among individuals that commenced use at a younger age, and
hence greater dependence. This adds to the argument by Kalivas and Volkow (2005)
that substance use may impair the ability to refrain from future substance misuse and, in
particular, relapse after abstention, but that age of use onset is an important factor as
well.
In conclusion, our highly novel study has demonstrated that long-term users of
cannabis have impaired recognition memory performance, particularly in making more
difficult discriminations. Alterations in brain electrical activity, and relationships with
duration, age of use onset, and current substance consumption patterns indicate that a
variety of factors impact upon the way cannabis users process information, as well as
their performance. Neuroadaptive processes are likely involved, illustrating the ability
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of the brain, even in the presence of substance use, to be able to successfully engage
compensatory pathways, albeit less optimal/efficient ones.
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CHAPTER 6:

CHRONIC CANNABIS USERS SHOW ALTERED

NEUROPHYSIOLOGICAL FUNCTIONING ON STROOP TASK
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Solowij, N. (2010). Chronic cannabis users show altered neurophysiological functioning
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6.1.

ABSTRACT

Rationale: Chronic cannabis use has been related to deficits in cognition (particularly
memory) and the normal functioning of brain structures sensitive to cannabinoids. There
is increasing evidence that conflict monitoring and resolution processes (i.e. the ability
to detect and respond to change) may be affected. Objectives: This study examined the
ability to inhibit an automatic reading response in order to activate a more difficult
naming response (i.e. conflict resolution) in a variant of the discrete trial Stroop colournaming task. Methods: Event-related brain potentials (ERPs) to neutral, congruent and
incongruent trials were compared between 21 cannabis users (mean 16.4 years of near
daily use) in the unintoxicated state and 19 non-using controls. Results: Cannabis users
showed increased errors on colour-incongruent trials (e.g. “RED” printed in blue ink)
but no performance differences from controls on colour congruent (e.g. “RED” printed
in red ink) or neutral trials (e.g. “*****” printed in green ink). Poorer incongruent trial
performance was predicted by an earlier age of onset of regular cannabis use. Users
showed altered expression of a late sustained potential related to conflict resolution,
evident by opposite patterns of activity between trial types at midline and central sites,
and altered relationships between neurophysiological and behavioural outcome
measures not evident in the control group. Conclusions: These findings indicate that
chronic use of cannabis may impair the brain’s ability to respond optimally in the
presence of events that require conflict resolution and hold implications for the ability to
refrain from substance misuse and/or maintain substance abstention behaviours.
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6.2.

INTRODUCTION

Goal-seeking behaviours and the ability to monitor and respond dynamically to
changing internal and external contingencies are believed to be compromised amongst
individuals who misuse substances and relapse after abstention (Gruber and YurgelunTodd 2005; Hester et al. 2009; Kalivas and Volkow 2005; Pattij et al. 2008). Behaviours
that relate to the initiation and discontinuation of substance use are thought to be
mediated by communication within the prefrontal cortex (PFC), specifically the
dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) (Gruber
and Yurgelun-Todd 2005; Kalivas and Volkow 2005; MacDonald et al. 2000), with
some suggestion also of involvement of the striatum and insula (Nestor et al. 2010).
Consequently, the disruption of successful communications within the ACC or DLPFC
and between these and other brain structures may occur with the introduction of
exogenous substances such as cannabis.
The primary psychoactive ingredient of cannabis, delta-9-tetrahydrocannabinol
(delta-9-THC), binds to cannabinoid 1 receptors (CB1) located throughout the brain
(Eggan and Lewis 2007; Kano et al. 2009). Densely populated within the prefrontal
cortex, CB1 receptors have been implicated in multiple executive functions, including
mood, goal/reward-seeking behaviours, attention and memory (Lundqvist 2005;
Quickfall and Crockford 2006). Acute doses of delta-9-THC have been observed to
interrupt the normal functioning of these receptors and of the structures within which
they are located (Pattij et al. 2008), with changes in executive function well documented
(for review, see Ranganathan and D'Souza 2006). There is increasing evidence for
enduring changes as a result of chronic use of cannabis (for reviews, see Pattij et al.
2008; Solowij and Battisti 2008), with brain structural alterations being associated with
greater cumulative exposure to cannabis (e.g., Yücel et al. 2008).
Tasks that tap the function of PFC structures can provide insight into potential
alterations associated with cannabis exposure. The Stroop colour-naming task (Stroop
1935) is frequently used to assess the ability to deal with conflicting stimuli and
response inhibition, functions subserved by activity within the ACC (Laird et al. 2005)
and DLPFC (Gruber and Yurgelun-Todd 2005). During this task participants are
presented with colour names written in non-matching ink colours (e.g. the word “RED”
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printed in blue ink), with the requirement to suppress the more automatic reading
response in favour of the colour-naming response. The concomitant increase in response
time and errors is known as the Stroop interference effect. It is therefore a useful task
for examining the neural correlates of substance misuse as the integrity of these
inhibitory functions is believed to be important for refraining from use with evidence
for impairment observed with cannabis (e.g., Hester et al. 2009; Pattij et al. 2008),
methamphetamine (Salo et al. 2009; Salo et al. 2007), and polysubstance users (heroin,
cocaine, alcohol) (e.g., Fernandez-Serrano et al. 2010). Acute delta-9-THC exposure has
been shown to increase the size of the Stroop interference effect (Hooker and Jones
1987). Among chronic users, poorer performance on the Stroop has been found to
correlate with a longer duration of use (Solowij et al. 2002), and be predicted by
frequency of use among lower-IQ users (Bolla et al. 2002). Functional imaging studies
have shown hypoactivity or altered activity in the PFC, DLPFC and ACC during
performance of a Stroop task in chronic cannabis users relative to controls (Eldreth et al.
2004; Gruber and Yurgelun-Todd 2005).
There have been no neurophysiological studies of the effects of either acute or
chronic exposure to cannabis on the Stroop colour-naming task. Neurophysiological
measures, such as event-related potentials (ERPs), allow examination of discrete
cognitive events with millisecond accuracy, and can reveal differences in brain
responses to tasks that may not be readily observable with other brain imaging methods.
ERPs consistently detect alterations in neural functioning during both acute exposure to
delta-9-THC (Ilan et al. 2005; Ilan et al. 2004; Leweke et al. 1998; Roser et al. 2008a;
Roser et al. 2008b) and during the unintoxicated state in chronic cannabis users (e.g.,
Battisti et al. 2010a; Patrick et al. 1995; Rentzsch et al. 2007; Skosnik et al. 2006a;
Skosnik et al. 2006b; Solowij 1998; Solowij et al. 1991; 1995b; Wölfling et al. 2008).
Within the Stroop task in normative studies (Larson et al. 2009; Liotti et al.
2000; Markela-Lerenc et al. 2004) and in other clinical populations (Markela-Lerenc et
al. 2009), ERPs contain two late electrical components, the N450 and a sustained
positivity (SP), that are related to conflict detection and conflict resolution, respectively.
The N450 is a negative-going ERP component that occurs approximately 450 ms
following a response conflict-eliciting stimulus (Larson et al. 2009) and is thought to be
generated within the ACC (Liotti et al. 2000; MacDonald et al. 2000; West 2003; West
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et al. 2005). A more sustained parietally positive and fronto-laterally negative conflictsensitive slow potential (conflict SP) begins approximately 500 ms following onset of a
stimulus and is expressed differently for incongruent vs. congruent trials (Larson et al.
2009; Liotti et al. 2000; Markela-Lerenc et al. 2009). Larson et al. (2009) argued that
the conflict SP may reflect controlled conflict resolution or signalling processes in the
parietal cortex, with its expression related to the level of conflict that is required to be
resolved. Cannabis users, who are hypothesised to have a decreased ability to
dynamically adjust to changing and conflicting stimuli, would therefore be expected to
differentially activate the conflict SP relative to healthy controls.
This study predicted alterations in the expression of the N450 and conflict SP
during performance of the Stroop task in chronic users of cannabis. It was hypothesised
that an impact of chronic cannabis use on the functionality of CB1 receptors located in
the ACC and PFC, may be manifest in greater incongruent trial error rates and altered
expression of brain electrical components generated by these structures, with users
being more susceptible to the colour-naming interference effect.
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6.3.

METHODS

6.3.1. Participants
Current cannabis users (n = 25) and healthy controls with a limited substance use
history (n = 23; less than 10 times lifetime use of any illicit substance, including
cannabis, and less than 4 times in the past year) were recruited from the general
community via advertisement in newspapers and posters. A 30-minute eligibility
screening interview was conducted over the telephone with each potential participant.
Inclusion required being between the ages of 18 and 55, no history of diagnosis with
any psychiatric disorder or neurological injury, and a native English speaker. To qualify
for inclusion as a cannabis user, participants were required to have been using cannabis
at least 4 days per month (n = 24 participants used 15 or more days per month) for a
minimum of 3 years. Control participants were selected to match cannabis users on key
demographics (i.e. sex, age, and educational experience). While meeting inclusion
criteria was based upon an assumption of truthfulness in participant self-reporting, and
self-report is generally considered to be valid and reliable in the substance use literature
(Del Boca and Darkes 2003), inclusion/exclusion criteria (other than for cannabis use)
were never revealed to participants.

6.3.2. Procedure
The study was approved by the University of Wollongong Human Research Ethics
Committee and all participants gave written informed consent. Each individual received
$50 for participating in the study.
Suitable participants were invited to attend a 3 hour test session at the University
of Wollongong where a more detailed history was taken via structured interview,
designed specifically for the study, and neurocognitive tests were administered.
Cannabis users were requested to abstain from use for at least 12 hours prior to the test
session and tobacco smokers from either group were allowed to smoke cigarettes up
until its commencement and then not until the completion of the session. Specified
periods of abstinence were used to minimise any potential effects of withdrawal and to
more accurately represent the day-to-day substance use profile of the sample. That is,
we aimed to assess cannabis users in the state in which they might operate on a daily
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basis when not acutely intoxicated. Urine samples were obtained from cannabis users
from the night prior and on the day of testing, and from controls on the day of testing, to
test for illicit drug use and for corroboration of self-reported abstinence from cannabis
(i.e., immunoassays for benzodiazepines, sympathomimetic amines, opiates, cocaine
and cannabis, and gas chromatography-mass spectrometry to quantify the cannabinoid
metabolite THC-COOH (carboxy-THC, creatinine normalised)). No control subject
tested positive for cannabinoid metabolites. While 2 participants tested positive for
sympathomimetic amines, this was corroborated by prior self-reported use of cold and
flu medication. Consequently, no participant was required to be excluded based upon
the toxicology screen. Participants underwent a face-to-face structured interview of
between 60 and 75 minutes followed by a 30 minute rest break. Information collected
included age, handedness, educational, medical, and mental health (both personal and
family) histories, as well as detailed questioning regarding any type of substance use
(including alcohol and tobacco). Given the very light levels of other (non-cannabis)
substance use, we did not formally assess for past other substance abuse/dependence but
no participant reported ever having been in treatment for or having been dependent on
any other substance. Handedness was assessed using the Edinburgh Handedness
Inventory (Oldfield 1971) with n = 22 users and n = 21 controls classified as righthanded. Age of first use of cannabis, as well as the age of onset of regular use (at least
twice/month) were determined as measures of the duration of cannabis use. Average
days of use per month, average number of occasions of use per day and average number
of cones per occasion of use were additionally determined as measures of frequency and
quantity of use. The range of frequency of use was 4 - 30 days per month. Three
participants used less than 20 days per month (one 4 days and two 15 days), with these
participants included due to long histories of use and a high number of cones consumed
per using day (11 years of use at 12 cones per day, 34 years and 39 cones per day, and 6
years of use and 13 cones per day, respectively). A questionnaire assessing withdrawal
symptoms was also used to determine the potential impact of at least 12 hours
abstention. This consisted of 8 items rated on a 0 – 4 Likert scale reflecting symptoms
of overall withdrawal, cravings, headaches, agitation, irritability, concentration and
coordination difficulties, low or sad mood, and anxiety. This produced a total
withdrawal score out of 40. Withdrawal symptoms were assessed via an adaptation of
the Marijuana Withdrawal Checklist (adapted from Budney et al. 1999; Vandrey et al.
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2005). An estimate of Wechsler Adult Intelligence Scale Revised (WAIS-R) Full Scale
IQ was obtained from the National Adult Reading Test (NART) (Nelson and Willison
1991), as a measure of premorbid intellectual ability (i.e. insensitive to brain insult or
injury and as such from prior to the onset of chronic cannabis use (see Fried et al.
2005a)) and as a means of matching participants between groups.
Following completion of these tasks, participants were fitted with an electrode
cap and were seated in a dimly lit, electrically shielded, sound-attenuated and airconditioned booth approximately 1.4 m in front of a computer cathode-ray-tube
monitor. They then completed several additional neurocognitive tasks while ERPs were
recorded, including for the Stroop task, the focus of the present study.

6.3.3. Experimental Task
Participants performed a modified version of the single-trial Stroop task, being
presented with colour names (RED, YELLOW, BLUE, GREEN), or a set of five
asterisks (*****), printed in one of the four colours, with the exception of the words
which could also be printed in white, on a black background. Congruent trials consisted
of words that matched the printed colour (e.g. RED printed in red ink); incongruent
trials consisted of words that did not match the printed colour (e.g. RED printed in blue
ink); neutral trials consisted of asterisks printed in any of the four colours (e.g. *****
printed in green ink); and, reading trials consisted of words printed in white (e.g.
GREEN printed in white ink). Participants were instructed to verbally name the printed
colour as quickly and accurately as possible; with the exception of the reading condition
where participants were instructed to read the printed word. There were 204 stimuli
(words or asterisks) distributed evenly across four blocks, with a preceding practice
block of 24 stimuli. Colour names and printed colours/asterisks were counterbalanced
for each of the naming plus reading conditions; this resulted in 50 of each the congruent,
incongruent and neutral stimuli, and 54 of the reading stimuli. Each block began with
the appearance of an upwards pointing fixation arrow in the centre of the computer
screen that remained for the entire block and preceded the first stimulus in each block
by a 10 second period. Two seconds prior to the first stimulus in each block, a 1500 Hz
tone sounded from a nearby speaker for 250 ms, so as to synchronize the presentation of
stimuli with verbal responses for response time calculation. Each stimulus was
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presented for 3 seconds above the fixation arrow and then immediately replaced by the
next. The arrow persisted for a 5 second period after presentation of the last stimulus in
each block. To record verbal responses, a multi-directional microphone was positioned
out of participant line of sight approximately 30 cm from their mouth. A microphone
sock was used to reduce distortion. Audio was recorded directly to a Sony minidisc
player and then later digitized for offline analysis and calculation of response times.
Response time (RT) was the time between the onset of each stimulus to the onset of the
subsequent first verbal response (if correct).

6.3.4. Physiological Measures
Scalp electroencephalogram (EEG) was recorded using an Electro Cap from 19
electrode sites (Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, T4, T5, T6, Pz, P3, P4, O1 and O2)
using the international 10-20 system with a ground electrode located between Fpz and
Fz. The electro-oculogram (EOG) was measured vertically by electrodes placed 1 cm
above and below the left eye. All electrodes were referenced to linked ears. Impedance
was below 3 kΩ for EOG and reference electrodes, and below 5 kΩ for scalp electrodes.
EEG was recorded at 500 Hz via a NuAmps system and Scan software and amplified 19
times with a bandpass filter of 0.1 Hz and 30 Hz. The use of amplification via a 32-bit
A/D converter allowed for high resolution sampling of small voltages.

6.3.5. Data Extraction and Statistical Analysis
In order for all data to be included in parametric comparisons, statistical normalization
(transformation) of those behavioural and substance use variables that violated
normality assumptions was carried out according to procedures recommended by
Tabachnick and Fidell (2000). Procedures used are cited within Table 1.
The ERP epoch was defined as 100 ms pre-stimulus to 900 ms post-stimulus.
Baseline correction used the 100 ms pre-stimulus period. Vertical EOG was calculated
averaging the two eye channels, and used for the ocular artefact reduction procedure
(Semlitsch et al. 1986) to remove the effects of blink and other eye-movements from the
EEG. Epochs containing amplitudes exceeding ±100 µV (considered artefacts), or
where an incorrect response was made, were excluded from further analysis. Forty
participants had more than 32 epochs available for averaging – thus the ERP analyses
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were carried out using data from 19 controls and 21 users. Excluded participants had
less than 15 epochs available for one or more conditions.
ERP amplitudes were measured at nine sites (F3, Fz, F4, C3, Cz, C4, P3, Pz and
P4) using region-based analyses (i.e. midline: Fz, Cz, Pz; frontal: F3, Fz, F4; central:
C3, Cz, C4; and parietal: P3, Pz, P4) with grand average ERPs inspected for prominent
positive and negative peaks. Based upon visual inspection of the ERP waveforms (see
Figure 2 for grand averages), and previous findings from Stroop electrophysiological
literature (see Larson et al. 2009; Liotti et al. 2000; Markela-Lerenc et al. 2009) two
specific components were examined: the N450, observed maximally at Fz and
quantified as the most negative peak in the 350 – 550 ms latency range, and a sustained
potential (known as the conflict SP), quantified as the mean amplitude across the 650 –
850 ms latency range.
A 2 (Group: user vs. control) x 3 (Condition: congruent, incongruent, neutral)
repeated measures analysis of variance (ANOVA) was used to examine accuracy and
response time, with planned contrasts for Condition (using pairwise comparisons). For
component amplitudes, two separate repeated measures ANOVAs were conducted; the
first a 2 (Group) x 3 (Condition) x 3 (Site: Fz vs. Cz vs. Pz), and the second examining
a region of interest (ROI), determined via identification of the site of maximum
amplitude (via planned contrasts along the midline, i.e. most negative site for N450 and
most positive site for conflict SP). Planned contrasts for the three midline (Fz, Cz, Pz)
and lateral sites within a ROI (e.g. F3, Fz, F4) were examined in terms of both condition
and site effects between groups. Peak latencies were examined from the site of
maximum amplitude between conditions in a 2 x 3 repeated measures ANOVA.
Greenhouse-Geisser corrections were applied for all violations of sphericity and tobacco
use was included as a covariate where significant group differences were present.
Pearson’s product-moment correlations were also performed for ERP amplitude
and latency measures with demographic and cannabis use variables for each group
separately. ERP amplitudes were averaged for each ROI (e.g. the mean of F3, Fz and F4
for frontal sites) prior to inclusion in analyses. Stepwise linear regression, with r2
calculated, was used to further examine relationships between cannabis use parameters
and behavioural and electrophysiological measures where significant correlations were
present.
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6.4.

RESULTS

6.4.1. Demographic and Cannabis Use Variables
Table 1 presents the mean values and statistical comparisons for demographics and
substance use measures. All comparisons were made using independent samples t-tests
unless otherwise specified. There were no differences between groups in gender
distribution, age, NART-estimated WAIS-R Full Scale IQ or number of standard
alcoholic drinks consumed per week. Educational experience was significantly lower
for cannabis users.
Cannabis users self-reported abstaining from cannabis for a median of 13 hours
and

Table

1

shows

levels

of

cannabinoid

metabolites

(11-nor-delta-9-

tetrahydrocannabinol-9-carboxylic acid, creatinine normalized) detected in urine
samples from the night before and day of testing. The high levels of metabolites
observed are consistent with the reported heavy use of the sample. Although median
metabolite scores did not vary between samples, the range of scores was reduced for the
day of testing relative to the evening before. A paired samples t-test on the transformed
metabolite levels showed a marginally significant drop from the evening before to the
day of testing (t[19] = 2.06, P = .053), suggesting truthfulness in requested abstention.
Examination of individual scores showed a drop in metabolite levels for n = 14
participants, with the remainder 7 showing very little change, suggesting that cannabis
use had not occurred between the provision of the two samples. Self-reported
withdrawal symptoms as a result of abstention from cannabis were minimal. No
participant currently met the criteria for substance abuse or dependence (other than for
cannabis) other than one cannabis user meeting the criteria for current alcohol abuse.
Cannabis users and controls did not differ on levels of current alcohol consumption.
There were more tobacco smokers within the cannabis-using group and all but 4 users
mixed their cannabis with tobacco. For cannabis use history, additional information was
collected about patterns and duration of use and methods of use (i.e., via ingestion, or
smoking via pipes, water pipes, joints or inhalers). The median days of use per month
was 30 and therefore quantity consumed per month, rather than frequency, was selected
for subsequent analyses. The majority of users preferred to use a water pipe (bong) - a
cylindrical device with a water chamber and recess for a cone. A cone is a small
receptacle where cannabis (with or without tobacco) may be placed and upon burning,
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the smoke inhaled in a single inhalation. Without loss of sidestream smoke, one cone is
thought to deliver delta-9-THC equivalent to smoking 1/3 of a standard cigarette sized
joint (Yücel et al. 2008).
Table 6-1. Demographic and substance use measures. Mean (SD) for normally distributed variables, or
Median [Range] for skewed variable distributions, is included for each group.
Gender (% females) 2
Age
Education
WAIS-R FSIQ
Age of first cannabis use 3
Duration since first cannabis use (years)
Age of regular cannabis use 3
Duration of regular cannabis use (years)
Frequency of cannabis use (days per month) 4
Quantity of cannabis use (cones per month) 3
Hours since last cannabis use 3
Withdrawal 3
Urinary metabolites (ng/mg) evening before 3
Urinary metabolites (ng/mg) day of testing 3
Standard alcoholic drinks per week 3
Cigarettes per day 3

Controls (n = 19)1

Users (n = 21)1

p

52.6
35.9 (11.5)
14.2 (2.0)
107.1 (6.5)
2 [0-14]
0 [0-15]

47.6
36.1 (11.1)
13.2 (2.8)
101.3 (11.7)
15 [12-25]
19.5 (10.1)
17 [13-42]
16.4 (9.6)
30 [4-30]
450 [30-1500]
13 [9-108]
4 [0-19]
1050 [109-4696]
1060 [126-3664]
7 [0-59]
0 [0-30]

.752
.966
.039
.119
.220
.006

1

Data reported for controls and users that were included in subsequent ERP analyses.
Pearson chi-square analysis.
3
A Log10 transformation was applied to the data to correct for normality violations.
4
This variable was not used in subsequent analyses due to a lack of variability (71.4% of cannabis users were
using 25 days or more per month).
2

6.4.2. Behavioural Data
6.4.2.1.

Accuracy (% Correct)

Figure 1 shows accuracy results for control and user participants for each Stroop task
condition. Accuracy scores were natural log transformed to correct for normality
violations. There was a significant main effect of condition (F[2,92] = 12.3, P < .001).
Planned contrasts showed lower accuracy on incongruent trials relative to congruent (P
< .001) and neutral trials (P = .001). There was a significant interaction of condition
with group (F[2,92] = 4.0, P = .021). Users had significantly lower accuracy on
incongruent trials (P = .009), and incongruent relative to congruent (P = .012) and
neutral trials (P = .048) in comparison to controls. There was no main effect of group
membership on accuracy (P > .05).
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6.4.2.2.

Response Time (RT)

Verbal response time varied significantly between the three colour-naming conditions,
(F[2,92] = 186.0, P < .001), with planned contrasts showing significant differences in
response time between all conditions (congruent vs. incongruent: P < .001; congruent
vs. neutral: P < .001; incongruent vs. neutral: P < .001). Between groups there was a
trend for an overall slowing of response time for users (F[1,46] = 3.4, P = .073),
although this did not interact with condition

(P > .40). Planned contrasts within

conditions showed a marginally significant effect of slower response time for users in
the incongruent condition (P = .059), that was not present on other conditions (P > .08).
Figure 1 illustrates response time for condition and group.
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Figure 6-1. Accuracy (a) and response time data (b) for users (solid line) and controls (dotted line) for
Stroop colour-naming conditions. The y-axis shows proportion correct for accuracy and seconds for
response time and vertical lines show standard error of the mean (SEM). The increased incongruent over
congruent and neutral condition errors was enhanced in the user group and a marginally significant effect
of increased user response time was also present.

6.4.3. ERP Results
Grand mean ERPs to word presentations at each of the 3 midline scalp sites are
displayed for the control and user groups in Figure 2 for congruent, incongruent and
neutral trials.

132

-4.5
Incongruent

Congruent

-2.5

Neutral

Amplitdue (µV)

-0.5
1.5
3.5
Controls

5.5

Users

7.5
9.5

N450

Fz

-100

100

300
500
Time (ms)

700

900

Conflict SP

Cz

Pz

Figure 6-2. Grand average ERPs for controls (dotted line) and users (solid line) for congruent (left),
incongruent (middle), and neutral trials (right) at midline frontal (Fz; top), central (Cz; middle) and
parietal (Pz; bottom) sites. Time (ms) is indicated on the x-axis and amplitude (µV) on the y-axis (where
negative is up).

6.4.3.1.

N450

There were no differences in N450 latency between groups or conditions (P > .05), nor
for amplitude between groups (P > .05). There was a main effect of condition for N450
amplitude at the midline (F[2,76] = 12.7, P < .001), with planned contrasts showing
reduced (i.e. less negative) N450 for neutral trials relative to congruent (mean
difference, MD 2.62 µV; P < .001) and incongruent trials (MD 2.759 µV; P < .001). A
main effect of site (F[2,76] = 62.7, P < .001) and planned contrasts indicated that N450
was maximal at Fz relative to Cz (MD 2.36 µV; P < .001) and Pz (MD 6.84µV; P <
.001). There were no interactions of either condition or site involving group (P > .05).
ROI analyses were performed for the frontal electrodes. There was a main effect of
condition (F[2,76] = 3.8, P = .028), with N450 again reduced on neutral relative to
congruent (MD 1.25 µV; P = .038) and incongruent trials (MD 1.41 µV; P = .025).
There were no effects involving group or site (P > .05).
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6.4.3.2.

Conflict SP

There was a significant interaction of condition and site (F[4,152] = 10.6, P < .001) for
SP amplitude along the midline. Planned contrasts revealed the greater amplitude on Fz
relative to Cz to be present on congruent (MD 1.54 µV; P = .025) and neutral (MD 1.63
µV; P = .050) but not incongruent trials (MD .41 µV; P > .05), and incongruent trials to
have greater amplitude at Pz relative to Cz (MD 1.26 µV; P = .008) with this not present
for congruent (MD .46 µV; P > .05) or neutral trial types (MD -.47 µV; P > .05). At Fz,
amplitude was also greater on neutral over incongruent trials (MD 1.29; P = .012) with
no differences for other conditions or at other sites (P > .05). There was a significant
interaction of condition with group (F[2,76] = 3.5, P = .034) with this remaining
significant after controlling for tobacco use (F[2,74] = 3.4, P = .040). A planned
contrast revealed that the difference between congruent and incongruent conditions
varied significantly between the groups (P = .008) with controls showing greater
amplitude on the congruent than incongruent trials while users showed the opposite
pattern, evident in figure 3. There were no other differences between groups for
condition and there was no main effect of group membership nor others involving site
(P > .05).
ROI analyses were conducted at central sites. Here there was a near significant
condition main effect (F[2,76] = 2.9, P = .063), with planned contrasts revealing
significantly greater amplitude on neutral than congruent trials (MD .99 µV; P = .036)
but not between other condition types (P > .05). The interaction of condition and group
was significant (F[2,76] = 3.819, P = .026) with this persisting after controlling for
tobacco use (F[2,74] = 3.8, P = .027). Planned contrasts revealed differences to lie in
the congruent vs. incongruent by group interaction (P = .006) with a congruent >
incongruent trial effect for controls and an incongruent > congruent effect for users, as
evident in figure 3. There were no significant main effects or interactions involving site
(P > .05).
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Figure 6-3. Mean conflict SP amplitude for control and user participants for each of the colour-naming
trials at the midline (a) and centrally (b). Amplitude (µV) is shown on the y-axis (where positive is up).
Vertical lines show SEM.

6.4.4. Correlation Analyses
As N450 was maximal at frontal sites, correlational analyses for frontal N450 with
behavioural (RT, Accuracy), demographic and cannabis use parameters were examined
(shown in Table 1). None of these correlated significantly with N450 latency or
amplitude (P > .05). Correlations with conflict SP are shown in table 2. Mean midline
amplitude was used for correlations due to this component varying in amplitude across
the scalp. Control participant congruent and incongruent trial response time each
significantly correlated with both conflict SP mean amplitude for congruent and
incongruent trial types. Control neutral trial response time correlated only with
congruent trial amplitude and there were no significant correlations with neutral trial
conflict SP. There were no significant correlations for users for response time and
conflict SP, although incongruent trial accuracy correlated significantly with congruent
trial conflict SP amplitude. Examination of cannabis use parameters showed a single
significant correlation with incongruent trial performance accuracy, such that early
regular use correlated with poorer performance on incongruent trial accuracy.
Incongruent trial errors did not correlate significantly with age (P > .05), therefore there
was no need to control for the influence of this variable. Stepwise regression analysis of
the incongruent trial accuracy by age of regular use relationship was examined along
with potentially moderating variables of age, IQ, withdrawal scores and number of
cigarettes smoked per day. The stepwise method resulted in a single predictor variable,
age of regular use, for incongruent trial accuracy (r2 = .372, P = .047). No cannabis use
parameters were significantly associated with any of the ERP measures.
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Table 6-2. Correlations for conflict SP amplitude and Accuracy across trial types with behavioural and
cannabis use parameters.
Congruent1

Incongruent1

Neutral1

Conflict SP

Controls
Congruent RT

-.511*

-.462*

-.308

Incongruent RT

-.496*

-.481*

-.350

Neutral RT

-.515*

-.410

-.303

Congruent Accuracy

-.225

-.192

-.190

Incongruent Accuracy

-.187

-.215

-.168

Neutral Accuracy

-.321

-.323

-.354

Congruent RT

.019

-.061

.027

Incongruent RT

-.016

-.146

-.060

Neutral RT

.099

-.036

.035

Congruent Accuracy

.131

.276

.042

Incongruent Accuracy

.526*

.349

.196

Neutral Accuracy

.236

.258

.384

Users

st

Age of 1 use (years)

.152

.075

.130

Age of regular use (years)

-.042

-.088

.034

Duration since 1 use (years)

-.160

-.001

.118

Duration of regular use (years)

-.058

.083

.131

Quantity of use (cones/month)

.057

-.058

-.068

Withdrawal

.123

.199

-.031

st

Accuracy
Age of 1st use (years)

-.067

.153

-.367

Age of regular use (years)

-.026

.429*

-.339

.086

.358

-.306

Duration since 1st use (years)
Duration of regular use (years)

.090

.080

-.235

Quantity of use (cones/month)

-.167

-.128

-.172

1

Correlations were performed using mean amplitudes for region of interest for conflict SP (i.e. mean of
midline sites).
* p < .05
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6.5.

DISCUSSION

This study indicates that chronic use of cannabis produces changes in accuracy and
brain activity associated with Stroop task performance during the unintoxicated state.
The age of onset of regular cannabis use was found to be a significant predictor of
accuracy on conflict eliciting (incongruent) trials. Changes in brain activation were most
evident for the electrophysiological marker of conflict resolution (‘conflict SP’)
whereby users varied in their level of activation between conditions in comparison to
healthy non-using controls. Our evidence of altered electrophysiological expression is
consistent with the imaging studies of Eldreth et al. (2004) and Gruber et al. (2005), and
illustrates disruption of the neural processes underlying conflict resolution in chronic
users of cannabis, likely within the parietal cortex.
Behaviourally, both groups showed slower response times on incongruent trials,
as expected; however, the cannabis users showed the slowest response, at a marginally
significant level, suggesting a deficit beyond a general slowing of information
processing. Also, as expected (Stroop 1935), accuracy on incongruent trials was also
decreased for both groups relative to other trial types. Notably, cannabis users did show
an exaggerated increase in the proportion of errors on incongruent relative to congruent
and neutral trial types in comparison to controls, indicating a greater susceptibility to
errors in the presence of conflict-inducing stimuli. Additionally, our finding of age of
onset of regular cannabis use predicting poorer incongruent trial accuracy appears to be
novel within the literature. To our knowledge, this is the first instance of demonstrating
an association between poorer conflict resolution and earlier onset of cannabis use
(controlling for potential maturation effects); other studies have shown duration
(Solowij et al. 2002) and frequency of cannabis use (Bolla et al. 2002) to be related to
Stroop performance. As difficulties in conflict monitoring and resolution processes are
linked with ongoing substance misuse and relapse (Kalivas and Volkow 2005), earlier
exposure to cannabis may encourage short-term reward seeking behaviours as opposed
to more beneficial longer-term goal-seeking.
The lack of significant N450 differences indicates that chronic use of cannabis
has limited impact upon conflict monitoring processes, the functional correlate of the
N450 (Larson et al. 2009; Markela-Lerenc et al. 2009; West et al. 2004; West et al.
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2005). While a visual fronto-central reduction in user N450 was present, there may have
been too great a variability in individual participant data to reach statistical significance,
with this becoming statistically apparent for the later conflict SP. The faster responding
and low errors on neutral trials suggest that cannabis users were able to adapt to the
demands of the task to produce an equivalent conflict monitoring response to that of
controls. Consequently, while chronic exposure to cannabis may interrupt CB1
functioning within the ACC, this has limited affect on conflict monitoring on our
variation of the Stroop. Future research with similar samples would benefit from
manipulation of trial type prepotency as well as measurement of early and late task
N450 effects, something that we were unable to do due to a limited number of epochs
but that would allow examination of within-task adaptation. The recent study by Hester
et al. (2009) utilising a Go/No-go response inhibition task while recording functional
magnetic resonance imaging (fMRI) found chronic cannabis users to have reduced
capacity for monitoring their own performance with impaired error awareness
associated with decreased activity in the ACC. Combined with our own, their findings
indicate that further investigations into this line of research are warranted.
Between conditions, cannabis users showed a distinctly different pattern of
conflict SP activity to that of controls, which also varied between regions of interest.
For cannabis users the most decreased conflict SP amplitude was recorded at midline
sites for the congruent trial; in contrast, for controls the most decreased conflict SP was
recorded at the midline for the incongruent trials. Between-condition changes in polarity
reflect activation of appropriate responding following the identification of colour
incongruence (Liotti et al. 2000). Correlational findings between behavioural measures
and conflict SP amplitude showed distinctly different relationships for each group.
Increased accuracy among cannabis users on incongruent trials was related to increased
congruent trial conflict SP amplitude, although no significant relationship was present
with incongruent trial conflict SP. In contrast, faster RT for controls in each condition
was related to increased congruent and incongruent conflict SP amplitude.
Taken as a whole, these findings suggest that there are alterations to the response
resolution process among chronic users of cannabis that are consistent with their
decreased level of incongruent trial accuracy. The additional altered relationships
between conflict SP amplitude and behavioural outcome measures, in comparison to
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healthy controls, is further evidence for disruption to normal neural functioning. While
the specific generators of the conflict SP are not clear, the ACC and DLPFC may be
implicated due to the abundant projections from both structures, and particularly the
ACC, to other cortical regions involved in the resolution of conflict, including the
parietal cortex (Gruber and Yurgelun-Todd 2005; Kalivas and Volkow 2005; Laird et
al. 2005; Pattij et al. 2008). Significant differences observed for the conflict SP, and not
the earlier N450, suggest that while there may be disruption to the normal functioning
of the ACC, it manifests at a later conflict resolution stage with additional disruption to
the parietal cortex also a possibility. The action of chronic exposure to cannabis upon
CB1 receptors may have led to neuroadaptation and hence the altered patterns of neural
expression observed. Relative to controls, users had an altered neural response across
the scalp that additionally varied with each condition. This suggests differences in the
engagement of underlying structures recruited to complete the task. The statistically
normal levels of performance observed in the cannabis using group may be due to
compensatory processes (since behavioural outcomes are virtually equivalent to that of
controls) that require the recruitment of alternate structures and/or processes, indicating
poorer neural efficiency. The recent paper by Ramaekers et al. (2009) supports this
interpretation and indicates that while more overt behavioural outcomes may be present
amongst lighter and/or shorter term users, a longer and more chronic history of cannabis
exposure appears to result in some ‘recovery’ of function, indicating a slow-developing
neuroadaptation, as we observed in an earlier study (see Battisti et al. 2010a). Taking
this further, Yücel et al.’s (2008) finding of reduced hippocampal volume among
cannabis users suggests that chronic exposure results in a more enduring insult to the
brain that requires the use of alternate structures to compensate for the disruption to
normal processes but that manifests behaviourally as more subtle impairment. This may
have implications for older individuals with potentially poorer cognitive reserves. A
recent study by Mata et al. (2010) observing alterations in cortical gyrification among
adolescent and young adult cannabis users similar to that observed among much older
individuals lends further support to the potential future impact of cannabis. Having a
median age of approximately 35 years in the present study precludes us from being able
to determine this possibility but this is likely an important area for future research.
Neither recency of use, urinary cannabinoid metabolite levels, or self-reported
withdrawal symptoms correlated with the behavioural or neurophysiological outcome
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measures; suggesting unlikely that there was

an influence of residual levels of

cannabinoids and/or withdrawal effects. The effects of nicotine withdrawal may be a
potential confound within our study. However, none of our significant group difference
findings changed after controlling for daily cigarettes smoked and there were no
significant correlations with any of the outcome measures. Additionally, due to the
relatively low frequency of cigarette use within our sample (i.e. a median of 0 cigarettes
per day) and only a short period of abstention (i.e. smokers allowed to smoke up until
approximately 1 ½ hours prior to ERP recording), serious withdrawal in any participant
was unlikely.
In terms of clinical significance, our findings indicate that brain response in the
presence of conflict is clearly altered among chronic users of cannabis. Behaviourally,
this resulted in minimal impact; however, it could be argued that the elicited conflict
was far more subtle than those experienced in more ecological contexts. This study
does, however, provide good ground for further examination of conflict processes
utilising neurophysiological measurement and in particular suggests that there will be
great value in establishing the degree and/or extent of the proposed functional
neuroadaptation. The use of larger samples with broader age ranges as well as groups
with varying levels and durations of use would provide further insight into this process.
As the ability to refrain from substance use and the likelihood of relapse are strongly
related to conflict adaptation processes (Kalivas and Volkow 2005), determination of
the extent and enduring nature of dysfunction may aid in the design of suitably rigorous
behavioural and pharmacological interventions.
In summary, cannabis users were shown to have dysfunction in the neural and
behavioural

expression

of

conflict

resolution-related

processes,

measured

electrophysiologically by the conflict SP, suggesting alterations in the functioning of the
ACC and parietal structures. The ability of cannabis users to adapt to conflict
monitoring, as measured by the N450, may appear intact, at least as measured in this
study, indicating that alterations manifest at a later stage of processing linked with overt
behavioural outcomes. Our key finding that poorer task accuracy under the more
cognitive intensive (incongruent) condition is related to age of onset of cannabis use
indicates that the susceptibility to failure in conflict processes is high at younger ages.
This novel finding suggests a potentially greater adverse impact of cannabis use on the
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adolescent brain with resultant changes increasing the vulnerability to continued
substance misuse. The results of this study therefore indicate that potentially enduring
neural impairments are present among chronic users of cannabis and that behaviours
linked with these are compromised, holding implications for substance misuse and
relapse.
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CHAPTER 7:

A NEUROPHYSIOLOGICAL PROFILE OF

CHRONIC CANNABIS USE EFFECTS DURING A STERNBERG
PROACTIVE INTERFERENCE TASK

EMPIRICAL STUDY 4
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7.1.

ABSTRACT

Tests of proactive interference (PI) are believed to be sensitive to changes in memory
ability. We sought to use a PI task based upon the Sternberg paradigm in order to
investigate behavioural and neurophysiological indices of memory function among a
group of long-term heavy cannabis users. Twenty-two chronic (near daily) users of
cannabis were tested in the unintoxicated state while event-related brain potentials
(ERPs) were recorded via electroencephalogram, and compared to 24 matched healthy
non-user controls. Cannabis users showed altered patterns of neurophysiological
functioning indicative of poorer neural efficiency and compensatory mechanisms on the
N2 (an early index of item familiarity and novelty), but not on the expression of a latter
late positive component (LPC) or on overt behavioural measures of target detection
ability and response bias. Neuroadaptation was evident in relationships between longer
duration cannabis use and more efficient neurophysiological activation and improved
behavioural performance.
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7.2.

INTRODUCTION

Working memory has been well established as being compromised amongst chronic
users of cannabis (for review, see Solowij and Battisti 2008), with evidence also of
increased impairment on more difficult tasks that may involve conflict eliciting
information (e.g., chapter 5; Battisti et al. 2010a; Bolla et al. 2002; Solowij et al. 2002).
It has been suggested that brain structures implicated in memory processes may be
activated differently and/or require the use of compensatory structures among users of
cannabis (Battisti et al. 2010b). Consequently, the way that memories are retrieved and
their susceptibility to interference may be compromised.
The primary psychoactive ingredient of cannabis, delta-9-tetrahydrocannabinol
(delta-9-THC), binds to cannabinoid 1 receptors (CB1) located throughout the brain
(Eggan and Lewis 2007; Kano et al. 2009). Densely populated within the prefrontal
cortex, CB1 receptors have been implicated in multiple executive functions, with
memory function, in particular, regularly observed to be impacted upon (Lundqvist
2005; Quickfall and Crockford 2006). While the acute administration of delta-9-THC
disrupts the normal functioning of these receptors and of the structures within which
they are located, as well as associated executive functions (for review, see Ranganathan
and D'Souza 2006), enduring changes associated with chronic use have also been
observed (for reviews, see Pattij et al. 2008; Solowij and Battisti 2008).
As there is good evidence that the memory system may be compromised
amongst chronic users of cannabis, tests sensitive to the nature of the impairment are
required. Measures of proactive interference (PI) have been demonstrated to be sensitive
to changes in both short- and long-term working memory capacity, including higher
cognitive functions (Just and Carpenter 1992). Sternberg-type memory scanning tasks
(Sternberg 1966) have been identified as sensitive to changes in PI ability, implicating
the left inferior frontal gyrus as the neural substrate for task-associated conflict
resolution within imaging research (e.g., Badre and Wagner 2005; D'Esposito et al.
1999; Jonides et al. 1998; Mecklinger 2000; Yi et al. 2009). Recent research by Du et al.
(2008) and Zhang et al. (2010) demonstrated the utility of electrophysiological
measurement, via the use of event-related brain potentials (ERPs), for the purpose of
more

discretely

examining

the

neurophysiological

and

associated

cognitive
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underpinnings of PI. Their use of a Sternberg-based paradigm identified two key ERP
components, the fronto-central N2 and parietal late positive component (LPC). The
negative-going N2 is believed to peak at approximately 300 ms post-onset of a memory
probe stimulus and, due to its apparent relationship with the frontal N400 (Zhang et al.
2010), is suggested to be an index of familiarity in recognition memory (Curran 2000;
Mecklinger 2000), but also of conceptual priming (Voss and Paller 2008) and stimulus
novelty (Tsivilis et al. 2001). Within tasks of PI, the N2 is observed to be smaller (less
negative) in the presence of interference (i.e. memory priming) in conditions where a
negative response is required in comparison to negative-response trials where
interference is not present. The LPC is believed to index both familiarity and episodic
memory retrieval and is the positive-going component present from approximately 500
ms post-stimulus onwards (Voss and Paller 2008). Typically examined in the context of
long-term recognition memory, this component has recently been shown to be sensitive
to short-term episodic memory processes (Zhang et al. 2010). Alterations in the
morphology of this component have also been demonstrated within a cannabis-using
population (Battisti et al. 2010b). The amplitude of this component has been observed to
be smaller in the presence of PI (Zhang et al. 2010). Given evidence for compromised
memory encoding (e.g., Battisti et al. 2010b) and recognition (e.g., chapter 5; for
review, see Solowij and Battisti 2008) among cannabis users, the use of a PI task will
provide further insight into the neurophysiological and cognitive process changes that
may underpin memory impairment associated with chronic use.
Recent studies have indicated that neuroadaptive effects are present amongst
chronic users of cannabis, suggesting a gradual reorganisation of function, if not
structure, with continued use (e.g., Battisti et al. 2010b; Mata et al. 2010; Ramaekers et
al. 2009), as well as greater change and/or greater impairment associated with an earlier
age of onset (e.g., Battisti et al. 2010a; Battisti et al. 2010b; Harvey et al. 2007). Given
the sensitivity of ERPs for identifying changes in neurophysiological functioning,
establishing relationships between cannabis use parameters and the N2 and LPC
components in the present study may provide further insight as to how cannabis use
affects memory recognition processes.
Consequently, our use of a PI task in the present study aims to identify
alterations in key electrophysiological components, specifically the N2 and LPC, related
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to the chronic use of cannabis during the unintoxicated state. Changes in performance
and the relationship between usage history factors and neurophysiological outcomes
will be examined.
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7.3.

MATERIALS AND METHODS

7.3.1. Participants
Current users of cannabis (n = 22) and healthy controls with a limited history of
substance use (n = 24; less than 10 times of use of any illicit substance and less than 4
times in the past year) were recruited from the general community via advertisement in
newspapers and posters. A 30-minute eligibility screening telephone interview was
conducted with each potential participant. Inclusion for all participants required being
between the ages of 18 and 55, having no history of diagnosis with any psychiatric
disorder or neurological injury, and being a native English speaker. Cannabis users were
required to have used cannabis at least 15 days per month for a minimum of 5 years.
Control participants were selected to match cannabis users on key demographics (i.e.
sex, age, and educational experience). While meeting inclusion criteria was based upon
an assumption of truthfulness in participant self-reporting, inclusion/exclusion criteria
(other than for cannabis use) were never revealed to participants. Additionally, selfreport is generally considered to be valid and reliable in the substance use literature (Del
Boca and Darkes 2003). Data from some of the participants included in the present
study have appeared in Battisti et al. (2010a; 2010b). Previously reported information
has been limited to basic demographic information only.

7.3.2. Procedure
The study was approved by the University of Wollongong Human Research Ethics
Committee and all participants gave written informed consent. Each individual received
$50 for participating in the study.
Suitable participants were invited to attend a 3 hour test session at the University
of Wollongong where a detailed history was taken via structured interview designed
specifically for the study, and neurocognitive tests were administered. Cannabis users
were required to abstain from use for at least 12 hours prior to the test session and
tobacco smokers from either group were allowed to smoke cigarettes up until its
commencement and then not until the completion of the session. Specified periods of
abstinence from cannabis (approximately half a day) were used to minimise any
potential effects of withdrawal and to more accurately represent the day-to-day
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substance use profile of the sample. That is, we aimed to assess cannabis users in the
state in which they might operate on a daily basis when not acutely intoxicated. Urine
samples were obtained from users from the night prior and on the day of testing, to test
for illicit drug use and for corroboration of self-reported abstinence from cannabis (i.e.
immunoassays for benzodiazepines, sympathomimetic amines, opiates, cocaine and
cannabis, and gas chromatography-mass spectrometry to quantify the cannabinoid
metabolite THC-COOH (carboxy-THC, creatinine normalised)). No control subject
tested positive for cannabinoid metabolites. The face-to-face structured interview lasted
60-75 minutes and information collected included age, educational, medical, and mental
health (both personal and family) histories, as well as detailed questioning regarding
any type of substance use (including alcohol and tobacco). Given the very light levels
of self-reported other (non-cannabis) substance use, we did not formally assess for past
other substance abuse/dependence but no participant reported ever having been in
treatment for or having been dependent on any other substance. Handedness was
assessed using the Edinburgh Handedness Inventory (Oldfield 1971) with n = 22 users
and n = 21 controls classified as right-handed. Determination of cannabis usage history
included assessing age of onset of initial and regular (at least twice/month) cannabis
use, to allow calculation of duration of use. Average days of use per month, average
number of occasions of use per day and average number of cones per occasion of use
were additionally determined as measures of frequency and quantity of use. Withdrawal
symptoms, due to at least 12 hours abstention, were assessed via a self-report
questionnaire, an adaptation of the Marijuana Withdrawal Checklist (adapted from
Budney et al. 1999; Vandrey et al. 2005). This consisted of 8 items rated on a 0 – 4
Likert scale reflecting withdrawal symptoms such as cravings, headaches, agitation,
irritability, concentration and coordination difficulties, low or sad mood, and anxiety,
producing a total withdrawal score out of 40. An estimate of Wechsler Adult
Intelligence Scale Revised (WAIS-R) Full Scale IQ was obtained from the National
Adult Reading Test (NART) (Nelson and Willison 1991), as a measure of premorbid
intellectual ability; i.e. insensitive to brain injury and a likely measure of pre-cannabis
use intellectual ability (see Fried et al. 2005a).
Following completion of these tasks, participants were fitted with an electrode
cap and were seated in a dimly lit, electrically shielded, sound-attenuated and airconditioned booth approximately 1.4 m in front of a computer cathode-ray-tube
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monitor. They then completed several additional neurocognitive tasks while EEG was
recorded, including a memory priming task, a variation of the Sternberg task (Sternberg
1966), the focus of the present study.

7.3.3. Experimental Task
For the memory priming task, participants were presented with four target letters
appearing horizontally (e.g. ‘CMYK’) above an upwards pointing fixation arrow in the
centre of a computer screen. The arrow appeared 6000 ms prior to the onset of the first
stimuli and persisted for the whole block, disappearing 1000 ms after the disappearance
of the final set of stimuli. The fixation arrow and all stimuli appeared in white on a
black background. Target stimuli appeared all at once and persisted for a period of 750
ms. Following a retention interval of either 3000 or 6000 ms (balanced factorially with
Condition) a single probe stimulus (e.g. ‘C’) would appear above the fixation arrow for
a period of 250 ms. Target and probe stimuli were all consonants (all alphabet
consonants were used) to reduce the possible effect of participants phonologically
clustering stimuli during memory encoding. Upon appearance of a probe, participants
were instructed to indicate a ‘Yes’ or ‘No’ response as to whether they had seen it
during the immediately prior target set by pressing as quickly and accurately as possible
the appropriate button on a 2-button response box. They were instructed to use both
thumbs to respond. The left/right yes/no response was counterbalanced across
participants.
Target and probe stimuli were arranged in such a way to result in four
Conditions (example shown in Figure 1): recent positive (R+), the probe appeared in
both the current and preceding target set, but was not the probe in the preceding set;
recent negative (R-), the probe did not appear in the current target set, but appeared in
the preceding set; non-recent positive (NR+), the probe appeared in the current target
set but not the preceding one; and, non-recent negative (NR-), the probe did not appear
in either the current or preceding target sets. This resulted in two sets of conditions:
recent trials (R) and non-recent trials (NR); and, positive (POS) and negative trials
(NEG). Target sets and linked probes were randomly distributed within the task within
the limitations set out by the different condition types. Additionally, the probe never
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appeared in the target set prior to the preceding target set, so as to avoid the effects of
any additional priming.
Recent Positive (R+)

Non-recent Positive (NR+) Recent Negative (R-)

CM YK

XM YK
B

Non-recent Negative (NR-)
XM YK

CM YK
HJCN

C

B

B

B
HJCN

HJVN

HJXN
C

C

C

Figure 7-1. Example layout of the four different trial types. In these examples, the probe for the current
trial is ‘C’, the immediate target set are those four letters prior (e.g. ‘HJCN’), the preceding target set are
those four letters prior to the previous probe (e.g. ‘CMYK’).

7.3.4. Physiological Measures
Scalp electroencephalogram was recorded using an Electro Cap from 19 electrode sites
(Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, T4, T5, T6, Pz, P3, P4, O1 and O2) with a ground
electrode located between Fpz and Fz. The electro-oculogram was measured vertically
by electrodes placed 1 cm above and below the left eye. All electrodes were referenced
to linked ears. Impedance was below 3 kΩ for EOG and reference electrodes, and below
5 kΩ for scalp electrodes. EEG was recorded at 500 Hz via a NuAmps system and Scan
software and amplified 19 times with a bandpass filter of 0.1 Hz and 30 Hz.

7.3.5. Data Extraction and Statistical Analysis
In order for all data to be included in parametric comparisons, statistical normalization
(transformation) of those behavioural and substance use variables that violated
normality assumptions was carried out according to procedures recommended by
Tabachnick and Fidell (2000). Procedures used are cited within Table 1.
The ERP epoch was defined as 100 ms pre-stimulus to 900 ms post-stimulus.
Baseline correction used the 100 ms pre-stimulus period. Vertical EOG was calculated
averaging the two eye channels, and used for the ocular artefact reduction procedure
(Semlitsch et al. 1986) to remove the effects of blink and other eye-movements from the
EEG. Remaining epochs containing amplitudes exceeding ±100 µV (considered
artefacts) were excluded from analysis. Two control participants were excluded for
excessive artefact in multiple channels. Epochs were classified by condition with only

150

behaviourally correct epochs included in the grand averages. An additional N = 4
participants were excluded for being outliers in component amplitudes (greater than 2
standard deviations from the mean) at five or more sites within at least one component.
This resulted in an equal number of users and controls (n = 20 in each group).
ERP amplitudes were measured at nine sites (F3, Fz, F4, C3, Cz, C4, P3, Pz, and
P4) using region-based analyses (i.e. midline: Fz, Cz, Pz; frontal: F3, Fz, F4; central:
C3, Cz, C4; and parietal: P3, Pz, P4) with grand average ERPs inspected for prominent
positive and negative peaks. Based upon visual inspection of the ERP waveforms (see
Figure 2 for grand averages), and previous findings from electrophysiological literature,
two specific components were examined: the N2, maximal at C3 and the most negative
peak in the 240-360 ms range; and a late slow wave (late positive component (LPC))
that was examined in terms of the mean amplitude across the 540-720 ms latency range
to capture a late positivity (LPCa), and the mean amplitude across the 720-900 ms
latency range to capture the reduction in positivity (LPCb). The site of maximum
amplitude was used for peak selection within the stated latency range.
Signal detection theory (SDT) analyses were conducted to assess participants’
ability to discriminate the target (‘yes’-response; R+, NR+) probes from distracter (Rand NR-) conditions (i.e. D-Prime (d’)), as well as any response bias (i.e. tendency for a
participant to say “no” or “yes”; beta). This resulted in SDT analyses for R+ vs. R-, R+
vs. NR-, NR+ vs. R- and NR+ vs. NR-. Hit rates (i.e. accurately detecting the target
probe) and false alarms (incorrectly responding to a non-target distracter probe) were
also examined. All SDT analyses involved independent samples t-tests. A 2 x 3 repeated
measures analysis of variance (ANOVA) was used to examine differences between
groups (control vs. user), for each condition on response time (RT) with planned
contrasts used to examine differences between and within Conditions for each Group.
For component amplitudes, 2 (Group) x 4 (Condition) x 3 (Site) ANOVAs were
used to examine differences between groups for each condition for the three sites within
regions of interest (ROI). ROI was determined via identification of the site of maximum
amplitude following inspection of the grand averages (i.e. most negative centrally, C3,
Cz, C4 for N2; most positive parietally, P3, Pz, P4 for the LPC). Planned contrasts were
used to identify differences between and within conditions for each group. Peak
latencies were examined from the site of maximum amplitude between conditions in a 2
151

x 3 repeated measures ANOVA. Polynomial contrasts were used for site amplitude
comparisons (e.g. linear contrast, C3 vs. C4; quadratic contrast, Cz vs. mean of C3/C4).
Greenhouse-Geisser corrections were applied for all violations of sphericity with
corrected p and normal degrees of freedom reported where applicable. Only significant
main effects of Group, Condition, Site and interactions involving group are reported.
So as to explore the effects of key demographic and cannabis usage variables on
behavioural outcome measures and individual ERP components, Pearson’s productmoment correlations were performed for each group separately for ERP amplitude
measures with key demographic (age, IQ) and cannabis use variables. ERP amplitudes
were averaged for each ROI (e.g. the mean of C3, Cz and C4 for central sites) prior to
inclusion in analyses. In those cases where duration of cannabis use and/or age of use
onset and the current age of participants correlated with outcome measures, partial
correlations were used to rule out the effect of current age.
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7.4.

RESULTS

7.4.1. Demographic and Cannabis Use Variables
Table 1 presents the mean values and statistical comparisons for demographics and
substance use measures. Demographic data from some of these participants has
appeared previously in Battisti et al. (2010a; 2010b). All comparisons were made using
independent samples t-tests unless otherwise specified. There were no differences
between groups in gender distribution, age, NART-estimated WAIS-R Full Scale IQ,
years of education, or number of standard alcoholic drinks per week. Number of
cigarettes consumed per day was significantly higher for cannabis users.
Cannabis users self-reported abstaining from cannabis for a median of 13 hours
and

Table

1

shows

levels

of

cannabinoid

metabolites

(11-nor-delta-9-

tetrahydrocannabinol-9-carboxylic acid, creatinine normalized) detected in urine
samples from the night before and day of testing. The high levels of metabolites
observed are consistent with the reported heavy use of the sample. A paired samples ttest on the transformed metabolite levels showed a non-significant drop from the
evening before to the day of testing. Although this was non-significant, the change in
scores is consistent with self-reported abstinence from cannabis use over at least
approximately a 12 hour period. There were more tobacco smokers within the cannabisusing group and all but 3 users mixed their cannabis with tobacco. For cannabis use
history, additional information was collected about patterns and duration of use and
methods of use (i.e. via ingestion, or smoking via pipes, water pipes, joints or inhalers).
The majority of users preferred to use a water pipe (bong) - a cylindrical device with a
water chamber and recess for a cone. A cone is a small receptacle where cannabis
and/or tobacco may be placed and upon burning, the smoke inhaled in a single
inhalation. Without loss of sidestream smoke, one cone is thought to deliver delta-9THC equivalent to smoking 1/3 of a standard cigarette sized joint (Yücel et al. 2008).
As has been previously reported in another paper of ours (see chapter 5), greater
self-reported withdrawal symptoms on the day of testing correlated significantly with an
earlier age of first (r = -.646, p = .002) and regular cannabis use (r = -.479, p = .033),
and a younger current age (r = -.542, p = .014). Controlling for the effects of current age
with partial correlations showed the relationship with age of first use to remain (r = -
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.453, p = .051). Controlling for the effects of age of first use within the withdrawal and
age correlation produced a non-significant relationship (r = -.193, p = .428).
Table 7-1. Demographic and cannabis use measures: Mean (SD) or Median [Range] for each group.
Controls (n = 20)
Gender (% females)

1

Users (n = 20)

p

50

40

.527

Age

36.75 (11.84)

35.25 (11.59)

.688

Education (years)

14.23 (1.94)

13.65 (2.84)

.462

WAIS-R FSIQ

106.67 (6.56)

102.95 (11.78)

.227

Age of first cannabis use 2

-

14.5[13-25]

-

Duration since first cannabis use (years)

-

19.5(9.8)

-

Age of regular cannabis use 2

-

17[13-42]

-

Duration of regular cannabis use (years)

-

15.9(9.2)

-

Frequency of cannabis use (days per month) 2

-

30[15-30]

-

-

360[30-1500]

-

-

13[9-60]

-

-

3.5[0-19]

-

-

1019[109-4696]

-

-

916[126-2935]

-

3.5 [0-15]

6.5 [0-32]

.189

0 [0-15]

0 [0-20]

.026

Quantity of cannabis use (cones per month)

2

Hours since last cannabis use 2
Withdrawal

2

Urinary metabolites (ng/mg) evening before 2
Urinary metabolites (ng/mg) day of testing
Standard alcoholic drinks per week

2

2,3

Cigarettes per day 2,3
1

Pearson chi-square analysis.
A Log10 transformation was applied to the data to correct for normality violations.
3
Mann-Whitney statistic calculated on non-transformed data. Cigarettes per day variable was not used in
subsequent analyses due to a low number of tobacco smokers in both groups (n = 9 cannabis users (other than
for mixing with cannabis) and n = 1 controls smoked tobacco weekly.
2

7.4.2. Behavioural Analyses
7.4.2.1.

Signal Detection Theory (SDT) analyses
Independent samples t-tests were used to compare groups on SDT measures of

d’, beta, hit rate and false alarm rate. There were no significant differences between
groups on any of these measures, indicating no difference in overt ability to detect the
target from distracters and no evidence of increased response bias within either group.
Table 2 shows the SDT, hit rate and false alarm results for each group.

7.4.2.2.

Response Time (RT)
A 2 (Group) x 4 (Condition) repeated measures ANOVA examined differences

in RT between the two groups for each level of condition. There was no significant
effect involving group. A significant main effect of condition (F(3,114) = 36.874, p <
.001) indicated that both groups responded similarly, and most quickly, on R+ and NR+
trials, being slower at rejecting the probe (i.e. returning a negative response), with
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slowest responding on R- trial types where they had been primed to make a positive
response by the preceding trial but were required to make a negative one. This was
evident by planned contrasts showing significant differences between R+ vs. R- (MD =
80 ms; F(1,38) = 62.611, p < 001), R+ vs. NR- (MD = 40 ms; F(1,38) = 28.108, p <
.001), NR+ vs. R- (MD = 77 ms; F(1,38) = 58.134, p < .001), NR+ vs. NR- (MD = 36
ms; F(1,38) = 16.527, p < .001), and NR- vs. R- (MD = 40 ms; F(1,38) = 20.172, p <
.001). Table 2 shows the RT results for each condition and group.
Table 7-2. Mean (SD) for d’, beta, hit rate, false alarm (FA) rate and response time (RT; in milliseconds,
ms) for each Group, SDT comparison, and Condition.
R+ vs. RControls
Users

R+ vs. NR-

d'

beta

d'

beta

3.50(.75)
3.31(.91)

.18(.07)
.21(.14)

3.03(.51)
2.90(.73)

.20(.06)
.23(.12)

d'

beta

d'

beta

3.23(.81)
3.19(.83)

.22(.09)
.23(.13)

2.76(.48)
2.78(.70)

.25(.08)
.25(.11)

Hit Rate
R+

Hit Rate
NR+

FA Rate
R-

FA Rate
NR-

.95(.03)
.93(.07)

.92(.06)
.92(.07)

.07(.09)
.08(.12)

.12(.04)
.13(.10)

RT
R+

RT
NR+

RT
R-

RT
NR-

762(93)
766(101)

768(89)
766(92)

830(69)
857(76)

796(92)
811(90)

NR+ vs. RControls
Users

Controls
Users

Controls
Users

7.4.2.3.

NR+ vs. NR-

Behavioural Correlations
Table 3 shows correlations for behavioural SDT and RT data with key

demographic (i.e. age, IQ) and cannabis use parameters. For brevity, and so as to
specifically examine relationships with memory priming and PI, SDT data for d’ and
beta scores were examined for the R+ vs. R- comparisons, respectively, only. As can be
seen, an older age, higher IQ and a longer duration of cannabis use were related to
improved ability to discriminate the targets from distracters (i.e. higher d’) among users,
with a similar relationship with IQ also observed for controls. Among the RT
correlations, a lower level of urinary metabolites and fewer cones smoked per day were
related to a longer RT on R- and NR+ trial types, significant only for urinary metabolite
levels from the night before testing. Additionally, a greater number of days of use per
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month was associated with longer RT on R+, R- and NR- trial types, although this was
only significant for R- trials. A pattern of longer response time moderately related to an
older age was present for controls only.
Table 7-3. Correlations for SDT scores for the R+ vs. R- comparison, and RT across all four conditions
with key demographic and cannabis use parameters. Only correlations greater than ± 0.3 were reported
except when comparing between groups or across conditions.
SDT Correlations
Controls

d’

beta

Age

-.004

.119

WAIS-R FSIQ

.495*

-.496*

.441

-.315

WAIS-R FSIQ

.560*

-.515*

Age of 1st use (years)

.357

-.252

Duration since 1st use (years)

.405

-.292

Duration of regular use (years)

.487*

-369

Days of use per month

.409

-.309

Withdrawal

-.399

.294

Users
Age

Controls

R+

Age

.421

Users
Age

RT Correlations
RNR+
.396

NR-

.373

.342

.040

-.055

.054

-.168

Urinary metabolites (ng/mg) evening before testing

-.384

-.458*

-.485*

-.307

Urinary metabolites (ng/mg) day of testing

-.331

-.426

-.411

-.271

Age of regular use (years)

.300

.084

.363

.138

Duration of regular use (years)

-.237

-.140

-.272

-.360

Cones per day

-.294

-.416

-.395

-.076

Days of use per month

.424

.461*

.260

.416

Cones per month

-.190

-.315

-.331

.028

* p < .05
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7.4.3. ERP Results
R+

R-

NR+

NR-

-4

0
2

Controls

4

N2
0

0
80

0

Users

60

40

20

0

6

0

Fz

Amplitude ( µV)

-2

Time (ms)

Cz

LPCa/b

Pz

Figure 7-2. Grand average ERPs for users (dotted line) and controls (solid line) at midline frontal (Fz;
top), central (Cz; middle) and, parietal (Pz; bottom) sites for R+ (1st column), R- (2nd column), NR+ (3rd
column), and NR- trials (4th column). Time (ms) is indicated on the x-axis and amplitude (µV) on the yaxis (where negative is up). Shaded areas show latency ranges for the N2 and LPC with the vertical dotted
line indicating the separation between LPCa and LPCb components.

7.4.3.1.

N2
Measured at Cz, N2 latency did not differ between Conditions or Groups (p >

.05). Users had reduced N2 amplitude at central sites (C3, Cz, C4) in comparison to
controls (MD = 2.14 µV; F(1,38 = 4.516, p = .040). Users also significantly differed to
controls for the Cz vs. mean of C3/C4 comparison for Site (F(1,38) = 4.279, p = .045).
Figure 3 shows users to have maximum negativity at C3 relative to Cz and C4, whereas
controls show a centro-left maximum and a reduction at C4. A main effect of Site and
follow-up contrasts indicated that N2 was larger at C3 than C4 (MD = 1.31 µV; F(1,38)
= 19.748, p < .001) and at Cz relative to the mean of C3/C4 (MD = .42 µV; F(1,38) =
4.275, p = .046), indicating a centro-left maximum. There were no significant effects
involving N2 amplitude and Condition.
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Amplitude (µV)

-4

Control
User

-2

0

Left

Midline

Right

Figure 7-3. N2 amplitude a central left (C3), midline (Cz) and right (C4) sites for controls and cannabis
users. Negative is up for this negative-going component.

7.4.3.2.

LPC
Measured at parietal sites (P3, Pz, P4), neither LPCa or LPCb amplitude varied

with Group. A significant effect of Site was present with maximal amplitude at the
midline (Pz) vs. the hemispheres (mean of P3, P4) for both LPCa (MD = .80 µV;
F(1,38) = 18.282, p < .001) and LPCb (MD = .71 µV; F(1,38) = 4.574, p = .039). Main
effects of Condition were present for both LPCa (F(3,114) = 11.969, p < .001) and
LPCb (F(3,114) = 5.272, p = .002). Planned contrasts revealed decreased amplitude (i.e.
less positive) for both LPCa and LPCb on R- compared to NR+ (LPCa MD = 2.87 µV;
F(1,38) = 46.565, p < .001; LPCb MD = 1.65 µV; F(1,38) = 13.598, p = .001) and NRtrials (LPCa MD = 1.71 µV; F(1,38) = 12.525, p = .001; LPCb MD = 1.73 µV; F(1,38)
= 13.598, p = .001). Decreased amplitude was also observed on R- compared to R+
(MD = 2.07 µV; F(1,38) = 18.343, p < .001), and NR- compared to NR+ trials (MD =
1.16 µV; F(1,38) = 4.484, p= .041) for LPCa.

7.4.3.3.

ERP Correlations

Table 4 shows correlations for N2, LPCa and LPCb amplitude with key demographic
(age, IQ) and cannabis use variables. Pearson’s r is reported for each group and
condition where a value greater than ± 0.3 was present in at least one instance (i.e. for at
least one condition or either group). Overall, the strongest relationships for cannabis
usage history variables were present on non-recent trial types. A longer duration since
first use and of regular use was related to increased N2 amplitude (i.e. more negative)
on NR+ and NR- trials (after controlling for age), respectively. For both groups, an
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older age was related to a larger (more negative) N2 on trials where the probe was most
novel (i.e. NR-), with weaker relationships observed on other trial types. Also, a higher
estimated premorbid IQ was related to a decreased (i.e. less negative) N2 on trials with
greatest PI (R-) for users only with weaker relationships observed on other trial types
and no relationships observed for controls. Greater reported withdrawal scores were
related to decreased N2 amplitude on trials where response priming was present (R+)
and on trials where there was minimal interference in order to correctly reject the probe
(NR-).
For LPC components, an earlier age since first use correlated with increased
LPCa amplitude on R+ trials, and an earlier age of regular use correlated with greater
positivity reflected in larger LPCa and smaller LPCb amplitudes on NR- trials.
Decreased LPCa amplitude was related to a longer duration of regular use on NR+
trials. Greater withdrawal was related to increased LPCa and decreased LPCb
amplitudes across most conditions (significant for LPCb on NR+ and NR- trials).
Higher premorbid IQ was related to decreased LPCa amplitude on the non-PI trials of
R+, NR+ and NR- and increased LPCb amplitude on NR- trials for users only.
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Table 7-4. Correlations with central N2 amplitude (mean of C3, Cz, C4) and parietal LPCa and LPCb
amplitude (mean of P3, Pz, P4) for each Group across each level of Condition, and key demographic and
cannabis use parameters. Correlations are reported for both groups and all conditions where at least one
correlation greater than ± 0.3 was present.
R+

R-

NR+

NR-

N2 Amplitude
Controls
Age
WAIS-R FSIQ
Users
Age
WAIS-R FSIQ
Age of 1st use (years)
Age of regular use (years)
Duration since 1st use (years)
Duration of regular use (years)
Cones/day
Frequency of use (days/month)
Hours since last use
Withdrawal
Urinary metabolites (ng/mg) day of testing

-.303
-.206
-.248
-.287
-.344
-.091
-.172
-.256
-.022
-.243
-.093
.411
-.055

-.135
.041

-.403
-.091

-.004
-.297
.700**
-.228
.160
.031
.135
.231
-.058
-.360
-.099
-.600**
.043
.162
-.039
-.469*
.210
-.332
.046
.203
.018
.409
LPCa Amplitude

-.641**
-.083
-.527*
-.382
-.337
.332
-.521*a
-.387
.307
-.061
.207
.461*
.082

Controls
Age
WAIS-R FSIQ
Users
Age
WAIS-R FSIQ
Age of 1st use (years)
Age of regular use (years)
Duration since 1st use (years)
Duration of regular use (years)
Frequency of use (days/month)
Hours since last use
Withdrawal

-.325
-.012

-.146
.172

-.411
-.033

-.397
.052

-.257
-.534*
-.483*
-.287
-.139
-.107
-.242
.172
.427

-.212
-.372
-.258
-.507*
-.238
-.286
-.225
-.064
-.168
-.341
-.065
-.450*
-.105
-.378
.364
.084
.428
.280
LPCb Amplitude

-.431
-.459*
-.382
-.450*
-.392
-.172
-.029
.262
.372

-.206
-.190

.064
.003

-.172
-.050

-.327
-.075

-.036
.018
-.082
.220
-.010
.244
.445*

-.443
-.466*
-.374
-.478*
-.409
.217
.445*

Controls
Age
WAIS-R FSIQ
Users

Age
-.015
-.105
WAIS-R FSIQ
-.310
-.189
Age of 1st use (years)
-.376
-.239
Age of regular use (years)
-.192
-.113
Duration since 1st use (years)
.110
-.044
Hours since last use
.253
.427
Withdrawal
.404
.348
* p < .05
** p < .01
a
Associated with both age of 1st use and current age in partial correlation
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7.5.

DISCUSSION

This study examined the effects of proactive interference (PI) on overt behavioural and
electrophysiological responding in a group of long-term heavy cannabis users during the
unintoxicated state in comparison to matched non-using controls. Cannabis users
showed evidence of altered brain activation indicative of compensatory processes that
were related to duration and onset of use as well as poorer neural efficiency. While
differences were present electrophysiologically, overtly there were no differences on
performance measures, indicating altered brain function in the presence of normal
responding and demonstrating the sensitivity of ERPs as a measure of brain
dysfunction, as well as their utility for use with a chronic cannabis-using population.
A principle aim of this study was to examine the response of cannabis users to
proactive interference. Specifically, we observed differences in the topographic
expression of the N2, irrespective of the influence of PI. Being an index of item
familiarity (Curran 2000; Mecklinger 2000) and novelty (Tsivilis et al. 2001), this
suggests that the N2 findings for users indicate an altered activation of the memory
comparison process that, functionally and in terms of the processing of PI information,
remains intact. Specifically, the chronic use of cannabis results in the use of
compensatory neural mechanisms for processes (i.e. familiarity and novelty detection)
that allow successful activation of separate processes related to PI. The observed
correlations provide further insight as to how chronic exposure to cannabis impacts
upon these processes. In particular, longer history of use being related to enhanced N2
on non-PI and non-priming conditions (i.e. neutral NR+ and NR- trials) indicates that
the ability to process less difficult information improves with a longer history of use,
suggestive of neuroadaptation, as reported in an earlier study of ours utilising a different
memory paradigm (see Battisti et al. 2010b). Additionally, greater withdrawal
symptoms were related to decreased N2 amplitude on the non-PI conditions of R+ and
NR-, with reduced amplitude on tasks such as this suggestive of competing and/or
interfering processes (Zhang et al. 2010), if not more global disruption. This illustrates
that a greater level of alteration co-occurs with a greater withdrawal experience.
Cannabis use history was related to alterations in the LPC components where a
PI effect was present (see Voss and Paller 2008; Zhang et al. 2010), with an expected

161

decrease in amplitude on R- trials relative to each other trial type. Although this
component did not vary between groups, the results of correlational analysis indicate
that the expression of this component is sensitive to the influence of chronic cannabis
use. On non-PI trials, an earlier age of exposure and increased withdrawal experience
were related to an increase in LPC positivity. These patterns are consistent with the N2
findings and a similar argument of a disruption of the optimal signalling pathways.
Evidence of neuroadaptation was evident in the relationship between a longer history of
regular cannabis use and decreased amplitude on the non-PI condition of NR+.
Specifically, on less difficult trials (i.e. minimal interference) where a positive response
was required, a longer history of use was related to the reduced amplitude that would be
expected on this condition. Alterations in the LPC-like electrophysiological components
with an increased history of cannabis exposure and/or earlier age of exposure has not
been reported previously in the literature. An earlier study of ours using a short-term
memory task observed history of use to be related to an earlier N400 and not the later
positive component (Battisti et al. 2010b). Given the different nature of the paradigms
used in these two studies however, direct comparisons cannot be made.
A lack of significant response time differences between groups indicates that
users were performing the task in a similar manner to controls. This was evident by the
main effects of condition showing longer response time on PI trials; where a prime had
been present but the probe needed to be rejected for a significant response (i.e. Rtrials). Although behavioural differences between groups were not present, relationships
for users between measures of SDT and cannabis use measures indicate that the changes
in response bias and ability to detect targets from distracters is related to usage factors.
This is consistent also with an earlier study of ours (see chapter 5) that showed a similar
finding. Considered in light of the neurophysiological findings, the observed
relationships may reflect processes related to, but not necessary specifically, PI. An
alternative explanation relates to the characteristics of our sample. All of our cannabis
users were long-term users with a mean of nearly 16 years of regular use and a
minimum of 5. It may be the case that neuroadaptation sufficient for the demands
required of this task was present within our sample. Further studies of regular users with
a shorter duration of use would help to clarify this interpretation, as would the use of a
more difficult paradigm, so as to attempt to elicit group differences.
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Additional relationships observed with premorbid intellectual ability raises
another interesting, although speculative, interpretation. That is, higher IQ may be
neuroprotective against brain insult associated with the chronic use of cannabis. The
direction of the relationships, i.e. reduced N2 on PI trials (R-) and reduced LPC on nonPI trials (R+, NR+, NR-), were consistent with the directions of brain electrical activity
hypothesised for this task. There is already evidence that individuals with higher
premorbid intellectual function show improved recovery following traumatic brain
injury with this believed to be due to increased neurocognitive reserve capacity (e.g.,
Green et al. 2008). We therefore tentatively suggest that higher IQ cannabis users may
show an increased ability to develop more efficient alternate neural pathways as a result
of insult that occurs with chronic cannabis use.
In summary, we observed electrophysiological differences between chronic
users of cannabis and healthy controls indicative of poorer neural efficiency and use of
compensatory mechanisms on a task designed to measure proactive interference. Overt
performance differences were not present in the current study, with our findings
suggesting that the cannabis users were successfully able to use compensatory processes
reflected by altered neural activity. Evidence of neuroadaptation was present with an
additional possibility of neuroprotection related to neurocognitive capacity.
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CHAPTER 8:

SUMMARY, STRENGTHS AND IMPLICATIONS,

LIMITATIONS AND FUTURE RESEARCH DIRECTIONS
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8.1.

SUMMARY

This chapter summarises the major findings from the literature review and the four
empirical chapters that assessed the same group of cannabis users on a range of different
cognitive tests whilst brain electrical activity was recorded via EEG. Implications of
findings for the understanding of the relationship between the chronic heavy use of
cannabis and alterations in cognition and brain electrical function are also discussed.
The primary literature review (chapter 2) and supporting brief review (chapter 3)
comprehensively examined available research indicating an association between chronic
cannabis use and alterations in cognition as well as impacts upon normal brain electrical
function, as measured by ERPs. The focus of the review in chapter 2 was primarily on
memory processes affected by chronic cannabis use, although it also explored some
animal and neonatal findings, as well as brain imaging studies that had some focus on
memory. One of the primary outcomes of the review was establishing a clear link
between chronic cannabis use and memory dysfunction, as well as an indication that
there was a lot of work to be done; much of the existing research has been confounded
by participant sampling issues such as limited assessment of cannabis usage history, coexisting psychiatric diagnoses and other substance use. It was hypothesised that
alterations in cognitive function associated with chronic cannabis use were likely
enduring in nature with some evidence for an increasing impact with an increasing
number of years of use and/or heavier use. It was also hypothesised that cannabis users
may be able to compensate for impairments in cognitive function via the formation of
novel neural pathways, but that this may be at the cost of neural efficiency and overall
neurological resource availability. Neural efficiency refers to a tendency for the brain to
form neural connections that are the most efficient in terms of the use of neural
resources, i.e. focusing the energy of the brain on smaller areas (Neubauer and Fink
2009). Individuals that chronically experience disruption to the normal optimal neural
pathways, such as traumatic brain injury patients (e.g. McWilliams and SchmitterEdgecombe 2008; Turner and Levine 2008), have a requirement of their brains to
produce novel pathways that, while possibly successful, do not represent optimal use of
neural resources had the brain insult not been present. This thesis argues that this effect
may also be present in the case of chronic exposure to exogenous cannabinoids, which
represents enduring disruption to optimal brain functioning. There is emerging evidence
that the chronic use of cannabis may be associated with actual brain injury. A recent
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example of this has been the decrease in hippocampal volume that was observed among
a group of chronic cannabis users in comparison to healthy controls in a study by Yücel
et al. (2008). The brief review in chapter 3 reviewed evidence for actual changes in
brain electrical function associated with both acute and chronic cannabis use. This
review recommended more tightly controlled research that aimed to better identify those
impairments specifically related to chronic cannabis use. It further recommended the
use of functional brain imaging studies, such as the use of psychophysiological
measures, so as to better understand the neural substrates that may underlie cognitive
impairment associated with chronic cannabis use.
The four empirical studies comprising chapters 4 through 7, summarised below,
were all administered on the same sample of participants. Following structured
interview, the verbal memory task of Chapter 4 was administered. This was followed by
the Stroop task of Chapter 6 and Sternberg task of Chapter 7, counterbalanced across
participants. The recognition memory task of Chapter 5 was administered last in order
to allow for a suitable delay to prevent the use of short-term memory.
The aim of empirical study 1 (chapter 4) was to use a verbal memory task to
examine chronic cannabis use effects whilst also examining brain electrical activity.
Verbal memory processes had already been reviewed as reliably impacted upon by
chronic cannabis use (see chapter 2) and therefore combining such a task with an
electrophysiological measure aimed to further understand the alterations in cognitive
processes associated with use, at both a cognitive and neural level. Twenty-four
cannabis users and an equal number of healthy controls matched on age, educational
experience and premorbid intellectual ability were included in this study. Cannabis
users were tested during the unintoxicated state and completed a comprehensive
screening interview assessing substance use, medical and psychiatric history prior to
commencement of cognitive testing. Participants were assessed on free recall ability
following the discrete presentation of word lists. ERPs were also generated at the point
of word presentation and key electrical components related to memory processing,
known as the subsequent memory effect, were examined; the frontal negative N4 and
parietal late positive component (LPC). Findings showed cannabis users to have poorer
verbal memory performance, attenuated N4 and increased LPC, with this interpreted as
indicative of poorer neural efficiency and the use of compensatory processes. Greater
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alterations in the N4 and LPC were associated with a longer history of use with
additional evidence of neuroadaptation present; a recovery of function with time as
indicated by improved performance with a longer history of cannabis use.
Empirical study 2 (chapter 5) was an extension of the verbal memory task in
chapter 4, as stimuli originally presented in the verbal memory task were re-presented to
assess participants’ recognition ability. This study examined overt measures of
recognition memory performance in the presence of simpler and more difficult
distractor stimuli as well as ERP measurement of discrete cognitive processes. Of the
total pool of participants recruited for the study, n = 21 users and n = 22 controls were
included, after exclusions for excessive artefact in the EEG signal. Cannabis users were
observed to have a poorer ability to discriminate between previously seen words and
unseen words in comparison to controls. Alterations were present in cannabis user ERP
components indicative of changes in early attentional processes (N1), and late cognitive
components related to recognition memory functioning (N4 and P3). Specifically, an
attenuation of the N1 and a broad increase in the P3 that varied with site, and patterns of
N4 activity that were indicative of discrimination between previously seen and unseen
(but similar) words. These alterations were consistent with hypotheses of poorer neural
efficiency and use of compensatory processes (i.e. alternate neural pathways). Evidence
of neuroadaptation was again present, with a longer history of use related to improved
behavioural and more efficient brain electrical functioning. The strong and diverse
range of differences observed in this study implicates recognition memory tasks as
highly sensitive to chronic cannabis use effects.
Empirical study 3 (chapter 6) used the classic Stroop colour naming task to
examine chronic cannabis use effects on inhibitory control processes. An adaptation of
the task was used so as to make it suitable for electrophysiological measurement.
Discretely presented colour names or series of neutral asterisks (“*****”) appeared
written in ink colours of red, yellow, blue, green or white. Cannabis users (n = 21) and
controls (n = 19) were compared on measures of response time and accuracy with the
ERP components N450 and a late positivity (the Conflict SP) examined for their utility
as measures of conflict detection and resolution, respectively. Relative to controls,
cannabis users showed altered functioning of conflict resolution processes (Conflict
SP), slower overall response time and increased errors on trials where maximum
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conflict was elicited; i.e. colour names appearing in an inconsistent ink colour (e.g.
“RED” written in blue ink). Electrophysiological findings were consistent with the
earlier-described poorer neural efficiency argument and use of compensatory
processing; the Conflict SP showed opposite patterns of electrical activity between trial
types at midline and central sites for users in comparison to controls. Additionally, an
earlier age of regular cannabis use onset was related to poorer performance during
instances of greatest conflict, indicating that cannabis use may have a greater impact
when introduced during the formative adolescent years. Findings were related to a
possibly diminished ability of cannabis users, and especially those who begin use at an
earlier age, to refrain from future substance misuse as well as greater relapse following
abstention.
Finally, empirical study 4 (chapter 7) used a variant of the Sternberg task,
adapted for electrophysiological measurement, for examination of chronic cannabis use
effects on proactive memory interference. Following exclusions due to contamination of
EEG signal, n = 20 cannabis users and an equal number of matched healthy controls
were compared on memory performance and ERP measures. Attenuation of the frontocentral N2 at midline and right hemispheric sites was present among cannabis users,
with this component related to recognition memory processes. Although there were no
group differences on overt outcome measures, correlational relationships between
outcome measures and cannabis usage variables indicated the presence of
neuroadaptation, via more efficient electrophysiological activation and improved
behavioural performance related to a longer history of use. This task highlighted the
utility of electrophysiological measurement for the assessment of the often subtle effects
of chronic cannabis use, as well as the need for more complex tasks in order to elicit
overt performance impairments.
8.2.

STRENGTHS OF THIS RESEARCH

This series of empirical chapters mark a clear advance in methodologies associated with
the research of chronic cannabis use effects. Specifically, these include: a participant
sample with minimal confounds and a long history of regular use; multiple different
tests of cognition; highly sensitive measures of brain function (ERPs) combined with
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measures of cognitive function; and, specific analyses that allowed examination of
usage history influences on both cognition and brain function.
The participants included in the studies were all long-term regular users of
cannabis with a very limited other substance use history and no evidence of current
psychiatric diagnoses or neurological injury or impairment. Control participants were
largely non-drug-naive but with a limited substance use history and were matched on
key demographic variables of age, premorbid intellectual ability and sex. Previous
research has been confounded by samples with highly variable (often light) use, with
psychiatric comorbidity and, in particular, high usage of other substances. While it may
be argued that a non-poly-drug-using sample lacks ecological validity, the lack of clear
findings in the literature implicating chronic cannabis use as a cause of cognitive
impairment necessitates the need for such research and strengthens the argument for any
causal relationships.
In regards to the assessments, tasks that tap into functions that have good
evidence for impairment in relation to cannabis use were used. As has been stated
throughout this thesis, impairments associated with chronic use are often quite subtle
and therefore task selection is vital for the elicitation of between group differences. The
use of highly temporally accurate ERPs within each of the cognitive tasks, allowed for
examination of discrete cognitive processes with a resolution that cannot be easily
afforded with other imaging measures. The development of the cognitive tasks for use
with ERPs is an advance in research methodology as each task was tailored for
appropriate psychophysiological recording while still maintaining those aspects that
allow for the assessment of cognitive function. This is especially the case for the
recognition memory task (see chapter 5), which has good apparent utility for future
research studies due to its sensitivity to multiple aspects of memory function;
recognition accuracy, memory-related response bias, interference from related stimuli,
and combination with ERP recording.
Lastly, participants were thoroughly interviewed on their cannabis usage history.
This allowed for examination of relationships between onset, duration, frequency, and
quantity of cannabis use with the different cognitive and psychophysiological measures.
Such relationships have been examined inconsistently within the literature with the level
of detail assessed often varying considerably. This thesis represents the use of what is
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most likely a best practice approach for long-term retrospective assessment in relation to
cannabis use so as to elucidate relationships with tasks of cognitive ability and measures
of brain function.
8.3.

SIGNIFICANCE AND IMPLICATIONS OF THIS RESEARCH

The current series of empirical studies significantly advance the understanding of
chronic cannabis use effects as they relate to both cognition and brain functioning; the
primary aims of this thesis. Across the studies, there were consistent findings of overt
behavioural impairment, consistent with chronic use studies within the literature (for
reviews, see Solowij and Battisti 2008; Solowij and Pesa 2010). Impairment in
memory-related processes as well as inhibitory function was observed; findings related
to difficulties for cannabis users to identify previously seen stimuli from related
distractor stimuli (see chapter 5) were particularly novel and suggest that conclusions
based solely around reduced short-term memory capacity or memory encoding
difficulties do not tell the whole story. Alterations in examined ERP component
morphologies for cannabis users were consistent with behavioural findings but
demonstrated the additional capacity to provide a higher resolution assessment of
underlying process changes, with dysfunction observed that did not always manifest
behaviourally. Of particular note were findings interpreted as evidence for poorer neural
efficiency and neuroadaptation, as well as earlier ages of use exposure related to greater
dysfunction.
The use of psychophysiological measurement, with ERPs the focus within this
thesis, were highly effective in the identification of dysfunction in brain functioning
among a group of long-term heavy cannabis users. Within the cognitive literature,
effects associated with chronic cannabis use are not always measurable and may, on
occasion, be considered quite minor and therefore of limited impact (for reviews, see
Solowij and Battisti 2008; Solowij and Pesa 2010). This thesis provides good evidence
that while some effects may not always be overtly measurable in terms of behavioural
performance, at a neural level, alterations are nevertheless occurring. While the
implications of this are speculative, what the findings do represent is that the tonic brain
function of long-term heavy users reflects activity that does not represent optimal
healthy function. It is likely that the presence of ERP alterations above and beyond, if
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not in the absence of, behavioural alterations simply indicates that the appropriate
research questions are not being asked of the behavioural measures, or that the existing
measures are limited in their resolution for the detection of dysfunction. Additionally,
psychophysiological measurement may be used in future research to better guide more
discrete investigations of cannabis-related effects.
As briefly discussed above, the terms neural efficiency and neuroadaptation
reflect sub-optimal neural pathways being utilised within the context of continued brain
insult (i.e. regular constant exposure to at least mild levels of cannabinoids), with these
novel pathways being used with increased efficiency over time. The theoretical rationale
for these processes to occur lies within the concept of neural plasticity. Neural plasticity
refers to the ability of the brain to alter its structure and physiology in the pursuit of
both reliable and stable changes in neural activity and behaviour. Manifested at the
synaptic and network levels, this is achieved through various mechanisms, including at
the genetic, cellular and molecular levels (Knoblauch et al. 2010; Teskey and Pellis
2010). Human research is limited to the examination of brains post-mortem and is often
confounded by factors such as age. Consequently, the majority of biological research
has involved animal studies (e.g. Auriat et al. 2010; Lukowiak et al. 2010; Merrett et al.
2010; Saucier et al. 2010). These have identified changes in the function and structure
of brain regions adjacent to the site of localised lesions, indicative of the formation of
compensatory novel neural pathways. Within humans, neural plasticity is largely
examined at the behavioural level with improvements in neurocognitive performance
following traumatic brain injury (TBI) having been observed over time and recently, in
particular, in the cognitive remediation literature (e.g. Galbiati et al. 2009; Tiersky et al.
2005). The general mechanism of neural plasticity therefore as a compensatory process
may be observed as adjacent neural structures and/or networks taking over for/assisting
nearby damaged/non-functional structures/networks, thus performing other than their
original intended role so as to compensate for loss of function.
Although measures of brain function cannot explicitly indicate when neural
plasticity has occurred, the current series of empirical studies within this thesis suggest
that such a process was present within studied participants. Specifically, improved
behavioural performance (chapters 4, 5 and 7) and levels of brain activity more similar
to those of controls (chapters 4, 5, and 7) were related to a longer history of cannabis
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use. Additionally, altered topography (chapters 4, 5, 6, and 7) suggests the use of
alternate structures. Given that the cannabis use of participants was very long-term,
regular and heavy, as well as the persistence of the parent compound (∆9 -THC) within
the body, the findings may be theoretically equated to TBI. In terms of cannabinoid
system functioning, the regular near-constant exposure to exogenous cannabinoids
would tonically alter the normal activation of CB1 receptors within the central nervous
system. As the brain is unable to optimally use these receptors to perform their normal
functions, the use of alternate pathways are required; with these strengthened and made
more efficient with continued use. As these are not the original (optimal) pathways, it
would be expected that the outcomes of their use would unlikely match those of healthy
controls. Within this thesis this phenomenon has been labelled as evidence of a
neuroadaptive process occurring as the brains of cannabis users are adapting to the
enduring impact upon regular functioning and producing novel, albeit less efficient,
neurological pathways. Without active remediation efforts that have been observed to
accelerate recovery from TBI (for review, see Cicerone et al. 2005), such an effect for
cannabis users would likely be expected to take place over many years, with this
consistent with the relationships observed within this thesis with duration of use and not
usage frequency (a reflection of more current use). This would indicate that it is not
merely a tolerance effect observed, which is believed to develop with increased
frequency of use within a relatively short period of time (months) (Hart et al. 2010;
Ramaekers et al. 2009). The implication of this may be considered both positively and
negatively. On the one hand, increasingly efficient neural connections would mean that
cannabis use would be having a decreasing influence with an increased number of years
of use. On the other hand, this would still be reflecting poorer neural efficiency in
comparison to the brain functioning of non-users which may have implications when
considered in the context of normal age-related cognitive decline, with decreased neural
resource availability occurring with increased age (e.g. Sambataro et al. 2010; Ziegler et
al. 2010). While these findings are quite speculative, they provide a clear path for future
research investigations.
Within empirical study 3 (chapter 6) there was an observed relationship with an
earlier age of use onset and poorer accuracy on the Stroop task. While this thesis did not
specifically examine impacts related to adolescent and childhood exposure to cannabis,
it may be suggested that earlier use exposure will relate to poorer outcomes in later life.
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Given the rapid brain development (i.e. synaptic pruning) that occurs during the
adolescent years (White et al. 2010), exposure during this time period to exogenous
psychoactive chemicals is likely to impact upon subsequent brain development. This has
already been suggested within the alcohol literature (Maldonado-Devincci et al. 2010;
Strong et al. 2010; Windle and Zucker 2010), and may also hold true for cannabis. The
likely greater impact for young people taking up the use of cannabis indicates an urgent
need for future research into this area with measurement instruments, such as those used
within this thesis, likely to be highly effective for such an endeavour.
8.4.

LIMITATIONS AND SUGGESTIONS FOR FUTURE RESEARCH

This thesis extends upon previous research via the contribution of four empirical studies
to the extremely limited field of psychophysiological cannabis research, providing much
needed insight into the effects underlying chronic cannabis use. There were though,
some general limitations present within each empirical study that potentially may be
addressed in future research. In particular, all studies were cross-sectional in nature and
therefore limit the ability to draw a causal link between chronic cannabis use and
outcomes observed. While our use of correlation analyses with usage history strongly
suggests causal links, this cannot be stated with absolute certainty. We were additionally
unable to make Bonferonni corrections, which aim to reduce Type I error associated
with multiple correlations but are unsuitable for exploratory studies with smaller sample
sizes, such as those within the present thesis, as they vastly inflate Type II error and
result in (incorrectly) null findings. Evidence of altered neural expression and
behavioural performance differences may have existed prior to the onset of cannabis
use, or they may represent markers of a vulnerability to chronic cannabis use. They may
also reflect more global cognitive deficits associated with the chronic use of cannabis
that is not specific to the tasks included within the present thesis. The lack of difference
in premorbid IQ between the cannabis users and controls suggests that cognitive deficits
were not global. Further, there is a well-established literature base that indicates that
deficits associated with the chronic use of cannabis are not global and are most evident
within the domains of memory and attention. Chapter 2 exhaustively reviews the
literature examining the cognitive impairments associated with chronic cannabis use.
Considered in light of this, the consistent findings within this thesis of a longer history
of use being related to a change in psychophysiological functioning and behavioural
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performance, a causal interpretation, at least in part, appears likely. In addition to this,
we assessed cannabis use history retrospectively, thus enabling the presence of error in
participant self-reporting. The use of a longitudinal study with repeated assessment
would be the optimal method of resolving these two issues; specifically, following a
large group of cannabis users from prior to their commencement of smoking and for a
period of at least five years, if not longer. Given the viability of such research being
very low, the current research is an example of near best practice available for
examination of chronic cannabis use effects. The use of a much larger sample would
help increase the confidence in findings observed but would continue to be limited by
the lack of a longitudinal design.
Across all four studies, there was a difficulty of several participants not being
available for analysis due to excessive artefact in the EEG signal precluding them from
analysis. Although this affected a very small number of participants (ranging from 1 to
5), this varied with each empirical study and participant samples therefore varied
somewhat across studies. Additionally, it is not possible to completely rule out the
effects of confounds related to mild intoxication levels and coexisting use of tobacco,
which was significantly higher in our cannabis-using sample, although not common
within that sample as well and controlled for in cases where it was of concern. Given
that participants were required to abstain for only approximately 12 hours prior to
commencement of the study, there was the possibility of residual effects. This period
was chosen to minimise the risk of any withdrawal, as well as acute influences from
cannabis use, with relationships with recency of use and levels of cannabinoid
metabolites present in urine examined to help rule out such effects from interpretation.
Additionally, as the intention was to examine the day-to-day cognitive and
electrophysiological profile of regular smokers, such a period of abstinence would be
most reflective of their regular state (minus acute use effects). The potential influence of
confounds was examined across the four empirical studies and it was concluded that it
was unlikely that they were responsible for the alterations observed, although they
cannot be ruled out entirely. The presence of strong relationships related to cannabis
usage history existed independently of these confounds and indicated that cannabis use
was the major explanatory variable. Lastly, given that the same pool of cannabis users
participated in all four empirical studies, this reduces the generalisability of the findings
and may indicate that what we observed was particular to this sample. In contrast

174

though, having observed similar effects across the studies strongly indicates that
findings were not spurious and quite clearly establish the processes examined as key
targets for future research and replication.
Recently, there has been an increased focus on what the impact of varying ∆9THC and CBD levels within cannabis may be in terms of both short- and long-term
effects, given the often contrasting effects in terms of psychotropic function and impacts
upon cognition (e.g. Long et al. 2010; Malone et al. 2009; Morgan and Curran 2008;
Morgan et al. 2010b; O'Tuathaigh et al. 2010). Within a retrospective study it is
impossible to establish with any degree of reliability the consistency of the different
plants that participants smoked over the course of their entire cannabis usage history. It
does remain a limitation though, as to what degree changes observed reflect exposure
levels to ∆9 -THC and CBD. What has been identified within the literature is a trend
within smoked cannabis sativa plants for CBD levels to decrease and∆9 -THC levels to
increase (Knight et al. 2010; Mehmedic et al. 2010; Morgan et al. 2010a; Morgan et al.
2010b). Although this is beyond the scope of the current thesis, it could be hypothesised
that future chronic cannabis users will have poorer outcomes than those observed in the
current series of studies.
Considering the empirical studies collectively, it is apparent that future research
should target memory processes, in particular recognition memory, with tasks of
sufficient complexity in order to elicit group differences. A careful examination of
cannabis use history would also allow for more thorough exploration of the concepts of
neural efficiency, compensatory mechanisms, and neuroadaptation. It is possible that
other factors, that have not already been discussed, may explain the deficits observed
and improvements in performance observed with a longer history of cannabis use.
Cannabis users may have fundamental differences in levels of motivation, be more
easily distracted or fatigue faster. They may also be employing alternate, albeit less
successful, strategies to complete the tasks. If such global processes were active, we
would expect poorer behavioural performance across all four empirical chapters. This
was only observed in three of the four studies. It is not apparent what other factors may
correlate highly with a longer history of use, but not with age, and relate to an
improvement in performance, which would substitute as an alternative explanation to
neuroadaption. It may be possible that strategy use could improve with time (i.e.
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continued use of cannabis). However, such an overtly cognitive process would not be
evident within five hundred, if not later, milliseconds of a cognition-eliciting event,
suggesting strategy use as an explanation unlikely. This could though be explored via
following the same set of cannabis users over a one to two year period so as to examine
performance and/or brain functioning changes that may relate to neuroadaptive
processes. Whether such an effect would manifest within such a timeframe is unknown
though with there being no precedent within the research literature to indicate the
likelihood of this occurring. The use of methods to retain participants for longitudinal
research would aid the establishment of more conclusive arguments related to the
chronic effects of cannabis.
Lastly, while attempts were made to ensure a lack of diagnosable psychiatric
symptoms within the sample, as the presence or history of diagnosis with any
psychiatric disorder was an exclusion criterion, levels that did not reach the thresholds
for diagnosis may have impacted upon study findings. The lack of differences in the
early portions of the ERP waveforms within each empirical study suggest that there
were not global differences present in the brain electrical activities of cannabis users
and controls, however it is possible that some level of psychopathology may impact
upon the remaining sections of the waveform. The likelihood of any possible impact
cannot be assessed within the current thesis as well as whether any levels of depression
or anxiety were greater for cannabis users than controls. Future research would benefit
from examining and controlling for these possible confounds.
8.5.

CONCLUSIONS

This thesis examined the performance of a group of chronic users of cannabis during the
unintoxicated state on several tasks of memory and inhibitory control, substantially
adding to the extant literature within this field. The findings showed evidence of chronic
cannabis use-induced impairments that were present outside the acutely intoxicated state
in all domains examined. The use of electrophysiological measurement was
demonstrated to be highly sensitive to neurological processes that are not measureable
in overt behaviour, via the identification of specific neural markers that are altered in
the context of chronic cannabis use. Additionally, the empirical studies of this thesis
were the first to suggest the presence of neuroadaptative processes amongst chronic
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users of cannabis, with only effects related to acquired tolerance reported elsewhere
(e.g. see Ramaekers et al. 2009). Specifically, behavioural and electrophysiological
outcomes can improve with a longer history of chronic use. With any substance that
produces a change in brain neurotransmitter action and/or quantity, such as is the action
of ∆9-THC, there exists the possibility of neural adaptation occurring, as was observed
in this thesis. Aside from demonstrating the ability of the brain to compensate for insult
in the presence of continued disruption, this strongly suggests an ability for the brain to
recover more efficient patterns of processing should cannabis use cease.
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APPENDIX A. PARTICIPANT INFORMATION SHEET FOR
EMPIRICAL STUDIES
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Neurocognitive and Electrophysiological Correlates of Memory Impairment Associated
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Chief Researcher:
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Additional Researchers:
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INFORMATION SHEET

This study is being conducted by researchers at the University of Wollongong. We are
interested in examining the long-term effects of heavy versus light use of cannabis on
memory and learning. We are particularly interested in observing these effects using
measures of brain electrical activity (electroencephalogram – EEG). EEG provides
information about ongoing brain activity, and changes in activity in the brain. The
procedure is painless and poses no danger or health risk as it is a completely passive
measure of brain activity. No cannabis or any other substance will be administered in the
course of this study. We will be looking at the long-term effects during an unintoxicated
state.
The testing will consist of a single testing session, which will take up to 4 hours to
complete. During this session you will be given written information about the study. If you
agree to participate you will be asked to provide written consent by signing a consent form
confirming your willingness to continue in the project. We will then proceed with an
interview in which you will be asked about details of your current and past history of
substance use and some relevant aspects of your psychological well-being. You will be
asked to complete a psychological assessment including one or two brief questionnaires and
a brief verbal IQ test. These questionnaires and assessments will take approximately 2
hours to complete. The EEG phase of the test session requires you to have an EEG cap
fitted to you. This process takes approximately 15 minutes and involves having a nonreactive (salt-based) electro-conductive gel placed within holes in the cap. You will then be
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seated within a testing booth where you will complete three types of memory tests while
your brain activity is monitored. Instructions for each test will be provided as needed. The
tasks will be computerised and will be presented to you on a computer display. Do not
worry if you are not familiar with computers, as the most that you will need to interact with
them will involve the pressing of one or two buttons. The length of time in the testing booth
is expected to be approximately 75 minutes.
At the end of this procedure you will have an opportunity to debrief about the session. At
some stage during the test session, we will request that you provide a urine sample as well
as provide one taken approximately 12 hours prior to testing. During your phone interview,
we requested that you refrain from using cannabis for at least 12 hours prior to your test
session and we will analyse the urine samples to confirm your abstinence. This procedure is
essential so that experimental effects will not be due to the acute or recent effects of
cannabis, as our interest is in investigating long-term effects.
Specific Requirements for Participants:
The study requires that you have consumed no cannabis (marijuana), alcohol, or any other
drugs (legal or illegal) for at least twelve hours prior to this testing session, and that you
consume no cannabis, alcohol or other drugs until testing is completed tomorrow.
We also require that you provide a urine sample from 12 hours prior and when you come in
for testing. These will be analysed for the presence of cannabis and other substances.
Participation requires that you be able to feel at ease in the EEG testing environment, as
you will be seated in a testing booth for up to 75 minutes.
The study also requires that you complete to the best of your ability, the entire test session.
However, you retain the right to withdraw from this study at any time without
repercussions.
Specific Requirements for Researchers:
Anonymity and Confidentiality
Only the researchers directly involved in this study will have access to your results. All
information you provide will be treated as strictly confidential and you will not be
personally identifiable in any way. Minimal contact details (i.e., name and contact
telephone number) will be kept separately locked away from the coded data and will only
be accessible to the immediate researchers involved in this study. At the conclusion of data
collection, your name and contact details will be destroyed. In this way, the information
that you provide about your illicit drug use and personal details will not identify you. The
data collected will be securely stored in the Department of Psychology at the University of
Wollongong.
The Research will Remain Voluntary
You are free to refuse to participate. Alternatively, having consented, you are free to
withdraw your consent without this affecting your relations with the researchers or the
University. If you do decide to withdraw your consent, your data will not be used without
your permission.
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Appropriate use of the Information Collected
The purpose of this research is to disseminate information that may assist in the education
of potential and current users of cannabis, and to facilitate the treatment of cannabis
dependence. Thus, it is hoped that the results of the study will be published in an
international scientific journal. Additionally, the study will be conducted in order to
complete the thesis requirement of a Research PhD program, which will be published in the
usual manner within the University of Wollongong. In publications that report the results of
this study, you will not be individually identified and the data will be published in terms of
group statistics. You will also be provided with an opportunity to obtain information about
the results and conclusion of the research.
Reimbursement for Participating
Participants will be provided the sum of $50 for participation in this research. This amount
is intended for travel expenses and time involved in participation. You may expect no
personal benefit from this experimental research. However, the information gained might
be useful in helping to better understand the effects of cannabis.
Legal Implications of Participation
You will not be required to possess or use cannabis during the experiment. Although the
use and possession of cannabis is prohibited, the NSW Bureau of Crime Statistics has
documented that the risk of being brought to Court for use or possession of cannabis (i.e.,
for personal use), is low even if you are found to have small amounts of cannabis in your
possession. Whilst simply admitting to having used an illicit substance is not incriminating,
a very small risk related to your participation in this study is a possible breach of
confidentiality (information related to harm to another person). However, the researchers
will make every effort to maintain your confidentiality under all circumstances, and as
stated before, your personal identifiers will be destroyed after completion of your
participation.
If you have any concerns or complaints regarding the way in which the research is
conducted you should contact the Secretary of the University of Wollongong Human
Research Ethics Committee on (02) 4221 4457. Thank you for your time so far. If you have
any further questions feel free to ask. The telephone number on which you can contact the
researchers at the University of Wollongong for further information is: (02) 4221 4511.
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APPENDIX B. PARTICIPANT CONSENT FORM FOR EMPIRICAL
STUDIES

DEPARTMENT OF PSYCHOLOGY – UNIVERSITY OF WOLLONGONG
Neurocognitive and Electrophysiological Correlates of Memory Impairment Associated
with Long Term Heavy Cannabis Use
Chief Researcher:
Robert Battisti
Additional Researchers:
Dr Steven Roodenrys
Dr Stuart Johnstone
Dr Nadia Solowij

(Ph: 4221 4511) Email: rab01@uow.edu.au
(Ph: 4221 4072) Email: steven@uow.edu.au
(Ph: 4221 4495) Email: sjohnsto@uow.edu.au
(Ph: 4221 3732) Email: nadia@uow.edu.au
Participant Consent Form

I have been provided with information about the research project “Neurocognitive and
Electrophysiological Correlates of Memory Impairment Associated with Long Term Heavy
Cannabis Use.” I have discussed the project with Robert Battisti, the PhD student who is
conducting this research. I have had an opportunity to ask any questions I may have about the
research and my participation. I have been advised to call the researchers at any time with any
further questions or problems.
I understand that I am anonymous in this experiment and I have been told that all
information I provide will be treated as strictly confidential and I will not be personally
identifiable in any way. I have also been informed that my name will be kept separate from my
records, which will be assigned a code number and that my identifiers will be destroyed after
completion of the two test sessions. My name will not appear in any publication. I understand
that there may be a small risk related to my participation in this study involving the possibility
of a breach of my confidentiality. However, I understand that the researchers will make every
effort to maintain my confidentiality and to ensure that no breach is made.
I have been told that I am free to choose not to participate. If I do consent to participate in
this research, I am free to withdraw from this study at any time. If I decline to participate, or if I
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withdraw, it will not harm my relationship with the researchers or the University of
Wollongong.
I understand that if I consent to participate in this project I will be asked to:
•
•
•
•
•
•

Consume no cannabis, alcohol, or any other drugs (legal or illegal) for at least 12 hours
prior to the test session;
Provide a urine sample 12 hours prior and at the test session, to be analysed for the
presence of cannabis and other drugs;
Participate in a test session lasting up to a total of 4 hours. However, I reserve the right
to withdraw from this study at any time;
Complete several questionnaires and inventories, a brief IQ test, and a memory and
learning test;
Complete a structured interview and some drug use and psychological questionnaires;
Complete an EEG measurement session of approximately 75 minutes.

I have been told that I will receive $50 compensation for my travel expenses and time
involved. I may expect no personal benefit from this experimental research. However, the
information gained might be useful in helping to better understand the effects of cannabis.
I understand that the data collected as a result of my participation in this study will be
published in an international scientific journal. Additionally, the data will be used in order to
complete the research requirement of a Research PhD program, and will be published as a
thesis within the University of Wollongong. I consent to the data being used in this manner.
I acknowledge that I have read the above statement, which explains the nature and
objectives of the investigation to my satisfaction. My participation in this study is entirely
voluntary and I may withdraw from the study at any time. By signing below, I am indicating
my consent to participate in this research as it has been described to me.

Signed:…………………………………………….

Date:…../….../……

Name (First Name and Initial Surname)…………………………………………...
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APPENDIX C. SCREENING INTERVIEW PROTOCOL
SCREENING INTERVIEW
DEPARTMENT OF PSYCHOLOGY – UNIVERSITY OF WOLLONGONG
Neurocognitive and Electrophysiological Correlates of Memory Impairment Associated
with Long Term Heavy Cannabis Use
Chief Researcher:
Robert Battisti
Additional Researchers:
Dr Steven Roodenrys
Dr Stuart Johnstone
Dr Nadia Solowij

(Ph: 4221 4511) Email: rab01@uow.edu.au
(Ph: 4221 4072) Email: steven@uow.edu.au
(Ph: 4221 4495) Email: sjohnsto@uow.edu.au
(Ph: 4221 3732) Email: nadia@uow.edu.au

Screening and Drug Use Questionnaire
“Not everybody who applies can be accepted into the project due to some specific
requirements for this research. To determine your eligibility we need to ask some general
questions and also some detailed questions regarding your use of marijuana, alcohol and other
drugs. It is extremely important that you provide accurate information. Any information you
provide will be treated as strictly confidential”.
1. Demographics:
1. What is your age? ____________________
2. What is your sex? ____________________
3. Are you right handed, left handed or ambidextrous? (Probe if necessary)

4. Is English your first language?
_____________________________
(Probe = What language do you mostly use at home? if English is not first language)

5. Are you able to travel to Wollongong University on a single occasion within the next
month?
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6. What is the highest level of education you have completed or are currently completing?

2 Medical:
1. Are you on any prescription medication or receiving treatment for any medical condition?

2. Have you ever been hospitalised for any reason/condition?

3. Have you ever had any of the following: for confidentiality, please do not elaborate on the
particular diagnosis that relates to you, just simply state yes or no after the list is completed
•
Fits, convulsions, epileptic seizures;
•
Stroke, brain tumour; meningitis, encephalitis, multiple sclerosis;
•
Serious head injuries or significant periods of unconsciousness;
•
Positive for HIV; again state only ‘yes’ or ‘no,’ “please do not elaborate”

4. Have you ever had any other serious illness not mentioned in the previous question but that
you suspect might affect our investigation in any way? Please elaborate

5. Do you have a visual impairment? What type? How severe is it? Do you have colour
blindness?

6. Have you ever consulted a psychologist, psychiatrist or counsellor or undergone therapy for
any reason? (probe)

7. Is there any psychiatric illness in your family?
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3. Substance Use:
1. Have you ever been in treatment for drug or alcohol problems?

2. Have you ever felt dependent on alcohol or any drug other than marijuana?

If yes, which substance and how long ago was that?

3. Have you ever felt that you may have had a problem with or were using too much of any
substance other than marijuana?

4. Have you ever used any substance other than marijuana on a regular basis, and by regular
we mean at least a couple of times per month?

If yes, which substance and how long ago was that?

5. Are you currently using any other substances on a regular basis? [Record responses
verbatim]

4. Cannabis Use:

CONTROLS
1. Have you ever tried marijuana?

2. Have you ever used it on a regular basis?
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3. When was the last time you used cannabis?

4. How many times have you had marijuana in total and over what time period?

CANNABIS USERS
1. How old were you when you first tried marijuana?

2. How old were you when you first started using it regularly (at least twice/month)?

3. How often are you currently smoking marijuana? E.g. how many days would you smoke
marijuana in a typical month?

4. How long have you been smoking at your current level?

5. Has your pattern of use changed over time?

6. Has there ever been a period when you smoked much more heavily?

7. Have you ever used on a daily basis?

8. When was the last time you were using on a daily basis and for how long?
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APPENDIX D. STRUCTURED INTERVIEW PROTOCOL
STRUCTURED INTERVIEW
DEPARTMENT OF PSYCHOLOGY – UNIVERSITY OF WOLLONGONG
Neurocognitive and Electrophysiological Correlates of Memory Impairment Associated
with Long Term Heavy Cannabis Use
Chief Researcher:
Robert Battisti
Additional Researchers:
Dr Steven Roodenrys
Dr Stuart Johnstone
Dr Nadia Solowij

(Ph: 4221 4511) Email: rab01@uow.edu.au
(Ph: 4221 4072) Email: steven@uow.edu.au
(Ph: 4221 4495) Email: sjohnsto@uow.edu.au
(Ph: 4221 3732) Email: nadia@uow.edu.au

Structured Interview: (Face to Face)
[Purpose: As a sequel to the telephone screening, this segment of the testing session will
review demographic information and try to repeat and expand on some of the information from
telephone screening in order to check consistency of the information and to collect additional
background information. Because a major exclusion criterion for this project is abuse of or
dependence on alcohol or other drugs, it is important to conduct a structured interview to make
such determinations. Thus, this procedure is to obtain detailed information necessary for the
researchers to make a final decision regarding the individual’s appropriateness as a study
participant and to elicit detailed information that will be coded and used as covariates in the
analysis of the data collected.]
“I would like to make sure I have the correct information for you. So, I have some more
questions that I would like to ask you about some serious medical or psychological conditions
and about your drug use history.”

General Medical
1. What is your date of birth? ___________________________
2. Have you ever had a serious head injury that resulted in trauma to the brain, or required
surgery, prolonged hospitalisation, and rehabilitation, and may have involved prolonged
unconsciousness or concussion? [If person can’t recall head injuries prompt by asking whether
they have ever had concussion or been unconscious].

211

4. Are you currently taking any prescription medications?

What is it [are they] called?

What dose do you take?

How long have you been taking this medication?

Psychiatric Information:
1. Do you, either of your parents or any of your brothers and sisters have a psychiatric
disorder?

2. Have you ever consulted a psychologist, psychiatrist, counsellor, or undergone therapy
for any reason?

3. Have you ever been diagnosed with schizophrenia or any other psychotic disorder that
requires ongoing medication? Seeing a therapist or counsellor for marriage problems, for
instance, does not count as a psychotic disorder. [A psychotic disorder is one for which you may
have been prescribed a medication such as Clozaril, Haldol, Compazine, Stelazine, Thorazine.]

4. Alcohol Use:
Now I would like to ask you some questions about your use of drugs and alcohol.
1. Do you drink alcohol? (For those who don’t drink ask – Did you ever drink alcohol?)
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2. When did you first try alcohol?

3. On how many days would you drink alcohol in a typical week?

4. On a day when you drink, how many drinks would you have (per occasion)?

5. How long have you been drinking at that level?

6. Has there ever been a period in your life when you drank much more heavily?

If so, can you tell me about the heaviest periods of alcohol use?

When were they?

How much were you drinking?

How often did you do this?

For how long did this period of heavy drinking go on?
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7. How much did you drink last week? [go through each day of week]

8. When did you have your last drink of alcohol?

How much did you drink?

9. Was this a typical week in terms of drinking habits?

4 Other drug use:
1. Do you, or have you ever used any of the following substances?
2. When did you first try it?
3. How often did you use it?
4. For how many years or months did you use it?
5. How often do you use it now?
6. When was the last time you used it?
Tobacco

Amphetamines

Cocaine

Barbiturates (downers)
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Tranquilisers

LSD, Mushrooms, Ecstasy

Opiates (heroin, meth, peth)

Inhalants (amyl, aerosols)

Anything else?

7. Have you ever had any problems associated with the use of these drugs or with alcohol?
[e.g. been arrested, involved in a car accident, felt you were dependent, been in rehab., etc.]

CANNABIS USE
Controls
1. Have you ever tried marijuana?

2. Have you ever used marijuana on a regular basis?

3. When was the last time you used marijuana?
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4. How many times have you had marijuana in total, over what period of time?

(Exclude those who have ever used cannabis recently or more often than once a month)
Cannabis Users:
1. Have you ever used marijuana?

2. Do you use it now?

3. When did you first try marijuana?

4. How old were you when you first started using regularly, that is, at least once a month?

5. Do you ever smoke anything other than heads (i.e. hash)? And do you use hydro or bushweed?

6. Do you mix your marijuana with tobacco?

7. Do you smoke joints, bongs, or pipes?

8. How many would you smoke in a typical session?
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9. On days when you smoke marijuana, how many sessions would you have?

10. On how many days would you smoke cannabis in a typical month?

11. How frequently have you smoked and has the amount you have smoked changed over
time? (i.e. more or less often in a month/day/etc.)

12. Has there been a period when you smoked much more heavily? Perhaps you have gone
through cyclic patterns of use?

13. Have you ever smoked on a daily basis, and if so, for how long?

14. Have you ever felt dependent on cannabis?

15. In the past 3 years what is the longest period you’ve gone without marijuana?

18. How many days did you smoke last week?

Was this a typical week in terms of marijuana use? (If not last week, think back to the last
time you smoked)?

217

19. Have you noticed any long-term psychological or mental changes that you associate
with cannabis use? This is not for just when you are stoned but all of the time.
Improved / Impaired / No Effect
Memory

Attention span

Concentration

Ability to cope with life’s problems

Physical health

General self-confidence

Work performance or studies

Ability to communicate

Relations with employers/seniors
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General coordination

General level of energy

Excitement and enthusiasm for life

Ability to relax

Driving ability

Enjoyment of sex

20. When did you last smoke marijuana?
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